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Abstract
The research centered on the development o f an antibody-based optical biosensor. The 
enzyme lactate dehydrogenase was chosen as the analyte, as it is a clinically important 
enzyme and is used as an indicator o f  various disease states such as heart disease. 
Polyclonal antibodies were raised in rabbits. These antibodies were purified, 
characterised and labelled with horse radish peroxidase and fluorescein. Enzyme-linked 
and fluorescent-linked immunoassays were developed using the HRP-labelled and FITC- 
labelled antibodies, respectively.
Antibodies specific for chicken heart lactate dehydrogenase (CHLDH), were immobilised 
on the exposed core o f optical fibres. The immobilisation procedure was optimised to 
ensure reproducibility o f immunoglobulin immobilisation. An optical immunosensor, 
based on the evanescent wave technique, was developed and optimised. The sensor was 
shown to be specific for CHLDH and sensitive to varying concentrations o f CHLDH. 
A  comparison was made between one-step and two-step assay systems using the 
evanescent wave immunosensor and the BIAcore (commercially available biosensor 
based on surface plasmon resonance). The sensors were also compared in an experiment 
to determine the effect o f high levels o f fluorophore labelling on antibody affinity. 
Anti-human H4LD H  (LDHj isoenzyme) antibodies were also raised and tested in an 
E L ISA  system using human serum samples. The isoenzyme profiles o f these serum 
samples were also prepared to see if  elevated LD H X (H4LDH) levels could be used as 
an indicator o f myocardial infarction. The specificity o f the antibodies was checked 
using immunoblotting techniques.
A minituarised colourimetric assay for total LD H  was developed and validated using 
patient samples.
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CHAPTER 1
INTRODUCTION
1.1 Introduction
A sensor is a device capable of providing a usable electrical signal output in response 
to the continuous recording of a physical parameter or the concentration of a specified 
chemical or biochemical species. The output signal is processed and displayed in a 
convenient format. The measurand is generally inherently different from the desired 
output signal and so at least one transduction step is required to convert the measurand 
quantity into an electrical signal, for the sensor to work. Biosensors are a subset of 
sensors, which employ the specificity of biological molecules, e.g. enzyme, antibody, 
cell etc., responsive to the property or analyte being determined, in contact with a 
suitable transducing element, that converts the signal sensed into a signal that can be 
conveniently processed (Vadgama and Crump, 1992). A schematic diagram of the 
biosensor set-up, is shown in Figure 1.1. The signal sensed is a result of a change in one 
or more physico-chemical parameters associated with the bioreaction, and manifests 
itself as the production of ions, electrons, gases, light, heat or mass (Hall, 1990).
The analysis of biochemical compounds, in relation to specific identification and the 
determination of their concentrations is a major activity all over the world. Medical 
diagnostics (Connolly, 1995), healthcare (Owen, 1994), agriculture, veterinary science, 
industrial process control (Liidi et al., 1991) and environmental monitoring (Dennison 
and Turner, 1995) are a few of the real life situations where analytical information is 
required every day. Any analytical device which would simplify the analytical 
methodologies employed, to a level where they could be routinely used in decentralised 
environments, by relatively unskilled operators, offers many advantages.
This was the rationale for combining expertise from many diverse disciplines including 
biochemistry, electrochemistry, optronics, physics and electronics, with the strategic aim 
of developing ‘biosensing devices’.
The first biosensor was described by Clark and Lyons (1962). The ‘enzyme electrode’ 
biosensor consisted of a platinum electrode which responded to peroxide generated by 
the following reaction;
glucose
glucose + 0 2 —> gluconic acid + H20 2
oxidase
Here, the substrate glucose, was acted upon by the enzyme glucose oxidase, to give rise 
to gluconic acid and peroxide. The amount of peroxide generated was proportional to
the concentration of glucose and, hence, the system could be used to monitor glucose 
levels.
Figure 1.1: Schematic of biosensor set-up. The biosensor has three main parts. The 
biological entity (A) normally interacts specifically with the analyte in the sample, 
resulting in a physico-chemical response (B). The transducer (C) converts the physico­
chemical response resulting from the binding of the analyte with the biological entity, 
into an electrical signal. This electrical signal is converted by the output device (D) into 
a format that may be monitored by the user via a signal display (E).
Biosensors have great potential for rapid analysis with the ability to determine specific 
analytes in complex environments. In some cases, the biological reaction is detected as 
it happens and the biosensors are said to operate in ‘real-time’. Ideally, a biosensor 
should eliminate the need for sample pretreatment, be easy to use, be of compact 
transportable size, allow one step reagentless analysis and have a rapid response turn­
around time (Figure 1.2). Such devices would allow analytical measurements to be taken 
in situ, giving information on dynamic processes which could be responded to, 
immediately, e.g. monitoring of blood glucose in diabetic patients (Greenough et al., 
1994).
The commercialisation of biosensors is hindered by practical problems which must be 
overcome, such as the stringent operational requirements of biomolecules which put 
limitations on biosensors (Griffiths and Hall, 1993). Also, the bioelement must come
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into direct contact with the test solution which may result in non-specific interactions 
with the transducer surface. Biological components are also inherently unstable and, 
therefore, operational life-times of biosensors tend to be short (Scheller et al., 1991).
Figure 1.2: Characteristics of an ‘ideal’ biosensor (Taken from Griffiths and Hall,
1993).
3
1.2 The Biological Component
Many key reactions in biological systems are based on recognition phenomena (enzyme- 
substrate, antibody-antigen, receptor-ligand), and it is the specificity of these recognition 
events in which lies the advantages of biosensors. Biosensors can be divided into two 
main groups: catalytic and affinity biosensors, depending on the biological molecule 
employed, but in each type, a recognition event is involved (Byfield and Abuknesha,
1994). In catalytic biosensors, the biomolecule recognises its analyte and changes it in 
some way, and it is a change in the concentration of some species involved in the 
catalytic reaction that is detected. With affinity biosensors, however, the binding reaction 
itself is monitored, either directly through some subtle charge effect, conformational or 
mass change, or indirectly, using a reporter molecule, such as an enzyme or fluorophore. 
Indirect methods are more common as direct methods of monitoring are often difficult 
to transduce (Leech, 1994).
1.2.1 Catalytic biomolecules used in biosensors
1.2.1.1 Enzyme-based systems
The most commonly employed biological component in catalytic biosensors is an
enzyme. Enzymes are routinely used as analytical tools outside the body due to the
numerous, diverse reactions they catalyse. They include oxidoreductases, transferases, 
hydrolases, lyases, isomerases and ligases. Oxidoreductases act by transferring electrons 
or hydrogen ions during the oxidation and reduction of substrates and so are particularly 
suitable for use in electrochemically-based biosensors.
Cass et al. (1984), described an amperometric-based biosensor, for the determination of 
glucose in whole blood samples. It was later commercially developed by MediSense 
(Cambridge, MA, USA) and collaborators at Oxford and Cranfield (England), into the 
ExacTech pen-type glucose sensor, for monitoring glucose levels in diabetic patients. 
The biosensor employed the oxidoreductase enzyme, glucose oxidase and the soluble 
mediator ferrocene (bis(ri5-cyclopentadienyl)iron), Fecp2R+. Direct electron transfer 
between the biomolecule and the electrode surface is obtainable but only if there is 
extremely short distances between the redox site within the protein and the electrode 
surface (Armstrong et al., 1988). For large proteins, the redox site may be buried deep 
within the protein and may not be accessible. A mediator is a low molecular weight 
redox couple, which can shuttle electrons from the redox centre of the enzyme to the
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surface of the sensing electrode. The general reaction scheme for the bioreaction and 
electron transfer is;
glucose + GOD(ox) —> gluconolactone + GOD(red)
GOD (red) + 2Fecp2R+ —^ GOD (ox) + 2Fecp2R + 2H+
2Fecp2R —^ 2Fecp2R+ + 2e —> electrode current
The enzyme glucose oxidase, GOD, is co-immobilised with the mediator, Fecp2R+, on 
the surface of the amperometric electrode. On converting the substrate glucose to its 
product, gluconolactone, the enzymes prosthetic group, FAD, is reduced to FADH2. 
Normally, the enzyme would be reoxidised by molecular oxygen present in the sample, 
but in this case, the mediator accepts the electrons, to reoxidise the enzyme. The 
mediator itself is reoxidised by surrendering the same electrons to the electrode surface, 
resulting in a faradic current, which is directly proportional to the concentration of 
glucose in the sample.
1.2.1.2 Whole cell and tissue-based systems
One of the principle problems associated with enzyme-based biosensors is stability. 
Many enzymes are extremely sensitive to pH and temperature, particularly in their 
purified form. The use of intact microbial or mammalian cells (tissue slices), rather than 
purified proteins, offers many advantages (Scheller and Schubert, 1992). Whole cells are 
sources of undamaged stable enzymes in their natural, fully optimised environment, and 
are inexpensive when compared to purified enzymes. Complex catalytic reactions which 
are difficult or impossible to reproduce outside the cell with purified enzymes, can be 
exploited in whole cell systems, but conversely the response may not be specific due to 
the plethora of enzymatic pathways present. The effect of an analyte on the overall 
metabolism (inhibition of growth, cell viability, substrate uptake, respiration) of the cell 
can also be determined (Karube and Nakanishi, 1994). Whole cell biosensors do have 
the disadvantage of high diffusional resistance of the cell, in that the substrate must 
diffuse in and the product out of the cell, and must then diffuse to the transducer surface 
before it can be detected. This effectively increases the response time of the sensor. 
Transducers used to create biosensors based on microbial reactions include 
potentiometric systems (ion-selective electrodes, p 0 2-, pC02- and pNH3-electrodes), 
thermistors, photometers and piezoelectric membranes. Oxygen-sensing electrodes have 
been most commonly used, due to the large number of sensing systems based on the
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metabolic activity of the microorganism. Increases in respiratory activity are normally 
caused by the assimilation of substrates (analytes) and is recorded as a decrease in 0 2 
tension.
The biochemical oxygen demand (BOD), is one of the most widely used and standard 
tests for the measurement of organic pollution in water. The main drawback of 
conventional BOD measurement is that it requires a five day incubation period. A rapid 
and more reproducible method is therefore required for measuring BOD. Biosensors 
employing microorganisms have been described for measuring BOD (Karube and 
Nakanishi, 1994). One example was reported by Tan et al. (1993). Their sensor 
consisted of a membrane containing the immobilised microorganisms, Bacillus subtilis 
and Bacillus lichenformis, to effect the biooxidation process, and an electrochemical 
oxygen probe. The selectivity of these microorganisms is low in that they have high 
biooxidation activity for a wide range of organics. The ability of the mixed microbial 
culture to biodegrade organics resulting in the consumption of oxygen due to microbial 
respiration, was measured by the Clark oxygen electrode (Clark and Lyons, 1962). This 
biosensor could indicate the level of pollution from the BOD in 15-30 seconds with a 
baseline recovery time of 4 minutes, using initial rate measurements, compared to the 
conventional methods which takes up to five days.
A "BOD-module" produced by Medigen (Prufergate-Werk Medigen GmBH, Germany), 
measures BOD in the range 2-22 mg/L in a response time of 50 seconds. Each 
membrane of immobilised microorganisms is viable for 2,000 or more assays, since the ■ 
biocatalytic activity can be replenished simply by placing the electrode in nutrient media 
(Dennison and Turner, 1995). New cells grow in situ. However, due to the build up of 
dead cells, the sensor eventually must be discarded.
Whole mammalian tissue slices or cells offer similar advantages to those provided by 
microbial systems (Wijesuriya and Rechnitz, 1993). Tissue slices can easily be 
immobilised to transducer surfaces by simple mechanical fixation using a semi­
permeable membrane or nylon net. They can be additionally crosslinked for mechanical 
stability. Tissue slices and purified enzymes can be co-immobilised thereby increasing 
the diversity of such biosensors.
An example of a tissue-based biosensor was reported by Xiuli et al. (1992). Rabbit 
thymus tissue contains a high concentration of adenosine deaminase which catalyses the 
release of NH3 from adenosine, and therefore can be employed for the quantitation of 
adenosine in body fluid samples. Xiuli et al. (1992), immobilised a slice of rabbit
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thymus tissue on a monofilament nylon mesh with glutaraldehyde, which was in contact 
with a NH3-gas sensing electrode. This sensor yielded an excellent electrode response 
for the quantitation of adenosine in body fluid samples, without sample processing. The 
sensor also had a longer lifetime than earlier biosensors, with the additional advantages 
of simplicity, lower cost and time saving.
Mammalian cells cultured in vitro can be used as the biological sensing element. For 
example, Nakamura et al. (1993), developed a rapid detection system for allergic 
reaction using rat basophilic leukemia (RBL-1) cells as the biological element and cyclic 
voltammetry as the transducing mechanism. The cultured cells were immobilised to a 
membrane by filtration. When DNP was added to anti-DNP IgE sensitised RBL-1 cells, 
it triggered them to secrete serotonin and histamine, which participate in a variety of 
acute allergic and inflammatory reactions. Serotonin present in the cell is 
electrochemically oxidised and measured by cyclic voltammetric techniques. The peak 
current increased linearly with increasing allergen (DNP) concentration within 20 
minutes. Such a sensor would be impossible without the use of whole living cells. 
Plant tissues are also effective catalysts as a result of the enzymatic pathways they 
possess, and are inexpensive compared to mammalian cell systems. Banana pulp tissue 
immobilised on the gas permeable membrane of a Clark-type oxygen electrode was used 
to measure dopamine, via the enzyme polyphenol oxidase (Sidwell and Rechnitz, 1985).
1.2.2 Affinity biomolecules used in biosensors
1.2.2.1 Antibodies and antigens as the biological component
Many biospecific recognition systems and interactions take place reversibly and without 
analyte conversion, i.e. in a non-destructive fashion. Antibody-antigen interactions are 
well documented (Jefferis and Deverill, 1991). The advantage of the immunoassay as 
an analytical system is that antibodies can be prepared against almost any molecule, 
whether naturally occurring or not, thus increasing the diversity of immunosensor 
applications. With the advent of the combinatorial phage display system, the entire 
immunological repertoire of an animal can be cloned (Barbas et al., 1991). That is to 
say that the all the possible combinations of antibodies produced by the body can be 
generated. Analytes as varied as food constituents, microbes, enzymes, drugs, hormones, 
tumour associated antigens, pesticides, and other pollutants can be measured employing 
antibody-based techniques (O’Kennedy, 1989). Some immunoassay formats are detailed 
in chapter 3.
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Since the physicochemical changes caused by immunoreactions are very slight, in many 
cases reporter molecules coupled to the antibody or antigen may be required depending 
on the transducing mechanism. A major drawback of immunosensing is reusability. 
Antibody-antigen dissociation kinetics are very slow and repeated regeneration by 
dissociation of the antibody-antigen binding, often results in denaturation of the 
immunoreactants (Miller and Anderson, 1989). Low affinity monoclonal antibodies may 
be selected, but this may compromise the sensitivity of the sensor.
Examples of antibody-based biosensors will be discussed in section 1.4, under the 
various transducing principles.
1.2.2.2 Receptors as the biological component
Some affinity-based sensors are based on cell receptors. Mammalian cells utilise 
receptors for the transmission of signals across the lipid bilayer membrane which 
separates intracellular and extracellular regions of the cell. In vivo, the binding of a 
ligand to its receptor, initiates a particular physiological response in the receptor-bearing 
organism, through activation or blockage of a series of biochemical reactions (Straub 
and Bolis, 1978). Such events include hormone regulation, viral replication and neural 
transmission. Ligands can be as varied as neurotransmitters, amino acids, steroid 
hormones, metal ions, hormones, toxins, etc (Taylor and Kennewell, 1993).
An example of such a ligand-receptor interaction is the binding of acetylcholine, a 
neurotransmitter, to its receptor in the sensitive ending of postsynaptic neurons, , 
stimulating them to transmit an impulse. In their isolated form, receptors can be used 
in biosensor devices, based on the specific recognition of the ligand for its receptor, in 
a similar manner to immunological reactions. Purified receptors, however, generally have 
stability problems, and are often labile at room temperature (Leech, 1994). Some 
receptors such as cholinergic receptors require the presence of phospholipids in order 
to function, and so must be reconstituted using phospholipid bilayers (Taylor, 1991) for 
use in biosensors.
An alternative approach, is to use the receptors in their natural form, as intact tissue 
slices or in isolated whole cells. Such intact biological systems, allow the ligand-receptor 
binding reaction to be transduced directly by the biological component. In contrast to 
most biosensors, in which only the molecular recognition element is biological, the 
antennular receptrode of the blue crab, uses biological components as both molecular 
recognition elements and transducers (Buch and Rechnitz, 1989). A disadvantage of such
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systems is that tissue extracts may contain receptors with other binding specificities, 
thereby reducing selectivity. Belli and Rechnitz (1986), used the antennular structures 
from blue crabs which were sensitive to amino acids in solution and the concentration 
of the amino acids were determined by the frequency of the potential spikes on an 
oscilloscope. Other examples of receptor-based biosensors, are discussed in section 1.4.
1.2.2.3 DNA as the biological component
DNA is a double helix consisting of antiparallel strands in which the nucleotide units 
are linked by phosphodiester bonds. The backbone provides the exterior and purine and 
pyrimidine bases are stacked in the interior in pairs, in which A is complementary to T 
while G is complementary to C. The strands separate and use complementary base 
pairing to assemble daughter strands in a semi-conservative fashion.
The blue print for every cell is encoded in its DNA in the form of a series of base 
sequences. Interchain binding in nucleic acids is extremely specific and recognition of 
these sequences is of fundamental importance in the control, reading and detection of 
this information (Lewin, 1990). The property of base complementarity makes possible 
the construction of DNA probes, which can be used for analytical techniques. If the 
sequence of bases comprising a certain part of the DNA is known, then the 
complementary sequence can be synthesised. This sequence is called a DNA probe. 
There is increasing awareness of the importance of genetic factors in diseases. DNA can 
be used as the sensing molecule in biosensors in the detection of, for example, mutations 
causing a particular disease. Target sequences for a particular gene (or mutated gene), 
can be synthesised by molecular biological (polymerase chain reaction) or chemical 
methods, thus supplying the probe. The probe can then be labelled with a reporter group 
to facilitate transduction.
One example of a DNA-based biosensor was described by Fawcett (1987). The 
piezoelectric DNA-based biosensor measured the DNA of the pathogen Salmonella 
typhimurium in food. No reporter molecule was required in this case as the binding 
reaction is transduced as a mass change, which alters the resonance frequency of the 
crystal.
A fibre-optic evanescent wave biosensor based on DNA intercalation was described by 
Pandey and Weetall (1995). Organic carcinogens, certain toxins and anti-tumour drugs 
intercalate with DNA. Double-stranded DNA was immobilised to the fibre surface and 
fluorescent ethidium bromide allowed to intercalate with the DNA, resulting in a
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fluorescent signal. There was a decrease in the response of the sensor when other DNA 
intercalators were reacted with the fibre probe, as they compete for the intercalation sites 
on the dsDNA, displacing ethidium bromide.
1.2.2.4 Other biological binding molecules as the biological component
There is also a class of binding proteins which are not strictly biological receptors. 
Binding pairs such as avidin-biotin (Wilchek and Bayer, 1988), protein A-IgG (Surolia 
et al., 1982), yeast mannan-concanavalin A (Janata, 1975), represent such interactions. 
These binding pairs of molecules have limited but useful interactions. They are more 
robust than biological receptors as regards immobilisation and therefore adsorption and 
covalent binding are usually employed (Taylor, 1991).
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1.3 Immobilisation of biomolecules for biosensors
The biosensing surface of biosensors is made up of enzymes, antibodies, antigens, 
microorganisms, mammalian cells, tissues or receptors immobilised on to a solid surface. 
There are a number of established procedures for immobilisation (Figure 1.3), which 
include;
a) physical adsorption on to a solid surface
b) use of cross-linking reagents,
c) entrapment using a gel or polymer,
d) use of membranes to retain the biomolecule close to the electrode surface,
e) exploitation of biomolecular interactions, e.g. avidin/biotin, protein A/Fc domain 
of class G immunoglobulins,
f) covalent attachment.
Figure 1.3: Methods of biomolecule immobilisation for biosensors
The choice of immobilisation method, depends on the biocomponent to be immobilised, 
the nature of the solid surface and the transducing mechanism. Whatever procedure is 
used, it must take into account the following factors;
11
a) the activity of the biomolecule must be preserved and the specificity must not 
be reduced,
b) the stability of the biomolecule should be maintained or preferably increased. 
This is important in relation to the stability of the sensor system for use, reuse 
and storage,
c) steps should be taken to ensure that no non-specific binding can occur as a 
consequence of the immobilisation procedure,
d) ideally, the methods used should be easy to perform and be highly reproducible, 
to facilitate mass production of the sensor device,
e) the immobilisation procedure should not involve extreme conditions of pH, 
temperature, salt concentration etc., which may adversely effect the activity of 
the immobilised biomolecule.
It should be noted, however, that many biomolecules, given the correct conditions, can 
be subjected to relatively high temperatures, for short periods of time. By using 
biomolecules from thermophilic organisms, or by using chemical and genetic 
modification, it should be feasible to produce ‘designer’ molecules capable of being 
reactive, under defined conditions (Ô Fâgâin and O ’Kennedy, 1991). This area is now 
under investigation.
Some of the immobilisation methods for biosensing devices and the advantages and 
disadvantages of each are outlined in Table 1.1.
Physical adsorption: Immobilisation via physical attraction or adsorption is not a 
reproducible and reliable method of biomolecule attachment to sensing surfaces because 
of the problems associated with leaching during long term storage. Plastic, glass and 
cellulose have been known to adsorb proteins, via binding forces such as hydrogen 
bonds, van der Waals forces, salt linkages and hydrophobic interactions. With the 
exception of hydrophobic interactions, such forces are not very stable and can easily be 
disrupted by changes in pH, temperature and ionic strength. Excess protein can also 
form multiple layers during adsorption. These layers are not very stable and easily 
desorb. The obvious advantage of adsorption is its simplicity and gentleness, although 
some loss in activity is observed. However, in the case of antigens, care should be taken 
to ensure that the antigenic binding sites are not denatured in any way.
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Use o f crosslinking reagents: Stabilisation of adsorbed proteins can be achieved by using 
bifunctional reagents such as glutaraldehyde. The proteins are crosslinked to each other, 
or inert proteins, such as bovine serum albumin, can be mixed with the desired protein 
prior to crosslinking. This adds greater stability to the immobilised protein although 
inevitably, some inactivation does occur, as the crosslinking chemical may interact with 
the active site of the biomolecule. With respect to immunosensors, the antibody binding 
site may be blocked or incorrectly orientated, so as not to favour antibody-antigen 
binding. Membranes can be cast on electrode surfaces using this method.
Entrapment: Immobilisation of biomolecules by physical entrapment in gel matrices such 
as polyacrylamide or gelatin, is a mild method of immobilisation. Basically, the polymer 
is allowed to crosslink in the presence of the substance to be immobilised. The porosity 
or degree of crosslinking can be controlled. Evidence has shown that polyacrylamide 
gels give the best retention of enzyme activity. Care should be taken however that the 
crosslinks retain the molecule, and that leaching does not occur. Microorganisms and 
antibodies are often immobilised by physical entrapment.
Use o f membranes to retain the biomolecule close to the transducer surface: Membranes 
of various porosities can be used to retain molecules close to transducer surfaces, 
without the need for actual immobilisation. The gentle method of retention can, 
however, lead to problems such as diffusional resistance. ‘Selective’ membranes can also 
be employed, in conjunction with potentiometric electrodes. Ion-selective membranes, 
such as an NH4+-selective membrane, has been employed in conjunction with the 
enzyme urease, for the measurement of urea (Petersson, 1988).
Exploitation o f biological interactions: The ability of protein A to bind to the Fc portion 
of class G antibodies has been exploited for antibody immobilisation. Such an 
interaction allows the antibody to be orientated so as to favour antibody-antigen 
interactions. The protein A molecule must first be immobilised by typically covalent 
methods, however. Other biological interaction immobilisation systems which have been 
exploited include the avidin-biotin system. Such systems, however, are limited by 
problems due to leaching and expense. The cost of purified preparations of these binding 
molecules is very high.
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Covalent attachment: Chemical coupling of biomolecules may provide stable biosensing 
surfaces which are resistant (in terms of leaching), to wide ranges of pH, temperature 
and ions. Covalent binding can result in some loss in bioactivity. Three types of supports 
have been used: inorganics, natural polymers, and synthetic polymers. The binding 
process must occur under conditions which do not denature the biomolecule. Often, the 
carrier must be activated in some way (e.g. silanisation), and the introduced functional 
groups are then utilised for chemical coupling either directly to the biological molecule 
or via a crosslinking reagent such as glutaraldehyde. Alternatively, nylon nets are 
activated by methylation, and treated with lysine, before the required biomolecule is 
covalently linked to the net. The nylon net disc is then simply fixed onto the sensor 
surface. The biological component of amperometric biosensors is often immobilised 
covalently for efficient transfer of redox species to the electrode surface.
The area of enzyme, antibody and receptor immobilisation for biosensors is discussed 
in excellent reviews by Guilbault et al. (1991) and Taylor (1991).
1.3.1 Immobilisation of receptor molecules
Receptor-based biosensors provide a unique capability for diagnostics and detection 
enabling the detection of an unknown analyte based on its biological activity. The 
immobilisation of cell-membrane receptor proteins requires special consideration. Studies 
have shown that if purified receptor proteins (such as adrenergic, cholinergic and opiate 
receptors), are reconstituted in lipid layers, such as bilayer lipid membranes, 
phospholipid vesicles and liposomes, many of them retain their functionality (Taylor, 
1991). These lipid layers have added stabilisers, such as membrane structural 
components and detergents. Gotoh et al. (1987), showed that the response of an ISFET 
sensor was increased threefold, when the acetylcholine receptor was reconstituted in a 
lipid membrane compared to when it was immobilised directly to the transducer surface. 
A practical biosensor employing lipid membranes is unlikely, however, due to the poor 
stability of the lipid membranes.
Studies are continuing into other methods of stabilising receptor proteins using non-lipid 
layer immobilisation technology. Albumin-based membranes stabilised with detergents, 
lipids and anti-oxidants, have been shown to stabilise acetylcholine receptors with 
complete retention of biological activity, for at least 6 months, whereas non-immobilised 
receptors lost all activity after 15 days storage (Taylor, 1988).
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Method Advantages Disadvantages Ref.
Entrapment into/by membranes 
and films coating or associated 
with a transducer
Non-chemical treatment; mild 
reaction conditions
Leakage possible; 
membrane/film may limit 
analyte diffusion
Aubeck et al. 
(1993)
Entrapment into a lipid bilayer 
or a liposome coating or 
associated with a transducer
Non-chemical treatment; mild 
reaction conditions; mimics 
natural membranes
Leakage possible; very 
susceptible to changes in pH, 
temperature and ionic 
conditions
Gotoh el al. 
(1987)
Adsorption directly to the 
transducer or a film/membrane 
on the transducer
Non-chemical treatment; mild 
reaction conditions
Leakage possible; very 
susceptible to changes in pH, 
temperature and ionic 
conditions
Rogers el al, 
(1991)
Biological binding to a specific 
molecule already immobilised 
on the transducer
Strong, reversible, non-covalent 
binding; mild reaction 
conditions
Leakage possible; binding site 
for matrix must be different 
from the analyte site
Colapicchioni 
el al. (1991)
Cross-linking into 
membranes/films
Mild reaction conditions; high 
analyte permeability; can mimic 
natural membranes
Possible loss of activity Boitieux el al. 
(1989)
Covalent binding directly to 
the transducer
Strong bond resistant to large 
changes in pH, ionic strength 
and temperature
Possible loss of activity; 
transducer recycling unlikely
Shriver-Lake el 
al. (1993)
Covalent binding to a 
membrane/film on the 
transducer
Strong bond resistant to 
changes in pH, ionic strength 
and temperature; transducer 
may be recycled
Possible loss of activity; 
stability may depend on 
membrane/film-transducer bond
Minunni and 
Mascini (1993)
Table 1.1: Biomolecule immobilisation methods for biosensors (Adapted from Taylor, 
1991).
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1.4 Transduction
In a biosensor, the function of the transducer is to convert the physicochemical change 
associated with the specific and reversible interaction of the biologically active material 
with the analyte, into an electrical signal, which can be further amplified, processed and 
displayed. The physiochemical change may be the production of ions, gases, electrons 
or a change in mass, light or heat. The three main types of transducers, electrochemical, 
optical and piezoelectric, will be discussed here, with reference to affinity-based 
biosensors.
1.4.1 Electrochemical systems
1.4.1.1 Amperometric affinity-based biosensors
Amperometric sensors operate on the principle of applying a constant potential between 
a working and auxiliary electrode in a test environment, which causes non-spontaneous 
electron transfer to occur. The potential chosen can selectively determine which species 
are made electroactive. A steady state current results from the electron transfer reaction 
which is directly and linearly proportional to the concentration of the electroactive 
species. A reference electrode of fixed potential is also required.
Amperometric biosensors are generally enzyme electrodes. Oxidoreductases, which 
catalyse oxidation and reduction reactions by the transfer of hydrogens or electrons, are 
the most commonly used in amperometric biosensors. Affinity-based sensors are 
generally based on analytical systems involving enzyme (usually of the oxidoreductase 
class) labelling of one of the binding partners, e.g. antibody or antigen. Amperometric 
biosensors are very prone to protein fouling of the surface at the electrode and hence the 
biological molecules are generally immobilised on selectively permeable membranes 
(Vadgama and Crump, 1992). These membranes prevent electrode fouling, control mass 
transport of the substrate and retain the bioactive layer.
An example of an affinity-based amperometric biosensor employing an enzyme label for 
indirect transduction of the binding event was described by Manning et al. (1994). 
The amperometric immunosensor was based on the catalytic effect of horseradish 
peroxidase on the reaction between hydrogen peroxide and hydroquinone.
H20 2 + HQ —> 2HzO + BQ
BQ + 2H+ + 2e —^ HQ (applied voltage -0.03V)
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The antigen inhibition competitive assay for factor VIII (a glycoprotein that is 
quantitated in the diagnosis of haemophilia), was performed in a batch mode of 
operation. Factor VIII was immobilised on the surface of a glassy carbon electrode, and 
it competed with test sample factor VIII for the HRP-labelled anti-factor VIII antibody. 
Peroxide and hydroquinone (HQ), were then added and the product, benzoquinone (BQ), 
was reduced electrochemically. The resulting current was measured.
The electrode probe was used only once for each sample reading and so required 
polishing, between each immobilisation. Heut et al. (1993), described a method for 
regenerating the electrode surface electrochemically by anodisation at 2.2 V vs SCE. 
This eliminates the need for polishing, thereby reducing the time between sample 
readings.
Boitieux et al. (1989), devised a novel method for dissociating immunocomplexes from 
the electrode surface. A competitive inhibitor of 3-galactosidase ([3-gal) was immobilised 
on the electrode surface via a membrane. Catalase-labelled anti-a-fetoprotein (AFP) 
antibody and P-galatosidase-labelled anti-AFP antibody (different epitope) were allowed 
to react with the analyte (AFP) in solution, and then allowed to bind to the electrode 
surface ((3-gal binds to its immobilised inhibitor). The production of 0 2 by enzymatic 
reaction involving catalase was measured at a the Clark-type electrode. The sensor was 
easily regenerated with borate buffer, pH 10, which dissociates the inhibitor - (3-gal 
complex in 2 minutes, ready for the next immunoassay.
Electrochemical detection of an immunoassay product does not always occur at the 
electrode surface. Some authors employed electrochemical techniques to measure the 
analyte after eluting from an immunoreactor. Creatine kinase (MB isoenzyme) was 
removed from serum by passing it through a bead column of immobilised antibody. The 
analyte was then eluted from the column, injected into the electrochemical cell and a 
product of its enzymatic reaction (NADH), detected electrochemically at +0.36 V 
(Toyoda et al., 1985). The sensor could determined CK-MB concentrations in the range 
20-250 U/L. Yu et al. (1994), performed a heterogenous sandwich ELISA for thyroid 
stimulating hormone, on antibody-immobilised beads, and detected the product of the 
enzyme reaction, electrochemically. Alkaline phosphatase catalysed the conversion of 
p-aminophenyl phosphate to p-aminophenyl, which was injected into the electrochemical 
cell and detected at +325 mV using a glassy carbon electrode (vs Ag/AgCl).
All the amperometric immunosensors described so far cannot be considered true sensors, 
in that following analyte addition to the system, further user-mediated steps need to be
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performed before signal readout. The following homogenous assays eliminate the 
requirement for such additional steps. A homogenous enzyme multiplied immunoassay 
technique (EMIT) for the drug theophylline was adapted by Athey et al. (1993), to 
produce a rapid amperometric immunoassay, requiring only 50 pi of whole blood. 
Glucose-6-phosphate dehydrogenase (G6PDH)-labelled theophylline and theophylline (in 
blood sample) competed for anti-theophylline antibody (in assay buffer). On binding 
with the antibody, the activity of the enzyme is blocked, and therefore, the activity of 
the unbound enzyme is directly proportional to the concentration of theophylline in the 
blood. NADH, generated by the enzymatic reaction was detected between 12-16 minutes 
after the reaction was initiated, at +150 mV (vs Ag/AgCl), using platinised activated 
carbon electrodes. A novel homogenous assay was developed which required a 
photochemical cell to detect electrochemically (anodic oxidation) generated 
luminescence. Luminol-labelled antibodies were mixed with the antigen in solution, 
followed by addition of hydrogen peroxide. The luminescence of luminol is greatly 
decreased on antibody binding to its antigen, due to steric hindrance of 
electrochemiluminescence. The unbound luminol was oxidised above +0.4 V (vs 
Ag/AgCl), and the resulting luminescence detected optically (Tanaka et al., 1993). The 
signal was inversely proportional to antigen concentration.
A electrochemical DNA sensor for gene detection is being studied by Hasimoto et al. 
(1994). The DNA intercalator, daunomycin, is electroactive when oxidised at a low 
potential, 446 mV, and gives a high current density of 6.5 jiA/cm2. The intercalator 
binds to double stranded DNA (hybridised), but not single stranded DNA (unhybridised),
and so can electrochemically distinguish between the two. The sensor may find 
applications for detecting genes with implications in pathological disorders.
1.4.1.2 Potentiometric affinity-based biosensors
Potentiometric biosensors operate on the principle of measuring the charge density 
accumulation, at the sensing electrode, brought about by some selective process (such 
as an enzyme reaction), compared with a reference electrode, under conditions of zero 
current flow (Hall, 1990). The sensors obey the Nernst equation relating electrical 
potential to the log of the concentration of a known species in solution;
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E=E°+2 . 303 ( — ) l o g a i
where E° = standard cell potential 
R = gas constant 
T = temperature 
n = charge on the primary ion 
F = Faraday constant 
aj = activity of the primary target ion 
By far the most common type of this kind of transducer are ion-selective or gas-selective 
enzyme electrodes. Ion-selective membranes, composed of metal salts or polymer 
membranes containing ion-exchangers or neutral carriers, are fixed on the sensing 
electrode (Solsky, 1990). The enzyme is immobilised on, or is physically retained close 
to the selectively permeable membrane. The conversion of a substrate to a product by 
the enzymatic reaction, changes the activity of an ion or gas for which the membrane 
is selective. Gas-selective electrodes represent a development on ion-selective electrodes. 
The gas itself is not measured directly but via a change in some other parameter, such 
as pH, due to the production of the gas, e.g. COz. The majority of cell and tissue-based 
sensors are based on ion-selective electrodes (Solsky, 1990).
Affinity-based potentiometric sensors are generally based on labelled systems, such as 
enzyme-linked immunosorbent assays. Fonong and Rechnitz (1984), reported a 
homogenous immunosensor method which utilises a C 02 gas-sensing membrane 
electrode. Human IgG (antigen) was mixed with chloroperoxidase (CI-POD)-labelled 
anti-human IgG. CI-POD catalyses the bromination of p-ketoadipic acid, causing the 
release of C 0 2. On binding to the antibody, the antigen blocks the activity of the 
enzyme. The gas was detected by the C 02-selective electrode, and the concentration of 
the gas produced is inversely proportional to the antigen concentration. The sensitivity 
of the sensor lay in the pg/ml range.
A new approach to the construction of potentiometric immunosensors was taken by 
Ghindilis et al. (1992). Their immunosensor for insulin determination employed the
enzyme label, laccase. Laccase is able to catalyse the electroreduction of oxygen by 
transferring electrons directly from a carbon-based electrode surface to the oxygen 
molecule via the active site of the enzyme as follows;
O z +  4 H + +  4 e  — >  2 H 20
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An antigen inhibition competitive assay for insulin was set up by immobilising insulin 
to the electrode surface. The electrode was composed of the water insoluble polymer 
polyethylenimine. This material was suitable because it binds carbon black and prevents 
non-specific adsorption of protein. Sample insulin competed with the immobilised 
insulin for laccase-labelled anti-insulin antibody. On binding to the immobilised insulin, 
in a manner inversely proportional to insulin concentration, the labelled antibody is close 
enough to the electrode surface to catalyse the reduction of oxygen. This results in a 
rapid increase in the electrode potential, the rate of this increase being indirectly 
proportional to the concentration of insulin in solution. No reaction substrates need to 
be added to this system since the substrate reagents involved are atmospheric oxygen 
and electrons.
Catalytic antibodies are antibodies that catalyse chemical reactions and do so by 
providing a microenvironment in which the reaction can proceed (the antigen-combining 
site), which lowers the potential energy of the transition state for the reaction. A novel 
potentiometric affinity sensor employing catalytic antibodies as the molecular 
recognition element was described by Blackburn et al. (1990). The catalytic antibody 
was raised against the transition state analogue of the hydrolysis reaction of phenyl 
acetate to acidic products. The resulting decrease in pH was detected by an underlying 
potentiometric pH electrode. The advantage of using catalytic antibodies is that the 
antigen rapidly dissociates from the active site of the antibody and so the sensor is 
regenerable.
Initial attempts at the direct, label free, potentiometric detection of analyte binding to 
an affinity surface were not very successful, due to interferences by salt ions and non­
specific binding. Antibodies and some antigens are proteins, and in aqueous solution 
proteins have a net electrical charge, the polarity and magnitude of which depends on 
the isoelectric point and on the ionic composition of the solution. When an antibody and 
antigen bind the net electrical charge of the complex will be different than the electrical 
charge of the individual proteins. Janata (1975), tested this theory using Concanavalin 
A (Con A), a molecule which binds strongly to the carbohydrate, yeast mannan. Con A 
was covalently attached to the surface of a thin dense poly(vinylchloride) membrane 
deposited on a platinum wire. When the Con A ‘immunoelectrode’ was measured 
against a Con A electrode with blocked binding sites, there was a dependence of steady 
state potential difference on the concentration of yeast mannan. The signal produced 
however was extremely small. Similar experiments with human chorionic gonadotropin
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(hCG) and anti-hCG were carried out by Yamamoto et al. (1980). The sensor, however, 
did not work with real samples (urine) as it was subject to interference from urine 
components.
Keating et al. (1984), attempted to amplify the response of direct antibody-antigen 
binding in a potentiometric ionophore-modulation immunoassay (PIMIA). Ionophores 
are neutral carrier ligands which complex metal ions, e.g. the antibiotic valinomycin is 
selective for K+ ions. The principle of the PIMIA described was as follows. Ionophore- 
labelled digoxin was incorporated into a plastic support membrane and this membrane 
was mounted in the sensing tip of a conventional potentiometric membrane electrode. 
The electrode was exposed to a constant activity of marker ion (K+), which bound to the 
ionophore. Charge separation occurred at the interface due to the selectivity of the
ionophore, to produce a stable and reproducible background current. When anti-digoxin
antibodies were added to the background electrolyte, a potential change proportional to 
the antibody concentration was produced. The addition of anti-digoxin antibodies always 
produces a potential change in the direction of increasing apparent potassium ion 
activity. The direct binding sensor could be used with a competitive immunoassay 
format.
1.4.2 Solid state transducers
1.4.2.1 Field effect transistors
Field effect transistors (FETs) operate on the same principle as potentiometric sensors, ■ 
measuring charge accumulation. Ion-selective field effect transistors are essentially 
insulated gate FETs, in which the usual gate metal electrode has been replaced by a 
suitable selective membrane and a reference electrode (Figure 1.4).
A semiconductor is characterised by the limited amount of the free charge carriers. The 
total concentration of free carriers can be increased by impurity doping. Taking a silicon 
semiconductor, if there is an excess of positive mobile charges, the silicon is p-type. If 
the silicon has an excess of negative mobile charges (electrons), the silicon is n-type. 
The mobile free charged carriers are affected by electric fields, making it possible to 
control the concentration and behaviour of these charge carriers by external means. A 
FET is composed of a p-type (positive) silicon substrate into which two n-type 
(negative) regions, the source and the drain have been embedded.
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Figure 1.4: Ion-selective Field Effect Transistor
In a normal FET, when a voltage is applied between the gate electrode and the p-type 
silicon substrate, electrons are attracted or repelled on the surface of the substrate under 
the gate. When this voltage is of a certain magnitude, the p-type substrate undergoes 
inversion to n-type. This results in a conducting channel developing between the drain 
and the source n-type regions, and a drain current flows. This drain current is dependent 
on the electrical resistance of the inversion layer, which in turn depends on the 
concentration of the ionic species present.
For biosensors based on ISFETs, an ion-selective membrane (e.g. H+-, Na+- or K+- 
selective) is placed over the gate insulator of the FET and the biologically active 
species, is immobilised on this. The sensor is then exposed to the analyte solution and 
any strongly binding species or catalytic reaction which alters the charge density at the 
gate changes the drain current. Development of FETs which can detect antibody-antigen 
interactions directly by direct reading of interfacial charge density changes have been 
mostly unsuccessful. Poor charge variation associated with antibody-antigen interactions, 
non-specific responses due to interfering ions and the requirement for very high charge 
transfer resistance to maintain the solution-membrane interface polarised (Hall, 1990), 
have attributed to this failure. Consequently, most affinity-based FET systems involve 
enzyme-labelled assays in conjunction with ISFETs.
A IMMUNOFET device was described by Colapicchioni et al. (1991), employing 
glucose oxidase-labelled antibody assays. The antibody was immobilised onto the ISFET 
gate surface via a protein A membrane. Two-site sandwich (human IgG) and competitive
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(herbicide atrazine) immunoassays were performed, and the H+ ions produced during the 
enzymatic reaction detected on the ion-selective electrode.
The IMMUNOFET described above requires that the antibody be immobilised via a 
membrane to the FET surface. This creates problems in terms of the reusability of the 
sensor. A novel ELISA for the determination of PCR (polymerase chain reaction) 
products was devised by Tsuruta et al. (1994). The system did not require any 
immobilisation to the FET. The primers of the PCR reaction were labelled with the 
haptens, digoxigenin and biotin, resulting in double stranded PCR products (DNA), with 
the hapten labels at both ends. The immunoassay was performed on the inside of a 
pipette tip, which was coated with anti-digoxigenin antibody, and required only lpl of 
PCR product. When the PCR products were bound to the antibody, avidin-labelled 
urease was introduced, which bound to the biotinylated DNA. The activity of the 
enzyme was determined by dipping the pipette tip, into the pH measuring cell of a pH- 
FET, containing urea solution. The system was found to be extremely sensitive, in that 
10 attomoles of labelled DNA in 1 pi of sample was detectable.
Gotoh et al. (1987), described an acetylcholine sensor composed of an ISFET and an 
acetylcholine receptor. The acetylcholine receptor protein is often employed in 
biosensing devices for the determination of cholinergic neurotransmitters. In its isolated 
form, the AChR is capable of identifying and binding to the neurotransmitters purely on 
the basis of structure. However, if the receptor is reconstituted in a lipid bilayer, the 
physiological activity of the receptor protein is retained and the binding event results in 
an influx of ions. The gate insulator was composed of silicon nitride, which is very 
sensitive to many different ions and surface charges. The system was composed of two 
modified ISFETs, one containing the acetylcholine receptor and the other containing a 
blank membrane. When acetylcholine was injected over the ISFET with the immobilised 
isolated receptor, the differential gate output voltage, shifted to the positive side due to 
the positive charge of acetylcholine. The initial rate of this shift in potential was found 
to be linearly proportional to the logarithmic value of the acetylcholine concentration, 
in the range 0.1-10.0 pM. When the receptor protein was immobilised in a lipid 
membrane, the response was amplified 3-fold, due to the additional flux of positive 
sodium ions towards the ISFET gate surface, as a result of the physiological activity of 
the receptor.
23
1.4.2.2 The light-addressable potentiom etric sensor
The light-addressable potentiometric sensor (LAPS) is based on FET technology, and 
forms the basis of the microphysiometer (its manufactured version is called the 
Cytosensor) developed by Molecular Devices Corp., California. The theory behind LAPS 
is detailed in Me Connell et al. (1992). Essentially, the microphysiometer is an 
extremely sensitive pH meter (61mV per pH unit at 37°C), exploiting the H+ sensitivity 
of silicon nitride. The basis of operation is that an appropriate reverse bias potential is 
applied to a silicon plate, which has its surface nitride layer exposed to the solution 
(analyte matrix). A voltage gradient is formed immediately below the insulator. This 
voltage gradient causes the separation of hole-electron pairs, which have been formed 
by the absorption of light from the LED (Figure 1.5). An AC-coupled photocurrent 
results and flows in an external circuit. The amplitude of this photocurrent is a function 
of the solution pH.
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Figure 1.5: Schematic diagram of a light-addressable potentiometric sensor (Me 
Connell et al., 1992)
Living cells acidify their environments due to the acidic products of energy metabolism. 
The Cytosensor allows observation of functional ligand-receptor interactions by the 
monitoring of cellular metabolic rates, which is transduced as a decrease in pH.The type 
of response observed, both in terms of magnitude and rate, is dependent on a variety of 
factors such as cell type, agonist/antagonist concentration and on which physiological 
systems are activated. The cytosensor system was used to study the specificity of 5
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muscarinic agonists for 4 different muscarinic receptor subtypes (Mj-Mt)» which had 
been transfected separately into a Chinese Hamster Ovary (CHO) cell line (Davis et al., 
1993). The results obtained showed good agreement with traditional methods 
(phosphoinositol (PI) turnover and cAMP inhibition). In effect, the cytosensor allows 
bioassays to be performed, as a rapid single assay, even when the ligand-receptor 
interaction is coupled to second messenger pathways.
Colston et al. (1993), use an ELISA method for the detection of subnanogram quantities 
of the Mojave toxin (MoTX) with light addressable potentiometric detection. Biotin- 
labelled and fluorescein-labelled anti-MoTX antibodies formed a two-site sandwich 
immunocomplex with MoTX in solution, at 37°C for 45 minutes. The immunocomplexes 
were filtered onto the surface of a test-stick (streptavidin-labelled nitrocellulose paper), 
to which they bound via avidin-biotin interactions, and then reacted with urease-labelled 
anti-fluorescein antibodies, resulting in five-layer immuno-sandwich as shown in Figure 
1.6.
Figure 1.6: Five-layer sandwich immunocomplex for the quantitation of the Mojave 
toxin by LAPS (Robinett and Herber, 1994)
Each test-stick was inserted in the cytosensor and immunoconjugates were monitored 
via the hydrolysis of urea. A similar method for the quantitation of nanogram quantities 
of the recombinant tick anti-coagulant protein, was described by Robinett and Herber
(1994).
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1.4.3 Optical Detection
1.4.3.1 Fibre-optical systems
Biological interactions are often accompanied by changes in certain optical properties, 
which form the basis of optoelectronic affinity biosensors. Changes in light absorption/ 
fluorescenee/phosphorescence/bioluminescence in the bioaffinity layer, changes in the 
layer thickness or refractive index, reflective behaviour of the incident light and light 
scattering, are used to generate measurable optical signals related to biomolecule 
concentration.
Optical sensor systems based on glass fibre technology, offer a high potential for 
biotechnological analysis. Transduction via optical fibre techniques offer many distinct 
advantages over other methods of transduction, some of which are outlined in Table 1.2.
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Property Comments
Advantages no electrical interference /  
absence of electrical connectors
safer to use in certain 
environments e.g. in the 
presence of explosive vapours
no reference signal required simple design
thin, long, flexible and 
conducive to miniaturisation
suitable for use in vivo and in 
remote sensing (low loss fibres)
inexpensive production o f disposable 
sensors
can carry several wavelengths 
simultaneously
multi-analyte analysis
signal can be monitored 
dynamically
real-time monitoring
Disadvantages interference from ambient light need to create a dark 
environment
sample solution turbidity interference due to scattering
often reporter labels are required 
to transduce bioreactions
added complexity
long term stability of reporter 
labels
photobleaching
Table 1.2: Advantages and disadvantages of optical fibre-based biosensing techniques.
Optical fibre affinity biosensors can be categorised into two major classes, extrinsic and 
intrinsic sensors (Figure 1.7). An extrinsic fibre sensor uses the optical fibre purely as 
an optical signal carrier. Light from a suitable source is transmitted into the fibre and 
directed to the region where it interacts with the analyte directly or an intermediate 
chemical/ biochemical transducer element. This interaction results in the modulation of 
the light intensity. The modulated light is collected and transmitted by the same or 
different optical fibre to the detection system, carrying with it some chemical 
information.
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An intrinsic optical fibre sensor, on the other hand, is one in which the light is perturbed 
within the fibre by the parameter to be measured, and so the fibre itself is an integral 
part of the sensing device. Evanescent wave biosensors are an example of intrinsic 
sensors.
Figure 1.7: Schematic representation of extrinsic and intrinsic optical fibre sensors
1.4.3.1.1 Extrinsic fibre-optic affinity based biosensors
Optical fibres can be employed for extrinsic affinity-based biosensing, conveying light 
from the source to the sampling area, and from the sampling area to the light detection 
system. Alaire et al. (1990), described a regenerable immunochemical-based fibre optic 
sensor for the detection of the naturally highly fluorescent metabolite (BPT) of 
benzo[a]pyrene (BP). Its significance is derived from the fact that it is a bioindicator, 
found in urine, of an individuals exposure to the carcinogen BP. Monoclonal anti-BPT 
antibodies are retained behind a highly permeable, low cut-off membrane, at the distal 
tip of the fibre. The principle of operation is based on the diffusion of BPT, into the 
fibres reagent chamber, where it complexes with the antibody, thereby concentrating the 
BPT in the fibres viewing region. Readings could be made under equilibrium and non­
equilibrium conditions. The sensor was not reversible due to the high affinity antibody 
used for sensitive analysis, but could be regenerated by flushing out the old 
immunoreagents and injecting fresh immunoreagents into the sensor chamber.
Most immunoassays performed at the distal end of optical fibres, required the used of 
an indicator molecule or label, because the analytes themselves do not have optical
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properties which can be transduced effectively. Immunoassays can be performed via 
heterogenous or homogenous and competitive or non-competitive assay formats. A 
heterogenous competitive fibre optic immunosensor was described by Thromberg et al. 
(1987). A competitive equilibrium was established between labelled and unlabelled anti­
rabbit IgG for rabbit IgG immobilised on the distal end of an optical fibre. The sensing 
region was washed following the incubation and prior to measurement, and so 
measurements were not in real-time. Such sensors, however, require additional steps 
after analyte addition and prior to signal readout, and so cannot be considered ‘true’ 
sensors. The homogenous systems described below, appear to fulfil the criteria better. 
Bright et al. (1990), employed homogenous immunoassays in a biosensor for human 
serum albumin. Fluorescently-labelled anti-human serum albumin, was immobilised 
covalently to the distal end of a fibre optic probe. On binding of the antigen (HSA), the 
environment surrounding the fluorescent label (dansyl chloride), is altered as the analyte 
shields it from the solvent water. This results in an increased fluorescence of the 
fluorophore. This homogenous sensor allows real-time monitoring without the addition 
of extra reagents. The sensor could be regenerated 50 times before there was a 
significant decrease in the activity of the probe. However, photobleaching of the 
fluorescent label was a problem.
Most antibody-based biosensors are irreversible because the affinity of the antibody must 
be high to ensure adequate sensitivity for most immunoassays. Astles and Miller (1993), 
described a sensor using antibodies with a high dissociation rate. The analyte phenytoin 
dissociated from the antibody with sufficient rapidity to permit rapid re-equilibration in 
response to a change in concentration. The antibody properties required for chemically 
reversible biosensor applications are discussed in Miller and Anderson (1989). The distal 
end sensor employed the membrane encapsulated design, and the fluorescence energy 
transfer between B phycoerythrin-phenytoin and Texas Red-labelled anti-phenytoin 
antibody. These high molecular weight conjugates are retained behind the membrane. 
On immunospecific binding, the fluorescence dyes come into close contact and non- 
radiative energy transfer (i.e. non-fluorescent), takes place from the B phycoerythrin 
(BPE) to Texas Red, thereby quenching the BPE fluorescence. When the low molecular 
weight analyte diffuses across the membrane into the reaction chamber, it competitively 
displaces the BPE-phenytoin, resulting in an increase in fluorescence, which is directly 
proportional to the concentration of phenytoin.
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A novel extrinsic fibre optic immunosensor was described by Walt et al. (1993), which 
employed control release polymers and the homogenous energy transfer system, as 
described earlier. Fluorescein-labelled antibody and Texas Red-labelled antigen were 
incorporated separately into the controlled-release polymer, ethylene vinyl acetate 
(EVAc) copolymer, in the form of microparticle beads. These polymers release the 
labelled antibody or antigen slowly on contact with water. The microparticles were 
shown to maintain a sustained release of immunoreagents over 1000 hours. A mixture 
of the antibody and antigen beads were immobilised in a thin layer of hydrogel, at the 
distal tip of the optical fibre (Figure 1.8). The analyte diffuses into the porous hydrogel 
and a competitive equilibrium is established involving homogenous energy transfer. The 
sensor is considered reversible since the immunoreactants are continuously replenished.
Optical
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Figure 1.8: Configuration of immunosensor based on controlled-release polymer 
microparticles containing labelled antibody and antigen (Walt et al., 1993)
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1.4.3.1.2 Intrinsic fibre-optic affinity-based sensors
Intrinsic fibre optical sensors, as stated earlier, employ the fibre cable itself as an 
integral part of the sensing mechanism. Biosensors based on the evanescent wave fall 
into this class of sensors. An electromagnetic wave, called the evanescent wave, is 
generated at the interface between two dielectric media, when a light ray strikes the 
interface from the optically denser medium, at an angle greater than the critical angle. 
This electromagnetic radiation penetrates a short distance (of the order of a fraction of 
a wavelength) from the denser into the rarer medium, and decays exponentially with 
distance from the interface. The evanescent wave is discussed in more detail in chapter
These properties of the evanescent wave, make it ideal for affinity-based biosensing. 
When the plastic cladding of an optical fibre is removed, the exposed core of the fibre 
can be placed in sample solution. This immersed probe functions as a dielectric 
waveguide, with the aqueous buffer as the ‘cladding’. The evanescent wave is able to 
interact with any molecules within its penetration depth. Fluorescently-labelled 
immunoassays performed on the surface of the fibre, can be monitored in real-time, 
without the requirement for a separation step (Anderson et al., 1994). The fluorescence 
resulting from interaction with the evanescent wave is coupled back into the same fibre 
and guided to the detection optics. Distal-face and evanescent wave generation of 
fluorescence was compared by Weber and Schultz (1992). They showed, using 
fluorescein solutions, that at a launching numerical aperture of 0.6, the evanescent wave 
signal from 2-3 cm of decladded fibre equalled the efficiency of end-face generation of 
fluorescence. Since the fluorescence signal is directly proportional to probe length, 
evanescent wave generation should be more efficient using longer probes. The intensity 
of proximal over distal face collection of evanescent wave generated fluorescence was 
investigated by Yoshida et al. (1988). The normalised intensities of the fluorescence 
signal (signal/background) for both configurations was equal, however, the collections 
optics required, for the proximal-end detection, are much simpler. This is because the 
background signal for the proximal-face collection is only due to back-reflected and 
scattered light, whereas the intensity of the laser light must be removed for distal-face 
collection.
Oroszlan et al. (1993), developed an evanescent wave fibre optic immunosensor (EWIS) 
for the determination of the pesticide, atrazine. Anti-atrazine antibodies were 
immobilised onto the exposed fibre core and FITC-labelled and unlabelled atrazine
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allowed to compete for the limited number of binding sites. The immunosensor was 
sensitive within the range 0.5-200 nM. With samples of surface water and soil extracts, 
showing a strong luminescence in bulk emission measurements originating from the 
sample matrix, practically no interfering background luminescence was observed, using 
the evanescent wave technique. An alternative competitive fluoroimmunoassay was 
employed by Bier et al. (1992), for the evanescent wave determination of pesticides. In 
this case, the antigen pesticide, terbutryn, was immobilised to the exposed fibre surface. 
Test samples containing the pesticide competed with the immobilised pesticide for FITC- 
labelled anti-terbutryn antibodies. The more pesticide in solution, the less labelled 
antibody that could bind to the immobilised pesticide and so again an inverse 
relationship resulted. They claimed a detection limit of 0.1 ng/ml.
Another competition-based fluoroimmunosensor was reported by Kumar et al. (1994). 
The fibre-optic sensor quantitated the protein neurotoxin, botulinum toxin (BoTX). The 
sensing assay was carried out in two steps, however, exploiting a second biological 
affinity-based interaction between biotin and streptavidin. Biotinylated and non- 
biotinylated (i.e. test sample) BoTX, was allowed to competitively bind to the exposed 
core immobilised antibody. Following a wash-step, FITC-labelled streptavidin was 
passed over the fibre, which binds to the biotinylated antigen, and the fluorescence 
signal determined after 2 minutes. The sensitivity of the immunoassay may be increased 
by the biotin-streptavidin system, however, the requirement for a wash step defeats the 
purpose of evanescent wave immunosensing, which allows direct sensing.
Starodub et al. (1993), described a EWIS which could detect two drugs, lidocaine and 
phenytoin, simultaneously. A mixture of antibodies against both drugs were covalently 
immobilised on the fibre probe. Competitive immunoassays between lidocaine and B- 
phycoerythrin-labelled lidocaine and phenytoin and FITC-labelled phenytoin were carried 
out, simultaneously, on the fibre surface. Both fluorescent labels could be excited by the 
same laser source. The resulting fluorescence was coupled back into the same fibre, 
guided to a higher effective beamsplitter, and split into two, so that a set of rays fall on 
different detection optics. The fluorophores FITC and BPE have different Stoke’s shift 
values (30 and 85 nm, respectively), which facilitates detection. With further 
development, such an immunosensor could be used for multi-analyte analysis. 
Two-site sandwich immunoassays can be performed in one- or two-step formats and 
detected via the fibre-optical evanescent wave technique. One-step assay formats fulfil 
the criteria for direct signal readout after addition of the analyte. Antigen molecules with
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two distinct (non-interfering) and spatially separated antibody binding sites on their 
surfaces can easily be employed in a one-step assay format, where one of the antibodies 
is immobilised and the other is labelled with the fluorophore. The labelled antibody is 
premixed with the antigen and then passed over the fibre, in one-step. Walczak et al. 
(1992), developed such an immunosensor for the clinically important isoenzyme, creatine 
kinase MB (CK-MB). The presence of elevated CK-MB, in the serum is an important 
indicator of myocardial infarction. Monoclonal anti-human CK-MB was immobilised to 
the fibre core. B-phycoerythrin (BPE)-labelled anti-CK-MB antibody, specific for a 
different epitope on the surface of the CK-MB, was premixed with the patient serum 
sample, before being passed over the fibre probe. The BPE-anti-CK-MB/CK-MB 
immunocomplex bound to the immobilised anti-CK-MB in one-step, at a rate directly 
proportional to the CK-MB concentration. The group performed some experiments to 
show that all background fluorescence was of surface origin and they corrected all their 
sample readings to take this into account. The immunoreaction was monitored in real­
time and showed pseudo-first order reaction kinetics for sample concentrations of 0.1- 
50.0 ng/ml, during the 15 minute incubation time.
Shriver-Lake et al. (1993), described an EWIS for the determination of the toxin, 
pseudexin, and the toxin produced by Clostridium botulinum. They compared the 
sensitivity of the one- and two-step assay formats. Pseudexin has a relatively low 
molecular weight (16,500 Da.), and the one-step assay employed two monoclonal 
antibodies against two non-interfering epitopes. The two-step assay for the larger 
molecule, botulinum (150,000 Da.), was performed by incubating the sample with the 
immobilised affinity-purified polyclonal anti-botulinum antibody, followed by 
tetramethyl rhodamine-5-isothiocyanate (TRITC)-labelled anti-botulinum antibody. This 
labelled antibody was prepared from the same polyclonal antibody batch as the 
immobilised antibody. Since the assay is performed in two steps and the molecule is 
large, epitopes will still be available for the labelled antibodies to bind after the 
immobilised antibody has bound. They showed that the sensitivity of both assays was 
equivalent (1 ng/ml). However, the magnitude of the response was much greater for the 
one-step assay employing the monoclonal antibodies. The reason for this was postulated 
to be due to a combination of two factors. Firstly, the monoclonal antibodies bind non­
interfering epitopes and so may allow more antigen to bind to the capture antibodies, 
whereas the number of available epitopes of the botulinum toxin may be reduced due 
to the use of polyclonal antibodies. Secondly, the pseudexin molecule has a smaller
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molecular weight, and so in the immunoassay, the fluorophore may be closer to the fibre 
core. Since the evanescent wave penetration depth decreases exponentially with distance 
from the core, the further away fluorophores are from the fibre core, the lower the 
signal. It is noteworthy that this group tapered the optical fibres, to reduce the signal 
loss due to V-number mismatch (Anderson et al., 1994). The fibres are partially clad 
and when the fluorescent signal enters the cladded portion of the fibre, a loss in signal 
results. This is due to the fact that the unclad portion of the fibre can support more 
light-carrying modes, and so some of the signal will be lost on entering the cladded 
portion which cannot support these modes. To compound the problem, fluorescence 
couples back into the highest order modes available, and so the loss of signal is 
elevated. Tapering the decladded portion of the fibre was shown to improve signal 
acquisition, the theory of which is discussed in Anderson et al. (1993). Feldman et al.
(1995), determined the kinetic response and absolute sensitivity of their tapered 
immunoprobe by evanescent wave techniques.
Evanescent wave fibre probes have also been developed for receptor-based systems. 
Rogers et al. (1991), studied the pharmacological specificity of the nicotinic 
acetylcholine receptor, nAChR. Three neurotoxic peptides (a-Naja toxin, a-bungarotoxin 
and a-conotoxin) were labelled with FITC and the association and dissociation kinetics 
of the peptides for the nAChR immobilised non-covalently to the exposed core fibre 
surface was determined from an analysis of the time course of binding. Various agonists 
and antagonists of nAChR quenched the optical signal generated by FITC-a-Naja toxin 
binding. The inhibition constants for some of these compounds were determined from 
competition studies. The optical biosensor was shown to exhibit similar pharmacological 
profiles as those observed for membrane bound receptor.
DNA can also be used as the biological element of such evanescent wave sensors. Short 
oligonucleotide sequences bound to the fibre surface were used to detect FITC-labelled 
complementary oligonucleotide sequences (Graham et al., 1992). The hybridisation was 
carried out at 65°C, the temperature being controlled using a jacketed flow cell. The 
hybridisation was reversed by raising the temperature to 80°C, and after 10-15 min, 
reducing it again to 65°C, ready for the next hybridisation. The rate of signal increase 
was linearly proportional to the oligonucleotide concentration in the nanomolar range 
(1-10 nM). The sensor could be used to monitor the products of polymerase chain 
reactions (PCR), using fluorophore-labelled primers. Gene probe biosensor assays are 
orders of magnitude faster than conventional fllter-membrane gene probe assays.
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1.4.3.2 N on-fibre based  evanescent wave biosensors
The evanescent wave is generated at dielectric interfaces once the optical criteria are 
fulfilled (section 4.2). Planar waveguides are also available for evanescent wave 
fluoroimmunosensing. Badley et al. (1987), patented the fluorescence capillary-fill 
device (FCFD). The FCFD consists of two pieces of glass, separated by a narrow gap, 
100 pm wide. One of the plates has a reagent layer of FITC-labelled antigen, retained 
within a soluble humectant coating. The other plate has a layer of immobilised antibody 
on its surface. When a sample is introduced into the narrow gap, the humectant layer 
dissolves and a competitive fluoroimmunoassay is set up (Figure 1.9). The sample 
volume is automatically controlled by the capillary gap. The immunoreaction is 
monitored by an evanescent wave generated at the surface of the plate, to which the 
antibody is immobilised. The fluorescence is coupled back into the planar waveguide 
and can be monitored by measuring the fluorescent light emerging at small angles to the 
axis of the waveguide. Such sensors can be mass-produced due to their simple geometry.
Figure 1.9: Fluorescent capillary-fill device
35
1.43.2.1 Integrated optical sensors
Input grating couplers are integrated optical sensors which can exploit the evanescent 
wave for label-free bioaffinity reaction monitoring. Coherent laser light is coupled into 
the planar waveguide by a surface relief grating. An evanescent field is generated at the 
sensing surface o f the waveguide. The efficiency o f the coupling o f the laser light into
the waveguide can be measured and is a direct function o f  the surface refractive index
(probed by the evanescent wave), according to the equation (Nellen and Lukosz, 1993);
N=naiz s in a i + i A
where N  =  effective refractive index 
nair =  refractive index o f  air
1 =  diffraction order
X =  wavelength o f  light in a  vacuum 
A  =  grating period 
d j =  optimal angle o f  incidence 
Hence monitoring o f bioaffinity reactions at the surface, which cause a change in the 
refractive index can be resolved (Nellen and Lukosz, 1993). Gao e t a l . (1995), 
demonstrated the label-free monitoring o f  a sandwich immunoassay for prostate specific 
antigen. Changes in the effective refractive index at the surface were transduced by 
measuring the incoupling angle.
1.4.3.2.2 Surface plasmon resonance and the BIAcore™
Surface plasmon resonance (SPR), is an optical phenomenon arising in a thin metal film 
at the interface between glass and liquid, observed as a dip in the intensity of reflected 
light under conditions o f  total internal reflection in the glass.
Light shone through a prism at an angle greater than the critical angle o f reflection, is 
totally internally reflected within the prism, and an evanescent wave is generated at the 
glass-liquid interface as described in section 4.2. This evanescent wave penetrates a 
small distance into the medium o f lower refractive index, i.e. the liquid. If  the interface 
between the two media is coated with a thin layer («cXq o f light) o f metal, e.g. gold, and 
monochromatic, plane-polarised light is totally internally reflected within the prism, then 
the evanescent wave component o f  the light under certain conditions, will interact with 
delocalised surface electrons in the metal layer. These delocalised surface electrons are
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called ‘plasmons’. At a specific angle of incidence, the plasmons become excited and 
absorb energy, resulting in a sharp decrease in the intensity of the reflected light. The 
position of the dip or ‘resonance angle’, is sensitive to the refractive index a few 
hundred nanometres outside the metal film. Changes in the refractive index out to 1pm 
from the metal film surface can thus be followed by continuous monitoring of the 
resonance angle.
The best developed and most sophisticated biosensor employing surface plasmon 
resonance for transducing biorecognition events is the BIAcore™. The BIAcore™ 
(Pharmacia Biosensor AB), uses a combination of SPR and continuous flow technology 
to monitor interactions between molecules in ‘real-time,’ without the requirement for 
labelling. One of the biocomponents is immobilised on the surface of a gold metal film 
via a 100 nm thick layer of carboxymethylated dextran, which facilitates several 
immobilisation chemistries. This dextran matrix is mobile in three directions, and so 
immobilised molecules are considered to be effectively ‘still in solution’. The other 
biocomponent is delivered in solution over the sensor chip. The BIAcore™ has an 
autosampler and microfluidics system to deliver all samples, buffers and regeneration 
solutions to the chip surface. A wedge-shaped beam of tight from a light emitting diode 
(LED), is focused through the prism on the side of the sensor chip opposite the gold 
layer, and the reflected light is monitored by a fixed two dimensional array of light 
sensitive diodes (Figure 1.10). A detailed description of the BIAcore™ and all its 
components is given in Jonsson and Malmqvist (1992).
The BIAcore™ can be used to monitor any biological recognition system (e.g. antibody- 
antigen, receptor ligand, DNA hybridisation), if one of the biological molecules involved 
in the recognition event can be immobilised to the sensor chip surface. If for example, 
the antibody is immobilised to the sensor chip gold layer surface and the antigen is 
allowed to bind to it, a change in the refractive index of the solution will occur just 
outside the metal layer (within the sensing volume), due to the accumulation of mass 
at the surface. A change in the resonance angle results. All interactions are monitored 
continuously, as the SPR angle is directly proportional to the surface concentration of 
molecules. A response of 1000 response units (RU), corresponds to a concentration of 
about lng/mm2. Some applications of the BIAcore™ and all its components are detailed 
in Fagerstam et al. (1992), and others are outlined in Table 1.3.
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Figure 1.10: Diagrammatic representation of the BIAcore™ sensor chip surface and 
the associated optics for surface plasmon resonance (SPR) sensing
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Biospecific Interaction Comments Reference
antibody-antigen quantitation of the pesticide 
atrazine in drinking water by 
competitive immunoassay
Minunni and Mascini 
(1993)
receptor-ligand exploration of the mechanism of 
receptor binding between the 
growth factor, EGF and its 
receptor
Zhou et al. (1993)
protein-DNA verification of the hypothesis 
that the nuclear oncoprotein, 
ETS1, interacts with DNA in a 
sequence specific manner
Fisher et al. (1992)
DNA-DNA real-time monitoring o f DNA  
hybridisation kinetics, DNA  
strand separation and enzymatic 
modifications
Nilsson et al. (1995)
antibody-antigen determination of the and 
of monoclonal antibodies 
for use in radioimmunodetection 
in vivo
Horenstein et al. (1993)
Table 1.3: Some applications of the BIAcore™
The BIAcore™ may find applications for the development of reversible biosensors. 
Antibodies with a high dissociation constant are required for reversible sensors to ensure 
that the sensor responds rapidly to changes in analyte concentration.
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1.4.3.23 The resonant mirror biosensor
The resonant mirror biosensor (IAsys™ ), is a  new biosensor launched by Fisons Applied 
Sensor Technology, Cambridge, U K  It is a novel design based on optical evanescent 
wave technology which combines the ease o f  use o f surface plasmon resonance and the 
enhanced sensitivity o f waveguiding techniques. It utilises a dielectric resonant structure 
to probe label-free affinity reactions in the sensing layer.
F igu re  1.11: The optical and biological components o f the resonant mirror-based 
system IA sys™  (Yeung e t a l . ,  1995).
The structure o f the device is shown in Figure 1.11. It consists o f a glass prism, onto 
which a  high refractive index dielectric resonant layer is deposited (lOOnm thick), 
separated by a low refractive index layer (spacer layer). Polarised light (directed at the 
prism by an angle which is swept repeatedly), is coupled into the resonant layer via the 
spacer layer, and propagates by multiple internal reflections along the monomode 
waveguide, before tunnelling back across the spacer layer to leave the prism. Efficient 
coupling only occurs for certain incident angles and for these angles an evanescent wave 
is generated at the waveguide surface. The evanescent wave probes the sensing layer 
(100 nm into the sample) and is particularly sensitive to the refractive index of the
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sample. Changes in the refractive index due to bioaffinity binding at the surface, alters 
the resonant angle, resulting in a shift in the phase of the reflected light, which is 
monitored by a suitable detection system (Cush et al., 1993; Yeung et al., 1995). 
Measurement of antibody-antigen and enzyme-substrate-inhibitor interactions using the 
resonant mirror have been described in Buckle et al. (1993).
1.4.4 Piezoelectric crystal sensors
When a mechanical stress is applied to anisotropic crystals, e.g. quartz, electrical charges 
are induced on the surface of the crystal, due to a phenomenon known as 
piezoelectricity. By the converse effect, when an A.C. voltage at the resonance 
frequency is applied to these materials, oscillations are induced within the crystals. The 
optimal resonance frequency at which these oscillations are induced is highly dependent 
on the properties of the crystal (e.g. thickness), and also on the mass on its surface. 
With the addition of small amounts of bound mass to the surface, the oscillating 
frequency of PZ crystals, when operated in air, is decreased according to the Sauerbrey 
equation;
where f0 is the resonance frequency of the unloaded crystal, pq is the shear modulus, pq, 
the density and A, the surface area of the active crystal face. A fractional change in the 
frequency Af, is equal to the fractional change caused by the added mass Am, in the 
surface density of the crystal.
There are two main configurations of piezoelectric biosensor, the quartz crystal 
microbalance (QCM) and the surface acoustic wave (SAW) device.
1.4.4.1 Resonant quartz crystal microbalance
The QCM device consists of an AT-cut quartz crystal, sandwiched between two 
electrodes. An A.C.-voltage is applied causing the crystal to oscillate at its normal 
resonance frequency. When mass is added to the surface of the electroded crystal 
surface, the resonance frequency of the crystal is decreased. If bioaffinity molecules are 
immobilised on the surface of the crystal, the QCM device can be employed as an 
affinity sensor.
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Ngeh-Ngwainbi et al. (1986), immobilised anti-parathion antibodies on a QCM, for the 
detection of the volatile insecticide, parathion, in the gaseous phase. Problems can arise, 
however, when using piezoelectric sensors in the liquid phase, in which most biological 
systems are found. Solvent adsorption and viscous drag can dampen the resonance 
frequency and cause interference (Walton et al., 1991). The PZ-crystal is sensitive to 
variations in the density and viscosity of the active sensing layers adjacent to its surface. 
To overcome the problems due to liquid interactions, some researchers employed the 
‘dip and dry’ technique, when making measurements. The resonance frequency of the 
biosensing crystal was determined before the crystal was dipped in the analyte solution. 
Following reaction with the analyte, the crystal was removed, dried (usually air-dried) 
and the change in resonance frequency due to the added mass determined. Herpes 
viruses (König and Grätzel, 1994), pesticides (Guilbault et al., 1992), human 
granulocytes (König and Grätzel, 1993) were determined using antibody-based QCM 
sensors employing the ‘dip and dry’ technique. Fawcett et al. (1988) monitored the 
complementary hybridisation of synthetic RNAs using the same method.
The ‘dip and dry’ technique is rather cumbersome and time-consuming, and so research 
is continuing into making measurements in the liquid phase. Muramatsu et al. (1987), 
measured IgG in solution using protein A-coated crystals. The change in the resonance 
frequency of the crystal was measured before and after incubation with IgG (in buffered 
saline) by flowing deionised water over the surface, thereby eliminating the need for 
drying the sensor. This non-continuous method of sensing was improved on by Davis , 
and Leary (1989), who studied the same bioreaction in liquids, using continuous 
measurements. They designed an oscillator circuit to compensate for the degraded 
quality of the AT-cut PZ crystal, in the energy absorbing medium.
Minunni et al. (1994), reported a PZ-immunosensor for the detection of pesticides in 
solution, using real-time measurements. The sensor was based on an antigen inhibition 
competitive assay. The same group (Sklädal et al., 1994), also reported the 
characterisation of monoclonal antibodies to the pesticide using the same sensor system. 
The association and dissociation kinetics were determined from real-time, frequency vs 
time curves.
The sensitivity of QCM sensors is often too low for certain applications. Ebersole and 
Ward (1988), enhanced the sensitivity of an antibody-based sensor for human chorionic 
gonadotropin (hCG), by performing a two-site ELISA on the surface of the crystal and 
developing the bound enzyme label (alkaline phosphatase), with a substrate (BCIP)
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which yields an insoluble product (oxidised dimer of BCIP). The deposition of the 
product on the crystal surface results in an amplified decrease in resonance frequency, 
which is proportional to hCG concentration. This method, however, magnifies the 
problems of regeneration or surface cleaning between sample readings.
Another approach taken by Ghourchian et al. (1994), did not require the formation of 
a thin film on the crystal followed by fixation of the antibody or antigen. Anti- 
rheumatoid factor antibody was immobilised onto the surface of latex beads. The beads 
were added to a cell containing the PZ-crystal, followed by standard serum containing 
rheumatoid factor. A decrease in frequency was observed as the agglutination reaction 
took place, at a rate proportional to the rheumatoid factor concentration. Formation of 
the agglutinated latex complex, changes the density and viscosity of the solution, which 
in turn changes the resonance frequency of the crystal. Some non-specific binding by 
the antibody-bearing latex was shown to take place to the crystal surface adding to the 
regeneration problems.
1.4.4.2 Surface-acoustic wave devices
SAW devices can also be used for the detection of mass accumulation, by monitoring 
changes in acoustic wave propagation along the surface (Rayleigh waves) of a PZ- 
crystal. Mechanical waves, generated by an applied voltage, are propagated from a 
transmitter to a receiver electrode, where an output voltage is determined by an inverse 
piezoelectric effect These waves are often referred to as surface acoustic waves. 
Anything which interacts with the launched surface wave, will alter the speed and 
amplitude of the wave. Bioaffinity sensors can be devised using SAW devices if one of 
the binding partners is immobilised on the surface of the PZ-material, in the path of the 
SAW. On binding with its complementary partner (e.g. antibody-antigen), the frequency 
of the launched wave is disrupted.
Two electronic techniques are used with SAW sensors. In one the output voltage is fed 
back into the input, to produce a sustained standing wave oscillation and the frequency 
is continuously monitored. In the other method the phase and magnitude of the output 
is compared with the input, and the phase difference related to the bound mass (Walton, 
1991).
There are two types of SAW sensors - Lamb wave devices and shear horizontal acoustic 
plate mode (SH-APM) devices. SH-APM devices are preferred for liquid measurements.
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SH-APM propagation does not excite any appreciable acoustic wave into the bulk 
solution and so is relatively insensitive to the bulk fluid properties.
Andie et al. (1992), described an SH-APM device and demonstrated the detection of 
DNA hybridisation. The biosensing device had the interdigital transducers (IDT) on the 
surface of the crystal opposite to where the fluid is placed, thereby eliminating any 
potential interactions between the biochemical solution and the IDTs. The propagation 
of the acoustic waves is through the bulk of the crystal and is altered by the deposition 
of mass. A dual delay-line device was used in which two sets of IDTs are employed 
(Figure 1.12). In the path of one of the oscillators, a biologically sensitive DNA coating 
is immobilised, while the crystal is passivated between the other set of IDTs. Systematic 
changes common to both delay lines, such as non-specific adsorption and temperature 
drift cancel out and cause little or no change in their relative response. The relative shift 
in frequency is measured.
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Figu re 1.12: Dual-delay line configuration of a surface acoustic wave biosensing 
device (Andie et al., 1992)
Walton et al. (1992), described the use of polymers with piezoelectric properties for 
biosensing devices. The sensitivity of SAW devices is inversely proportional to its 
thickness. Practically, however, there is a limit to the thinness of PZ-crystals, that can 
be handled. The thickness of polyvinyidine difluoride (PVdF), can be reduced greatly 
relative to quartz crystals. The polymer also exhibits excellent protein binding 
capabilities, for use in biosensors.
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Aims
The aim of this project is to develop a fibre optical-based fluoroimmunosensor, which 
employs the evanescent wave to probe an immunoreaction occurring at the exposed fibre 
probe interface in real-time.
The model analyte chosen was chicken heart LDH (CHLDH), since it was readily 
available and inexpensive. In chapter 3, ■ the production of' specific anti-CHLDH 
polyclonaT antibodies will be- described. These antibodies will be used in the 
development of an enzyme-linked immunosorbent assay. The antibodies will also be 
labelled with the fluorescent label, FITC, for use in the development of the optical 
immunosensor.
The development of this optical fibre-based fluoroimmunosensor will be described in 
chapter 4. Different assay formats will be compared and the effect of fibre regeneration, 
fibre realignment and matrix viscosity on the sensor performance will be determined. 
The same assay formats will also be performed on the BIAcore™, a commercially 
available biosensor system, which also monitors immunoreactions in real-time, but in 
the absence of a label species. The effect of the ratio of the number of FITC molecules 
per antibody molecule, will also be described using both the evanescent wave 
fluoroimmunosensor and the BIAcore™.
In chapter 5, the development of an ELISA for human LDH (H4 isoenzyme) will be 
examined, and the possibility of using this ELISA for the determination of the onset of 
acute myocardial infarction will be assessed.
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CHAPTER 2
MATERIALS AND METHODS
2.1 Materials
All buffers and reagents used in the experimental work were of analytical grade, and 
were purchased from Sigma Chemical Co., Poole, Dorset, England; BDH Chemicals 
Ltd., Poole, Dorset, England and Riedel-de Häen AG, Aktiengesellschaft, D-3016, Seelze 
1, Hannover, Germany.
Chicken Heart LDH was kindly donated by Baxter Dade AG, CH-3186, Diidingen, 
Germany.
All antibodies except those produced ‘in house’ were purchased from Sigma Chemical 
Co., Poole, Dorset, England and Dako Ltd., 16 Manor Courtyard, Hughenden Avenue, 
High Wycombe, Bucks, HP 13 5RE, England.
Bicinchoninic acid assay (BCA) kit and Immunopure® Immobilised Protein A gel were 
purchased from Pierce and Warriner (UK) Ltd., 44 Upper Northgate St., Chester, 
Cheshire, CHI 4EF, England.
BioRad protein assay reagent was purchased from BioRad Laboratories, BioRad House, 
Maylands Ave, Hemel Hempstead, Hertfordshire, HP2 7TD, UK.
Sephadex G-25 gel filtration matrix was purchased from Pharmacia Fine Chemicals AB,
P.O. Box 175, S-75104 Uppsala 1, Sweden.
The HPLC column used for protein separation, Phenomenex Biosep-Sec S4000, was 
purchased from Phenomenex®, Melville House, Queens Avenue, Hurdfield Ind. Est., 
Macclesfield, Cheshire, SK10 2YF, England.
All solvents were HPLC-grade and were purchased from Lab-Scan, Unit T26, Stillorgan 
Ind. Park, Co. Dublin, with the exception of the anhydrous solvent toluene which was 
purchased from Aldrich Chemical Co. Ltd., The Old Brickyard, New Road, Gillingham, 
Dorset, England.
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Mercaptopropyltrimethoxysilane (MTS) was purchased from Fluka Chemika AG, CH-
9470, Buchs, Germany.
Pre-poured mini-electxophoresis 5-20% gradient gels were purchased from ATTO 
Corporation, 2-3, Hongo 7-chome, Bunkyo-ku, Tokyo 113, Japan.
Microtitre plate were purchased from Nunc Immunosorb, Denmark.
MicroFluor™ "W" Plates (microtitre plates for the fluorimeter) were purchased from 
Dynatech Laboratories, Inc., 14340 Sullyfield Circle, Chantill, Virginia 22021, USA.
Electrophoresis Systems™, LD Isoenzyme System was purchased from Ciba Coming 
Diagnostics Corporation, 490 San Antonio Road, Palo Alto, CA 94306, USA.
All BIAcore™ reagents (for immobilisation procedure) were obtained from Pharmacia 
Biosensor AB, S-75182, Uppsala, Sweden.
Optical fibre was purchased from CeramOptec Inc., Enfield, CT, USA
All fibre polishing solutions were purchased from Logitech, Glasgow, Scotland.
Equipment used is outlined in the relevant ‘methods’ section.
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2.2 Methods
2.2 Antibody Production
2.2.1 Immunisation protocol for the production of rabbit anti-chicken heart LDH 
antibodies
A 1000 (Jg quantity of chicken heart lactate dehydrogenase enzyme (CHLDH), was 
dissolved in 600 pi 0.15M phosphate buffered saline (PBS), pH 7.4. An equal volume 
of Freund’s Complete Adjuvant was added. This mixture was vortexed vigorously to 
form a stable emulsion. A 1000 pi sample was injected into a number of sites 
intramuscularly, into the back of a New Zealand White rabbit. The animal was boosted 
on day 28, using an emulsion prepared as above except that Freund’s Incomplete 
Adjuvant was used. The animal was bled 11-14 days later from the marginal vein in the 
ear. The cycle was repeated to achieve a sufficiently high titre and 20 ml aliquots of 
serum taken as required.
2.2.2 Immunisation protocol for the production of rabbit anti-human LDH (H4 
isoenzyme) antibodies
A New Zealand White rabbit was immunised with 500 pg quantities of human lactate 
dehydrogenase enzyme (H4 isoenzyme), prepared as described in section 2.2.1 . Serum 
was taken as required.
2.3 Preparation of serum
Whole blood taken from the marginal vein in the ear of the rabbit was allowed to clot 
at room temperature for 1 h. The clot was loosened away from the sides of the universal 
and centrifuged (Heraeus Labofuge GL) at 3000 rpm for 20 min. The supernatant was 
removed and centrifuged again to remove any remaining red blood cells. The resulting 
serum was stored frozen at -20°C in suitable aliquots.
2.4 Antibody purification
2.4.1 Ammonium sulphate salt precipitation
Rabbit antiserum was cooled to 4°C and the pH adjusted using IN NaOH to between 
7.0 and 7.4. An equal volume of cold 100% (w/v) saturated ammonium sulphate (S.A.S.) 
was added dropwise to the serum, stirring continuously at 4°C for 1 h. The suspension 
was then centrifuged at 3000 rpm for 15 min. The precipitate was washed twice with
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45% (w/v) S.A.S. and, following centrifugation, the pellet was solubilised in a minimum 
volume of PBS. The protein solution was dialysed overnight at 4°C against 1 L PBS, 
with at least 2 changes of buffer.
2.4.2 Affinity chromatography
2.4.2.1 Preparation of affinity column (for purification of anti-chicken heart LDH 
antibodies)
A 1.4 g quantity of CNBr-activated Sepharose (Sigma) was suspended in 11 ml 0.001M 
HC1 and transferred to a sintered glass funnel, where it was washed over 15 minutes 
with 280 ml 0.001M HC1 followed by 8 ml coupling buffer (0.1M NaHC03 4- 0.5M 
NaCl, pH 8.3). Chicken heart LDH (30 mg) was dissolved in 10 ml coupling buffer and 
added to a conical flask. The washed gel was then added. This gave a gel to buffer ratio 
of 1:2. The gel and antigen were mixed for 2 h with gentle shaking at room temperature. 
The gel was returned to the sintered glass funnel and washed with 18 ml coupling 
buffer. It was then transferred to a flask containing 10 ml blocking buffer (0.2M glycine 
in coupling buffer, pH 8.0) and left on a shaker for 1 h at room temperature.
To remove non-covalently bound protein, the gel was washed with three cycles of 
alternating pH, consisting of 30 ml 0.1M acetate buffer containing 0.5M NaCl, pH 4.5 
and 30 ml 0.1M Tris buffer containing 0.5M NaCl, pH 8.5 . The gel was suspended in 
0.02M PBS, pH 7.4, and added to a 50 ml syringe barrel. The column dimensions were 
2cm high x 2.5cm diameter. A layer of PBS (0.02M) was then added to prevent the gel, 
from drying out.
2.4.2.2 Use of affinity column
The column was washed with 30 ml 0.02M PBS, pH 7.4, to remove any protein which 
may have leeched from the gel during storage. Fractions (2 ml) were collected and the 
absorbance of these fractions monitored at 280 nm to ensure it was less than 0.03 
absorbance units before applying the resuspended pellet sample (section 2.4.1). The 
dialysed sample ( following S.A.S. precipitation) was added slowly to the column, 
followed by washing with 0.02M PBS to elute unbound material from the column. 
Fractions (2 ml) were collected and monitored for the presence of protein at 280 nm. 
The washing process was continued until no more protein was detected in the fractions 
(i.e. absorbance < 0.03).
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The washing buffer was allowed to run to the top of the gel and then dissociating buffer 
(0.1M glycine/HCl, pH 2.5) was added. Fractions (1 ml) were collected in eppendorfs 
containing 100 pi 0.1M Tris/HCl, pH 9.0, which alters the pH of the eluted 
immunoglobulin to neutral. This quick adjustment of pH prevents denaturation of the 
antibody. Those fractions containing protein (checked by BCA protein assay, section 
2.7.1), were pooled and dialysed overnight at 4°C against 0.1M PBS, pH 7.4 . The 
column was regenerated by washing with 20 ml each of 0.1M Tris/HCl, pH 8.0, 0.1M 
sodium acetate, pH 4.0 and 0.02M PBS, pH 7.4 . The column was stored for reuse, at 
4°C in 0.02M PBS containing 0.02% (w/v) NaN3.
2.4.3 Protein A chromatography (for purification of anti human-H4LDH 
antibodies)
Five millilitres of ImmunoPure® Immobilised Protein A gel (Pierce Chem. Co.) was 
poured into a 10 ml syringe barrel. The column (3cm x 1.5cm) was equilibrated with 
25 ml binding buffer (0.1M Tris/HCl buffer, pH 7.5). The dialysed sample (following 
S.A.S. precipitation), was applied to the column. Binding buffer (100 ml) was allowed 
to flow through the column under gravity, to remove any unbound protein. Fractions (2 
ml) were then collected and monitored for the presence of protein, by measuring the 
absorbance at 280 nm. Once the absorbance was < 0.03, the bound protein was eluted 
using 0.1M glycine buffer, pH 2.5. Fractions (1 ml) were collected in eppendorfs 
containing 100 pi 0.1M Tris/HCl, pH 9.0, to adjust the pH back to a more physiological, 
pH. Fractions were monitored at 280 nm for the presence of protein, and those 
containing protein were pooled and dialysed against 1 L PBS, at 4°C, with at least two 
changes of buffer.
The Protein A column was regenerated with 30 ml 0.1M citric acid, pH 3.0 and stored 
for reuse, in doubly distilled water containing 0.02% (w/v) NaN3.
2.5 Enzyme-linked immunosorbent assay (ELISA)
2.5.1 Screening for antibody production
Serum from immunised animals was screened for the presence of specific antibodies, 
by an enzyme-linked immunosorbent assay. Each well of 10 columns of a 96-well 
microtitre plate (Nunc Immunosorb), was coated with 100 pi antigen (5 pg/ml), in 
carbonate buffer, pH 9.6 (0.01M sodium carbonate, 0.035M sodium hydrogen
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carbonate). Carbonate buffer was added to the two remaining columns. The plate was 
incubated at 4°C, overnight. (Alternatively, the plate could be incubated at 37°C for 1 
h or for 2 h at room temperature). The plate was washed five times with 0.15M PBS 
containing 0.05% (v/v) Tween 20 (PBS-Tween), and once in 0.15M PBS, pH 7.4 (PBS). 
Each well of the plate was then coated with 200 pi 3% (w/v) BSA prepared in 0.15M 
PBS, pH 7.4, and incubated at 37°C for 1 h. The plate was then washed once with PBS, 
inverted and shaken dry.
Sera to be tested, or control serum, was diluted in 0.15M PBS, pH 7.4, and 100 pi added 
to suitable wells. The plate was incubated at 37°C for 2 h. Control wells containing no 
antibody (PBS alone) were also included. The plate was washed five times with PBS- 
Tween and once with PBS, as described above. Commercial anti-rabbit IgG antibody 
labelled with horseradish peroxidase enzyme was diluted to 1:15,000 (working dilution), 
in 3% BSA (w/v) in PBS. This secondary antibody was added to each well (100 pi) and 
the plate incubated at 37°C for 30 min., followed by washing five times with PBS- 
Tween and once in PBS. Substrate (100 pi) for the enzyme (0.01 g o-phenylenediamine 
diluted in 25ml of 0.15M citrate buffer, pH 5.0, and 5 pi of 30% (v/v) H20 2) was added 
to each well and the plate incubated at room temperature until sufficient colour had 
developed. The absorbance of each well was read at 405 nm using a Titretek 
Twinreader® Plus microtitre plate reader.
2.5.2 Labelling of anti-CHLDH antibodies and anti-H4LDH antibodies with horse 
radish peroxidase enzyme
Two milligrams purified IgG was dialysed overnight at 4°C, against 0.1M sodium 
carbonate buffer, pH 9.0. The solution volume was reduced following dialysis to 
approximately 500 pi by reverse osmosis on a bed of sucrose. Horse radish peroxidase 
(1 mg) was dissolved in 100 pi 0.1M sodium carbonate buffer (freshly prepared) in an 
eppendorf tube. One hundred microlitres sodium periodate (8 mM) was added and the 
reaction allowed to proceed at room temperature for 2 h in the dark. The 
immunoglobulin solution was then added to the activated peroxidase in the eppendorf 
and 2-3 mg Sephadex G-25 powder (Pharmacia Fine Chemicals) added rapidly. The 
reaction was incubated in the dark at room temperature for 3 h. The conjugate was 
eluted from the reaction mixture by centrifugation at 10000 rpm for 10 min. Five 
percent volume NaBH4 (5 mg/ml in 0.0001M NaOH, freshly prepared) was added to the
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eluant to stabilise the conjugate. The solution was inverted several times to ensure good 
mixing and then incubated for 30 min at room temperature. Ten percent volume NaBH4 
was then added and the solution incubated at 4°C for 1 h. The HRP-conjugated IgG and 
the unconjugated IgG were purified from unconjugated peroxidase by ammonium 
sulphate precipitation, as outlined in section 2.4.1. The final pellet was resuspended in 
500 pi PBS, and dialysed overnight at 4°C against PBS. Following dialysis, an equal 
volume of glycerol was added and 100 pi aliquots were stored at -20°C.
2.5.3 Determination of the working dilution of HRP-anti-CHLDH antibody or 
HRP-anti-H4LDH antibody conjugate
A 96-well microtitre plate (Nunc Immunosorb) was coated with 5 pg/ml of the 
appropriate antigen in carbonate buffer, pH 9.6, and blocked with 3% (w/v) BSA or 1% 
(w/v) glycine as described in section 2.5.1. (Glycine (1%) was used for HRP-anti- 
H4LDH conjugates as some non-specific binding was seen with BSA.) Dilutions of the 
HRP-anti-CHLDH or HRP-anti-H4LDH (as prepared in section 2.5.2) were prepared in 
0.15M PBS, pH 7.4, containing 0.05% Tween (PBS-Tween), and 100 pi added to 
appropriate wells. PBS-Tween was added to control wells. The plate was incubated at 
37°C for 1 h. Following incubation, the plate was washed five times with PBS-Tween 
and once with PBS. Substrate (100 pi) for the enzyme (see section 2.5.1), was added to 
each well and the plate incubated at room temperature for an appropriate length of time 
to allow colour development. The absorbance of each well was read at 405 nm using the, 
Titertek Twinreader® Plus microtitre plate reader. The working dilution of the conjugate 
was determined from the dilution curve. It was taken to be the dilution value which gave 
an absorbance reading, of half the absorbance reading of the upper plateau of the 
dilution curve.
2.5.4 Two-site sandwich (ELISA) for the detection of CHLDH or H4LDH
Each of 10 columns of a Nunc Immunosorb 96-well microtitre plate was coated with 
100 pi anti-CHLDH antibodies or anti-H4LDH antibodies depending on the antigen to 
be detected (5 pg/ml), in carbonate buffer, pH 9.6 . The plate was washed and blocked 
with 3% (w/v) BSA or 1% (w/v) glycine as described in the section 2.5.3. Antigen 
samples were prepared at several concentrations (comparable to LDH levels in normal 
serum), in 0.15M PBS, pH 7.4, and 100 pi added to appropriate wells. Reference
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negative samples were also included. The plate was incubated for 1 h at 37°C. Following 
incubation, the plate was washed five times with PBS-Tween and once with PBS. HRP- 
anti-CHLDH antibody (100 pi) was added at its working dilution in PBS and incubated 
at 37°C for 30 min. The plate was washed five times in PBS-Tween and once in PBS, 
and the label detected as outlined in section 2.5.1.
2.6 Fluorescence-linked immunosorbent assays
2.6.1 Labelling of anti-CHLDH antibody with fluorescein isothiocyanate (FITC)
Affinity purified anti-chicken heart LDH antibody was dialysed overnight at 4°C against
0.1M sodium carbonate buffer, pH 9.6. The antibody solution was concentrated on a bed 
of PEG (average m.w. 10,000 Daltons), until the protein concentration was between 2-5 
mg/ml (checked by absorbance at 280 nm). Stock fluorescein isothiocyanate solution (10 
mg/ml) was prepared in DMSO. The fluorophore was added to the antibody solution in 
5 pi aliquots, with quick vortexing between additions, until 50 pg FITC was added per 
mg of protein. The conjugation reaction was allowed to proceed at room temperature for 
3 h in the dark.
The conjugated and free antibody were separated from the free FITC by gel filtration 
on a 15 ml Sephadex G-25 column (18cm x 1cm) in PBS, pH 7.4, containing 0.02% 
(w/v) NaN3, at a flow rate of 0.5 ml/min. The first coloured fractions eluted, 
corresponded to the FTTC-anti-CHLDH conjugate. The fluorophore/protein ratio was 
estimated from the formulas given below (The and Feltkamp, 1970).
_F_ 2 . 8 7 x A b s  . 4 9 5 nm________
P  A b s . 2 8 0 n m - ( 0 . 3 5 x A b s . 4 95 nm )
The protein concentration was estimated by absorbance from the following formula:
r G] _ A b s .  2 8 0 nm -  (0  . 3 5 x A b s .  49  5/z/n)
9  1 .4
The Bio-Rad protein assay (section 2.7.2) was also used to determine the protein 
concentration.
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2.6.2 Labelling of CHLDH (antigen) with fluorescein isothiocyanate (FITC)
The antigen, CHLDH, was labelled with FITC, as outlined for the antibody, anti- 
CHLDH, in section 2.6.1. The protein concentration of the antigen solution was 4 
mg/ml, and so 50 pg FITC per mg of protein was used for labelling.
2.6.3 Labelling of anti-CHLDH antibody with FITC at several fluorophore/protein 
ratios
Anti-CHLDH antibody (1.8 mg/ml), purified by protein A affinity chromatography, was 
labelled at 20, 50, 100, 200, 400, 800, 1600 pg FITC per mg of protein as described in 
section 2.6.1. The conjugates were purified by gel filtration. A control was prepared by 
adding 25 pi DMSO alone to the antibody solution. The fluorophore to protein ratio and 
protein concentrations were estimated from the formulas shown in section 2.6.1.
2.6.4 Fluoroimmunoassays
Fluoroimmunoassays were performed in the same manner as ELISA’s (see sections 2.5.3 
and 2.5.4), with the following changes:
1. Dynatech 96-well fluorimeter microtitre plates were used.
2. Following the final washing step, 100 pi 0.15M PBS, pH 7.4, was added to each well. 
The fluorescence of each well (due to FITC-labelled antibody or antigen), was 
determined using the well plate reader accessory of the fluorimeter (Perkin-Elmer, 
Model LS-50). The excitation and emission wavelengths were set at 488 nm and 520 nm, 
respectively, with excitation and emission slit widths set at 10 nm and 15 nm, 
respectively.
2.6.4.1 One-step fluorescence-linked immunosorbent assay
Dyantech fluorimeter microtitre plates were coated with anti-CHLDH antibodies and 
blocked with 3% (w/v) BSA, as described for the ELISA (section 2.5.4). Antigen 
(CHLDH) concentrations in the range 0.015 - 10.0 pg/ml, were premixed with FITC- 
labelled anti-CHLDH antibodies, at their working dilution (1:100), and incubated in 
appropriate wells (lOOpl), in triplicate, for 1 hour at room temperature. H4LDH was used 
as the antigen in control wells. Following the incubation step, the plate was washed five 
times with PBS-Tween and once with PBS, and 100 pi PBS added to each well. The 
fluorescence intensity of each well was determined as outlined in section 2.6.3.
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2.6.4.2 Two-step fluorescence-linked immunosorbent assay
Dynatech fluorimeter microtitre plates were coated and blocked, as outlined in section
2.6.3.1. Antigen (CHLDH) samples in the range 0.015 - 10.0 pg/ml, were added to 
appropriate wells (lOOpl), in triplicate, for 1 hour at room temperature. Negative controls 
were also included. The plate was washed five times with PBS-Tween and once with 
PBS. FITC-labelled anti-CHLDH (100 pi), was added to each well, at the working 
dilution (1:100). The plate was incubated for 1 hour at room temperature and then the 
plate was washed five times with PBS-Tween and once with PBS. PBS (100 pi) was 
added to each well and the fluorescence intensity of each well determined as outlined 
in section 2.6.3.
2.7 Protein assays
2.7.1 Bicinchoninic acid (BCA) protein assay
In this assay, Cutf reacts with the protein under alkaline conditions, to give Cu+, which 
in turn reacts with BCA to give a coloured product (Smith et al., 1985). Two hundred 
microlitres of commercial working BCA reagent (Pierce Chem. Co.) was added to 10 
pi test sample or standard protein solution (10-2000 pg/ml), in 96-well microtitre plate 
wells. BS A was typically used as the standard protein but when IgG concentrations were 
being measured, this protein was used as the standard. The plate was gently agitated to 
ensure thorough mixing and incubated at 37°C for 30 min. The absorbance of each well 
was read at 560 nm using a Titertek Twinreader® Plus microtitre plate reader. Protein 
concentrations were determined from the standard curve. Typically, BCA standard 
curves for protein determination gave r values of 0.999.
2.7.2 Bio-Rad protein assay
The Bio-Rad protein assay is based on the observation that the absorbance maximum 
for an acidic solution of Coomassie Brilliant Blue G-250 shifts from 465 nm to 595 nm, 
when binding to protein occurs (Compton and Jones, 1985). Forty microlitres 
commercial Bio-Rad reagent (BIO-RAD Laboratories) was added to 160 pi of test 
sample or standard protein solution (5-25 pg/ml), in 96-well microtitre plate wells. 
Typically, BSA was used as the standard protein, however if IgG was to be determined, 
this protein was used as the standard. The samples were diluted with 0.15M PBS, pH 
7.4, so that the protein concentration was in the range 5-25 pg/ml. The contents of each
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well was mixed thoroughly using a micropipette as the solutions do not mix readily. The 
absorbance of each well was read at 620 nm on the Titertek Twinreader® Plus 
microtitre plate reader, 5-60 min after sample mixing. Protein concentrations were 
determined from the standard curve. Typically, protein standard curves prepared with 
the BioRad assay had r values of 0.990 - 0.997.
2.8 Electrophoresis
2.8.1 SDS-PAGE with Coomassie Brilliant Blue staining
Polyacrylamide gel electrophoresis (PAGE), in the presence of sodium dodecyl sulphate 
(SDS), was carried out using commercially available 5-20% (w/v) gradient 
polyacrylamide gels (ATTO Corporation, Japan).
Samples (~lmg/ml) were diluted 1:1 in solubilisation buffer (0.08M Tris/HCl, pH 6.8; 
2% (w/v) SDS; 10% glycerol and 0.2% (w/v) Coomassie Brilliant Blue R-250) and 
boiled for 2-10 minutes. Samples (20 pi) were loaded into the wells of the gel while 
only 5pi (as recommended by the suppliers), of the prestained molecular weight standard 
mixture (Sigma SDS-7B) was loaded. The gel was run in electrode buffer, pH 8.3 
(0.025M Tris; 0.192M glycine and 0.1% (w/v) SDS) at 20mA per gel using the Atto 
vertical mini-electrophoresis system, until the blue dye reached the bottom of the gel. 
Gels were stained for 15 minutes in 0.5% (w/v) Coomassie Brilliant Blue R-250 in 
acetic acid: water: methanol (1:10:8 v/v/v) and destained overnight in the same solvent 
system.
2.9 High performance liquid chromatography (HPLC)
2.9.1 HPLC with UV/vis detection
Purified antibodies and antibody conjugates were prepared as outlined in the relevant 
sections. These preparations were characterised by HPLC. The HPLC system used was 
a Beckmann System Gold programmable, solvent module 126 and detection module 166. 
The absorbance units full scale were set at 0.015, with detection set at 280 nm. The 
proteins were separated by gel filtration using a Phenomenex® Biosep-Sec S4000 10 pm 
column. The mobile phase was 0.1M sodium phosphate buffer, pH 7.0 (filtered and 
degassed), at a flow rate of 0.75 ml/min. Samples (20 pi) were injected into the system 
at concentrations between 0.5-1.0 mg/ml and the resulting chromatograms recorded.
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2.9.2 HPLC with photo-diode array detection
Antibody-fluorophore conjugates were analysed by HPLC with photodiode array (PDA) 
detection. The system consisted of a Waters 990 Millipore PDA detector; Waters 990 
plotter; Waters 990 Millipore pump; Waters 990 30 chromatogram measure APC 3 
computer and a protein Pak SW 300, 10 pm column. The mobile phase used was 0.1M 
sodium phosphate buffer, pH 7.0 (filtered and degassed), at a flow rate of 0.5 ml/min. 
Conjugate and non-conjugate samples (20 pi), were injected into the system, at protein 
concentrations of between 0.5-1.0 mg/ml. The peak of interest for each sample 
chromatogram was scanned from 230-500 nm using the PDA facility, and the resulting 
contour pattern recorded.
2.10 Fibre immunosensor fabrication
2.10.1 Fibre Polishing
Plastic clad silica fibre of core diameter 600 pm (CeramOptec Inc., Enfield, CT, USA), 
was used for the fabrication of the optical immunosensors. The fibres were first cut into 
-11 cm lengths using a fibre cutter. Both ends of these fibres had then to be polished 
to give an optical finish.
Approximately, 40 of these fibres were placed in a polishing chuck and fixed firmly in 
place using cementing wax. The fibre rods were left standing proud of the polishing 
chuck by approximately 1 cm. Three chucks were set up in the chuck-holder, as shown 
in Figure 2.1, and a spirit level was used to ensure that the fibre ends were parallel to 
the lower face of the chuck and chuck-holder, and in exact line with one another. The 
chuck-holder containing all of these rods was then placed on a Logitech PM2A polishing 
rig (Logitech Ltd., Glasgow, Scotland), as shown in Figure 2.2.
The polishing rig has 2 polishing plates, a steel plate for use with 9pm and 3pm 
polishing suspensions and a polyurethane plate for use with 0.125 pm polishing 
suspensions. A semi-circular mechanical arm sweeps across the radius of the polishing 
plate. The chuck-holder is placed in the semi-circular arm and as the arm sweeps across 
the rotating polishing plate, a spinning action is induced into the chuck holder. This 
spinning action improves the quality and uniformity of the polished surface. The rig also 
has a rotating drum mechanism which deposits polishing suspensions, dropwise, onto 
the rotating plate. The 9 pm A120 3 suspension was used first, until the majority of the 
cracks were removed from the fibre end face. The grinding action of this fluid,
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combined with the rotation of the steel polishing plate, for a duration of approximately 
3 h, polishes the end faces of the rods. The polishing solution was then replaced with 
the 3 pm A120 3 fluid and the process continued. The final polishing was carried out 
using the polyurethane plate and the 0.125 pm polishing suspension, to give a finer 
optical finish. After 3 hours, the fibre end face surfaces were examined microscopically. 
The fibre rods were removed from the chucks once the polishing was deemed 
satisfactory. The other ends of the fibres were now set up in the system exactly as 
before and the process repeated. The result is a bundle of ~10 cm long plastic clad silica 
fibre rods with both end faces polished.
Following cleaning with water and then alcohol, to remove any remaining polishing 
suspension and cementing wax, ~8 cm of the plastic cladding (primary coating) 
surrounding the fibre core was removed using a sharp scalpel, taking care not to damage 
the silica fibre core. The silicone cladding was removed using an etchant solution based 
on a methylene chloride /  sulphuric acid mixture, commercially available from Lumer 
(Bagnolet, France). The declad rods are left in contact with the etchant solution for 
about 15 min and then washed with water, followed by ethanol. An ethanol soaked lens 
tissue was used to wipe each rod individually, to ensure complete removal of cladding.
2.10.2 Antibody immobilisation to fibres
2.10.2.1 Cleaning of fibres
The exposed core was acid cleaned by immersion in a 1:1 mixture of concentrated HC1, 
and methanol for 30 min. Following washing several times in ultra pure water, the fibres 
were immersed in concentrated H2S 0 4 for 30 min and washed in ultrapure water. The
fibres were then placed in a beaker of boiling ultrapure water for 30 min. The fibres 
were then allowed to air dry.
2.10.2.2 Silanisation of fibres
A 2% (v/v) solution of mercaptopropyltrimethoxysilane (MTS) was prepared in 
anhydrous toluene and the acid-cleaned exposed core optical fibres were immersed in 
this solution for 2 h at room temperature. The reaction was carried out under an
atmosphere of nitrogen. Following silanisation the fibres were rinsed in dry toluene and 
allowed to air dry.
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2.10.2.3 Crosslinking of antibodies to the exposed core of optical fibres
N-gammamaleimidobutyryloxy succinimide ester (GMBS), was dissolved in 100 pi of 
dimethylformamide (DMF), and diluted in absolute ethanol to a final concentration of 
2mM. The fibres were immersed in this solution for 1 h and then washed in 0.15M PBS, 
pH 7.4. The purified antibody solution was diluted in PBS to a final concentration of 
50 pg/ml. The silanised and crosslinked exposed core optical fibres were immersed in 
the antibody solution for 1 h at room temperature. A ratio of 1 fibre per millilitre of 
solution was maintained, i.e. 20 fibres were immersed in 20 ml antibody solution. 
Antibody coated fibres were stored, until required, in 0.15M PBS, pH 7.4, containing 
0.02% (w/v) NaN3, as preservative.
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2.11 Fibre ELIS As
2.11.1 Working range of fibre probes
One-step and two-step enzyme-linked immunosorbent assays were performed on the 
fibre surfaces, in order to determine the working range of the fibre probes.
Fibre probes coated with affinity purified anti-CHLDH antibodies, were incubated in 1% 
(w/v) BSA in 0.15M PBS containing 0.05% (w/v) Tween 20, for 1 h at room 
temperature, to block the non-specific binding sites. For the two-step assay, each fibre 
was then incubated, in triplicate, in 3 ml CHLDH samples (0.39-10 pg/ml) in 1% 
BSA/PBS, (one fibre per test tube, such that 5.5 cm of the fibre length was covered), 
for 15 min at R.T. Each fibre was washed five times in 4 ml PBS-Tween and once in 
PBS alone. Three millilitres HRP-anti-CHLDH (working dilution, 1:4000), in 1% 
BSA/PBS, was then added to each test tube and incubated for 30 min at R.T. The fibres 
were again washed five times with PBS-Tween and once with PBS. Substrate (3 ml) for 
HRP (see section 2.5.1), was added to each test tube and incubated at 37°C for 30 min. 
The reaction was stopped by removing the fibres from the test tubes. The absorbance 
of each sample solution was measured at 405 nm on the Shimadzu spectrophotometer 
UV-160A.
A one-step assay was performed in a similar manner, except that the antigen samples 
and the second antibody were premixed for 1 min prior to incubation with the fibre. 
Controls (fibre probes coated with anti-mouse IgG) and blanks (no antigen) were also 
included.
2.11.2 Reproducibility and optimisation of antibody immobilisation procedures
The optimal coating concentration and the reproducibility of the immobilisation 
procedure was determined by performing an ELISA on the fibre surfaces. Commercially 
available HRP-anti-rabbit IgG (3 ml) was incubated with the rabbit anti-CHLDH coated 
fibres for 30 min at R.T. Following washing five times with PBS-Tween and once with 
PBS, the fibres were incubated with the substrate for HRP (see section 2.5.1), for 30 
min at 37°C. The reaction was stopped and read at 405 nm, as described in section
2.11.1. All coating concentrations were performed in triplicate. Goat-anti mouse IgG- 
coated fibres were used as the controls.
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2.12 Evanescent wave immunosensing
2.12.1 Optical System
The optical system used for the immunosensing experiments is outlined in Figure 2.3. 
In order to detect evanescent wave excited fluorescence, the system was required to 
separate the excitation radiation from the returning fluorescent light, as efficiently as 
possible.
An argon-ion air-cooled laser (Cathodeon, Oxford, U.K.), with a 488 nm line was used 
as the excitation source. This corresponds very closely with the excitation maximum of 
fluorescein. The light from the laser is passed through expanding optics; a microscope 
objective (A) of numerical aperture (NA.) 0.65, and a collimating lens (B). The light 
is then reflected from a Raman holographic edge filter C, (Physical Optics Corporation, 
Torrance, CA, U.S.A.), and launched via a microscope objective (D), of N.A. 0.65, to 
the antibody (or antigen) coated fibre, which is mounted in the flow cell. The thicker 
dotted line represents the expanded and collimated laser beam light. The holographic 
edge filter is designed to be used off-axis from 5-20 degrees. The reflecting mirrors E 
and F, are adjusted such that angle a  has a value of 12°. This corresponds to 0% 
transmission at 488 nm and approximately 77% transmission at 520 nm, the emission 
maximum of FITC.
The flow cell (manufactured by AGB Scientific), consists of a 9 cm long glass tube, of 
internal diameter 0.4 cm, with inlet and outlet ports at opposite ends and opposite sides, 
as shown in the diagram. Screw-on caps at both ends, hold rubber septums in place,, 
through which the fibres are threaded and held firmly in place during the experiments. 
Flow of liquids through the flow cell was controlled by a peristaltic pump at 5 ml/min. 
The flow cell is held in position in a metal frame which is attached to an X-Y-Z 
micropositioner, thus allowing optimisation of the launching position of the fibre.
The evanescent field of the guided radiation excites the fluorescein within the 
penetration depth (due to the immunoreaction) and a fraction of the fluorescence is 
captured by the fibre. The returning fluorescent light is coupled back along the same 
path, by higher order modes. It is transmitted by the holographic edge filter (which 
blocks 488 nm and transmits 520 nm), and is then focused by the optical lens (G) onto 
the detecting optical arrangement.
The fluorescein fluorescence is detected by a Hamamatsu photomultiplier tube (PMT), 
whose signal is amplified using a Ithaco current sensitive amplifier (model number
6 2
1642), and fed into a lock-in amplifier, LI A (Stanford Research systems, model SR510), 
for synchronous detection. The chopping wheel (I), operating at a frequency of 213 Hz, 
provides the reference signal for the LIA. A glass filter, H (Reynard Corp., San 
Clemente, CA, USA), which blocks 488 nm to 0.01% and transmits 520 nm at 95% was 
placed in front of the PMT for further spectral filtering of the exciting radiation from 
the fluorescence. The detected analogue signal was converted to digital format, and then 
passed to the PC for storage. The computer software measures the fluorescence signal 
as a function of time.
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Figure 2.3: Optical Arrangement for Evanescent Wave Immunosensing
A: microscope objective 
C: holographic edge filter 
E,F: reflecting mirrors 
H: glass filter
J : chopping wheel controller
B: collimating lens 
D: microscope objective N.A. 0.65 
G: focusing lens 
I: chopping wheel
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2.12.2 Evanescent wave immunosensing assays
Fibre probes with immobilised anti-CHLDH antibodies were incubated in 1% (w/v) BSA 
in 0.15M PBS, pH 7.4, until a steady baseline was established. The sample was prepared 
in the same solution and pumped into the flow cell at 5 ml/min, without exposing the 
fibre to air. Once the sample filled the flow cell, the pump was stopped. For all the 
immunoassays, a new fibre was used for each sample concentration. Controls (goat anti­
mouse antibody coated-fibres) were included in all experiments. The fluorescence signal 
was monitored for approximately 4 min, and the initial rate of fluorescence increase 
determined.
2.12.2.1 Two-step immunoassay
For the two step assay (Figure 2.4 (1)), the fibres were preincubated with different 
concentrations of CHLDH (30-10000 ng/ml) in 1% (w/v) BSA/PBS, for 15 min. FITC- 
labelled anti-CHLDH (20 pg/ml), in 1% (w/v) BSA/PBS was pumped into the flow cell, 
at 5 ml/min, and the fluorescence signal recorded.
2.12.2.2 One-step immunoassay
CHLDH (39-10000 ng/ml) prepared in 1% (w/v) BSA/PBS, was premixed with 20 pg/ml 
FITC-anti-CHLDH and within 1 min, injected into the flow cell at 5 ml/min, for the 
one-step assay (Figure 2.4 (2)). The fluorescent signal was recorded.
2.12.2.3 Direct immunoassay
FITC-labelled CHLDH samples (section 2.6.2), at concentrations ranging from 125-5000 
ng/ml, were pumped directly into the flow cell at 5 ml/min, for the direct assay (Figure
2.5 (1)). The fluorescent signal was recorded.
2.12.2.4 Competitive immunoassay
CHLDH (0.1 -10 pg/ml) was premixed with an excess of FITC-CHLDH and pumped into 
the flow cell at 5 ml/min. The CHLDH and FITC-CHLDH competes for binding to the 
fibre-immobilised antibody (Figure 2.5 (2)). The fluorescent signal was recorded.
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2.12.2.5 Regeneration experiment
A one-step assay (2000 ng/ml CHLDH + 20 pg/ml FITC-anti-CHLDH premixed) was 
performed 10 times, using the same fibre probe. The fibre was regenerated between 
experiments by pumping 0.1M glycine, pH 2.5, through the flow cell for 1 min.
2.12.2.6 Effect of increased FITC labelling on anti-CHLDH affinity using the 
evanescent wave immunosensor
Fibre probes coated with antigen (CHLDH) were used for this experiment. Anti-CHLDH 
purified by protein A affinity chromatography (section 2.4.3), was labelled at several 
fluorophore to protein ratios (50-1600 pg FITC per mg of protein) as outlined in section 
2.6.3. The effect of increased labelling on antibody affinity was determined by pumping 
100 pg/ml of each sample into the flow cell. A new fibre was used for each sample. The 
fluorescence signal was monitored for 7 min.
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Figure 2.4: Schematic representation of enzyme-linked or fluorescence-linked 
immunosorbent assays. The antibody is immobilised to the solid surface (A), and the 
non-specific binding sites on the surface are blocked with BSA (B). In the two step 
assay (1), the antigen is incubated with the immobilised antibody (C), followed by a 
washing step to remove any unbound antigen (D). The second labelled antibody is then 
added (E), followed by a washing step to remove any excess labelled antibody (F). If 
the label is a fluorophore, it is measured fluorimetrically. If the label is an enzyme, 
substrate (S) for the enzyme is then added, and the product (P) measured optically (G). 
In a one step assay (2), the antigen and second antibody are premixed and incubated 
with the immobilised antibody (C). The excess antibody and antigen are removed by 
washing (D) and the label detected as before (E).
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Figure 2.5: Schematic representation of direct and competitive fluorescent-linked 
immunoassay. The antibody is immobilised to the solid substrate (A), and the non­
specific binding sites on the surface blocked with BSA (B). In the direct assay (1), the 
FITC-labelled antigen is incubated at various concentrations with the immobilised 
antibody (C). Unbound labelled antigen is removed by washing (D), and the 
fluorescence detected using a fluorimeter (E). In the competitive assay (2), unlabelled 
and FITC labelled antibody, compete for binding to the immobilised antibody (C). 
Unbound moieties are removed by washing (D) and the label detected as before (E). An 
indirect relationship of fluorescence to antigen concentration results, because the more 
unlabelled antigen present, the less antibody sites left available for labelled antigen 
binding.
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2.13 BIAcore™ Studies
The BIAcore™ (Pharmacia Biosensor AB), is a biosensing device which operates on the 
principle of surface plasmon resonance (SPR). The details behind the principle of SPR 
and the operation of the Biacore™ are given in section I.4.3.2.2. All BIAcore™ 
experiments were performed with the assistance of Mr. Gary Keating, School of 
Biological Sciences, D.C.U.
2.13.1 Immobilisation to sensor chip surface
Antibody or antigen were immobilised (for different applications), to the Sensor chip 
CM5 (Pharmacia Biosensor AB). The sensor chip was inserted into the BIAcore™ 
instrument with the dextran/gold surface side in contact with the flow cells. The 
immobilisation procedure was controlled via the BIAcore™ computer and microfluidics 
system.
Filtered and degassed Hepes buffered saline, HBS, (lOmM HEPES, pH 7.4; 150mM 
NaCl, 3.4mM EDTA, 0.05% BIAcore™ Surfactant P20), was injected over the sensor 
chip, for 5 min at 5 pl/min. N-hydroxysuccinimide in H20  (lOOmM) and N-ethyl-N'- 
(dimethylaminopropyl)carbodiimidein H20  (400mM), were mixed 1:1 and 35 pi injected 
over the sensor chip at 5 pl/min, to activate the surface. Antibody or antigen solution 
(200 pg/ml), in lOmM sodium acetate buffer, pH 5.5, was then injected over the chip 
at a flowrate of 5 pl/min for 7 minutes. Excess reactive groups were deactivated by 
injecting 35 pi 1M ethanolamine hydrochloride, pH 8.5, at 5 pl/min. Finally, non- 
covalently bound material was removed via 2x1 minute pulses of lOmM HC1 and lx l 
minute pulse of 5mM NaOH at 5 pl/min.
Running buffer (HBS) was allowed to flow continuously over the chip at 5 pl/min 
between experiments.
2.13.2 BIAcore™ immunoassays
Direct (antigen alone), two step (antigen followed by second antibody) and one step 
(antigen and second antibody premixed) immunoassays were performed in the flow 
channel coated with the anti-CHLDH antibody. The antibody coated chip was 
regenerated between each new sandwich using 2x1 min pulses of lOmM HC1 and lx l 
min pulse of 5mM NaOH.
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2.13.2.1 Direct immunoassay
For the direct assay (Figure 2.5 (1)), the sample containing CHLDH (9-5000 ng/ml), in 
0.15M PBS, pH 7.4 was injected over the immobilised antibody chip for 2 min at a 
flowrate of 10 pl/min and the sensorgram recorded. Each sample was injected randomly 
and in triplicate with regeneration between each sample injection.
2.13.2.2 Two-step immunoassay ......
For the two-step assay (Figure 2.4(1)), the sample containing CHLDH (9-10000 ng/ml), 
in 0.15M PBS, pH 7.4 was injected over the immobilised antibody chip for 2 min at 10 
pl/min, followed by 20 pg/ml anti-CHLDH (FITC-labelled) for a further 2 min at 10 
pl/min, and the sensorgram recorded. This second antibody amplifies the signal and 
improves sensitivity. Each sample was injected randomly and in duplicate with 
regeneration of the surface between each sample.
2.13.2.3 One-step immunoassay
For the one-step assay (Figure 2.4(2)), the CHLDH sample (9-10000 ng/ml), in PBS was 
premixed with 20 pg/ml anti-CHLDH (FITC-labelled), and injected over the sensor chip, 
within 1 minute of mixing. The premixing was controlled by the computer and 
microfluidics system. The sample was injected for 2 min at 10 pl/min, and the 
sensorgram recorded. Samples were injected randomly and in duplicate, with surface 
regeneration between each sample.
2.133 FITC-labelled antibody studies
Anti-CHLDH antibodies were labelled at various fluorophore/protein ratios (section 
2.6.3), and the effect of increased labelling on the antibody affinity assessed using the 
BIAcore™.
FITC-anti-CHLDH (100 pg/ml) in PBS, was injected over the CHLDH-coated chip, for 
20 minutes at 2 pl/min and the sensorgram was recorded. The chip surface was 
regenerated using a 3 min pulse of lOmM HC1, 3 min pulse of 0.1M glycine, pH 2.5, 
and another 3 min pulse of lOmM HC1, at a flowrate of 2 pl/min.
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2.14 Miniaturised assay for LDH determination
A colorimetric assay for total LDH determination was miniaturised so that it could be 
performed in 96-well microtitre plates. Test or standard serum (40pl) was added to 
appropriate wells of a 96-well microtitre plate. Buffered lactate solution (0.07M lactate;
0.3M Tris/HCl, pH 8.5; 0.2% (w/v) BSA) was added to each well (110 pi) and the plate 
incubated at room temperature for approximately 10 min. Colour reagent (7:5mM NAD;
4.0mM INT; 1.6mM PMS) was added to each well (35 pi) and the plate ineubated at------------
room temperature, protected from light, for exactly 10 minutes. One molar HC1 (80 pi) 
was added to each well to stop the reaction. The absorbance of each well was read at 
492 nm on the Titertek Twinreader® Plus microplate reader.
2.15 LDH isoenzyme analysis by electrophoresis with densitometry scanning
The five isoenzymes of human LDH were separated by electrophoresis using a 
commercially available kit, Electrophoresis Systems™, LD Isoenzyme System (Ciba 
Coming Diagnostics Corporation).
One microlitre of sample (<1000 U/L) was applied to the 1% agarose gel (LD 
Isoenzyme Gel) and electrophoresis carried out in the barbital buffer provided (43mM 
sodium barbital; 7mM barbital) for 35 mins in the Universal Electrophoresis cell.
Following electrophoresis, the LDH isoenzymes were developed using the LD Reagent 
provided ((0.5M lithium L(+)-lactate; 15mM NAD; 7.3mM nitro blue tetrazolium and 
0.2mM methoxyphenazine methosulphate) diluted in 0.4% bicine-2-amino-2-methyl- 1,3- 
propanediol solution), at 37°C for 20 min, according to the manufacturers instructions.
The gel was washed in deionised water, to remove excess LD reagent and dried in an 
oven at 65°C for 2 hours.
The developed gel was scanned using a transmittance/reflectance scanning densitometer 
(Hoefer Scientific Instruments GS300), and the relative percentages of the individual 
LDH isoenzymes determined by integration.
2.16 Western blotting
Western blotting of proteins was carried out using the method described in Towbin et 
al. (1979). Samples to be blotted were first subjected to SDS-PAGE electrophoresis 
using 5-20% gradient gels, under non-reducing conditions, as outlined in section 2.8.1.
Following electrophoresis, the gel was soaked for 15 - 20 min in a bath containing 50
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ml blotting transfer buffer (25mM Tris + 192mM glycine, pH 8.3, containing 20% (v/v) 
methanol). The gel was blotted to nitrocellulose paper (Electran®, BDH), using a wet 
blotting system (Pharmacia Midget System™), for 45 min at 30V, followed by 45 min 
at 60V.
The blot was then transferred to a bath containing blocking solution, 3% (w/v) BSA in 
TBS-Tween (lOmM Tris/HCl, pH 8.0 + 150mM NaCl, containing 0.05% (v/v) Tween 
20), for 1 h at room temperature, and then washed once with TBS-Tween. The blot was 
then transferred to a bath containing 15 ml 1:100 dilution HRP-labelled anti-H4LDH 
antibody (section 2.5.2), diluted in 3% (w/v) BSA in TBS-Tween, and incubated for 2 
h at room temperature, with gentle agitation. The nitrocellulose blot was washed five 
times with 15 - 20 ml TBS-Tween, and once with TBS.
The HRP label was developed with 3,3’ diaminobenzidine tetrahydrochloride (10 mg 
DAB dissolved in 10 ml 50mM Tris buffer, pH 7.6 + 15 pi 3% (v/v) H20 2), which 
yields an insoluble brown product. The blots were developed at room temperature for 
15 min, washed with deionised water and air dried.
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CHAPTER 3
PRODUCTION, PURIFICATION AND 
CHARACTERISATION OF ANTIBODIES TO 
CHLDH AND THEIR USE IN THE 
DEVELOPMENT OF ANTIBODY-BASED ASSAYS
3.1 Introduction
This chapter is concerned with the production of polyclonal antibodies to chicken heart 
LDH (CHLDH), for use in the development of a model evanescent wave immunosensor 
(chapter 4). Antiserum was raised in rabbits, and the specific antibodies were purified 
by ammonium sulphate precipitation followed by affinity chromatography. The 
antibodies were labelled with horseradish peroxidase enzyme (HRP) or fluorescein 
isothiocyanate (FITC), and used in the development of enzyme-linked or fluorescence- 
linked immunosorbent assays, respectively, for the determination of CHLDH. Antibody 
and conjugate preparations were characterised by high performance liquid 
chromatography (HPLC), SDS polyacrylamide gel electrophoresis (SDS-PAGE) and 
spectral analysis.
3.2 Polyclonal antibodies.
Antibodies can be produced against any molecule capable of eliciting an immune 
response in a host animal. If an antigenic response is produced, then specific antiserum 
is obtained. This antiserum is polyclonal in nature, in that it contains a mixture of 
antibodies which will bind the antigen, but not at the same site or ‘epitope’, and with 
varying strength or ‘affinity’. Production of polyclonal antibodies rather than monoclonal 
antibodies is often more practical (Cahill et al., 1995). A monoclonal antibody 
preparation consists of identical antibodies which bind the same epitope on the antigen 
surface, with the same affinity. Production of monoclonal antibodies is much more time- 
consuming, relatively more expensive and requires a much higher level of expertise than 
polyclonal antibody production (Köhler and Milstein, 1975).
3.3 Immunisation.
Large molecular weight proteins (>10,000 Da), e.g. CHLDH (140,000 Da), tend to be 
much stronger immunogens than smaller molecules (haptens), such as drugs and 
hormones, which require crosslinking to a large carrier protein in order to produce an 
immune response (Erlanger, 1973). Although high molecular weight molecules generally 
elicit an immune response readily, adjuvants are used to maximise the response. 
Adjuvants consist of a number of substances, whose physical and/or biological properties 
when applied with immunogen affect the antibody response in various ways, but most 
importantly by potentiating class G immunoglobulin production, by increasing the
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efficiency of antigen presentation. Typical adjuvants include aluminium salts, heat- 
inactivated Bordetella pertussis, liposomes and muramyl dipeptides. The most commonly 
used adjuvant was developed by Freund. Freund’s Complete Adjuvant consists of a 
mixture of mineral oil, a suspension of heat killed Mycobacterium tuberculosis and the 
emulsifier Arlacel A. This preparation is used for the initial immunisation because the 
mycobacteria act as powerful stimulants for the cells of the immune system (Tijssen, 
1985). Freund’s Incomplete Adjuvant (no mycobacteria) is used subsequently for booster 
injections in subcutaneous sites because of its reduced pathogenic effects. The antigen 
solution is emulsified in the adjuvant to form a stable, oil-in-water emulsion and injected 
intradermally, subcutaneously, intramuscularly, intraperitoneally or intravenously 
depending on the physical nature of the injection, the species and the stage of the 
immunisation routine (Catty and Raykundalia, 1988).
The choice of animal is generally based on convenience. For polyclonal antibody 
production where large quantities of serum are required, the choice of animal is 
commonly between rabbits, goats, donkeys, sheep, horses and guinea pigs. Rabbits tend 
to be the most common choice since they are relatively inexpensive, easy to handle and 
maintain, and they yield relatively large amounts of serum (Bunin and Newman, 1991).
3.4 Antibody purification.
Removal of non-immunoglobulin serum proteins and non-specific immunoglobulin from 
antisera is important for many antibody applications. Specific antibodies can be purified 
from serum to different degrees using techniques such as ammonium sulphate 
precipitation, affinity chromatography (Yarmush etal., 1992), absorption of antisera and 
HPLC (Carty and O ’Kennedy, 1988). These techniques can be used singly or in various 
combinations.
Ammonium sulphate precipitation is commonly used as an initial crude preparation step. 
Salt precipitation works on the principle of differential solubility. The solubility of 
protein species differ according to their degree of hydrophobicity and increasing the 
amounts of salt will enhance hydrophobic interactions between the proteins and cause 
precipitation. Thus, we may selectively precipitate specific fractions of the dissolved 
protein in the sample. This purification step removes up to 50% of contaminating 
proteins.
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If it is known which non-specific antibodies are present in the serum sample, these may 
be removed by absorbing the antiserum on a matrix to which these antigens have been 
immobilised. The advantage of absorption is that the harsh denaturing conditions 
required for the dissociation of the bound antibody in affinity chromatography are 
avoided.
Affinity chromatography isolates antigen-specific antibodies by immobilising the antigen 
to a gel matrix, typically CNBr-activated Sepharose. The antibody binds specifically to 
the antigen and subsequent to removal of all other proteins by washing with the binding 
buffer, the specific antibody is eluted by conditions which do not favour antibody- 
antigen binding, such as a pH change (Hudson and Hay, 1980).
Protein A affinity chromatography columns can be used to selectively remove antibodies 
of the IgG class. Protein A, isolated from Staphylococcus aureus, binds to the Fc portion 
of class G immunoglobulins. Again, the class G immunoglobulins can be eluted by 
changing the environmental conditions so that they are unfavourable for binding (Zola 
and Brooks, 1982). Antibodies can be further purified by HPLC, based on size exclusion 
methods where differences in molecular weights of proteins or classes of 
immunoglobulins is exploited.
3.5 Labelling of antibodies with HRP enzyme.
Horseradish peroxidase (HRP), (3-galactosidase and alkaline phosphatase are the most 
commonly employed enzymes for labelling of antibodies for use in immunoassays. The 
properties of these enzymes which make them suitable for ELISA’s include a) high 
turnover number, b) stable on storage, c) ease of conjugation, d) easily detectable 
activity and e) compatibility with immunoassay conditions.
HRP was employed for labelling of anti-CHLDH antibody. HRP is a glycoprotein and 
is therefore most easily conjugated to antibody proteins via the periodate method. The 
method of Tijssen and Kurstak (1984) was used. The carbohydrate residues on the 
enzyme are oxidised yielding aldehyde groups. These aldehyde groups are then allowed 
to react with the amino groups of the immunoglobulin molecule, forming Schiff bases. 
These Schiff bases are stabilised by sodium borohydride, which acts by reducing the 
aldehyde groups, thereby preventing hydrolysis. The labelled antibody and unlabelled 
IgG are purified from the free HRP by ammonium sulphate precipitation. HRP is soluble 
in solutions of (NH4)2S 0 4 up to 70-80% saturation, and therefore, solutions of 50%
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(NH4)2S 04, can be used to selectively precipitate the labelled and unlabelled IgG. It has 
been reported that using this procedure 90% of the HRP is conjugated, retaining 90% 
of its activity.
3.6 Labelling of antibodies with fluorescein.       ..
Fluorescence is the emission of a photon of light, from a molecule which has been 
placed in the excited state by the absorption of another photon. This emitted photon is 
of lower energy than the absorbed photon, and therefore, is of a longer wavelength 
(Ward and Fothergill, 1976).
Several fluorescent compounds have been used to label proteins, including amino- 
methyl-coumarin-acetic acid (AMCA), tetramethyl rhodamine isothiocyanate (TRITC) 
and highly fluorescent algal pigments called phycobiliproteins (Kronick, 1986), but by 
far the most commonly used fluorophore is fluorescein isothiocyanate (FITC), a 
functionalised derivative of fluorescein.
Fluorescein has several properties which makes it suitable for use as an antibody label. 
It has a high fluorescent yield (extinction coefficient and quantum yield), is available 
in a form that can be easily conjugated with proteins and does not change the isoelectric 
point of the protein on conjugation, is highly fluorescent at neutral pH and compatible 
with immunoassays conditions. However, it has a small Stoke’s shift and is subject to 
photobleaching (Haughland, 1991).
The conjugation of antibodies with FITC proceeds by nucleophilic attack of the 
unprotonated e-amino group of lysine on the fluorochrome, resulting in a thiourea bond. 
At pH 9.5, most of the lysines are unprotonated, and maximal efficiency of conjugation 
is achieved. Antibody and fluorophore are mixed at controlled ratios, depending on the 
protein concentration. Conjugation is favoured at high antibody concentrations, but the 
significance of competing hydrolysis increases at low antibody concentrations (<2 
mg/ml). It has been shown that a fluorophore/protein ratio of 1-4 is optimal for labelled 
antibodies. However, quenching due to overconjugation is not a serious problem with 
FITC, as it is for TRITC (Goding, 1983).
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3.7 Enzyme-linked and fluorescence-linked immunosorbent assay.
The development of methods for chemically coupling detectable entities such as 
enzymes and fluorophores to antibodies, so that they both retain their biological activity 
and the realisation that antibodies and most antigens could be immobilised to solid 
surfaces in functional form, led to the concept of enzyme-linked (reviewed by 
O ’Kennedy, 1989), and fluorescence-linked immunosorbent assays (Smith et al., 1981). 
In such immunoassays, the quantification of antigens or antibodies is facilitated by this 
enzyme or fluorophore labelling, as they allow detection of immunocomplexes formed 
on a solid phase. The fixed enzyme, once washed free of excess reagents, and on 
subsequent reaction with its substrate, yields a coloured product, which can be detected 
optically. The optical density of the coloured product can be related to antigen 
concentration. In the case of a fluorescent label, the fluorescence can be detected directly 
using a fluorimeter.
Immunoassays can be divided into homogenous or heterogenous assays. In a 
heterogenous assay, a separation step is required where the free antibody and antigen is 
separated from the complexed solid-phase bound antigen-antibody. The quantifiable 
signal from the complex does not differ from the free entity and therefore without this 
separation step, interference would occur. In a homogenous assay, this separation step 
is not required. The binding of antigen and antibody results in a change in the activity 
of the label and therefore this activity can be detected without the problems of 
interference.
Immunoassays can also be divided into competitive (Egan et al., 1991) and non­
competitive assays (Cousin et al., 1992). The former is based on a competitive 
equilibrium between an excess of labelled and unlabelled antigen (or antibody), i.e. the 
analyte to be determined, for a limited amount of its binding protein. The more 
unlabelled species present, the less of the labelled species that will bind and an indirect 
relationship results. In a non-competitive assay, the analyte to be measured complexes 
with its binding protein bound to a solid phase. A second labelled antibody binds to this 
complex and is measured.
The two-site sandwich immunoassay presented in this chapter is a non-competitive, 
heterogenous assay. The same polyclonal antibody preparation was used as the 
immobilised capture antibody and the second labelled antibody. The antigen CHLDH
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is large, having a molecular weight of 140000 Da, and so has sufficient epitopes for 
both antibodies in the sandwich (Shriver-Lake et ah, 1993).
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Results
3.8 Production and purification of anti-CHLDH antibodies
3.8.1 Titre of anti-CHLDH antiserum
Antisera to chicken heart LDH (CHLDH) was obtained by immunisation of New 
Zealand White rabbits, with the commercially available purified protein (section 2.2.1). 
The antigen was prepared in Freund’s adjuvant and injected intramuscularly. The highest 
antibody titre achieved was 1:32,000. The titre was taken to be the serum dilution which 
gave an absorbance reading of half the absorbance reading of the undiluted serum. 
Normal rabbit serum (taken before the rabbit was immunised), was also titred as a 
control (Figure 3.8.1).
3.8.2 Purification of anti-CHLDH antibodies
Specific anti-CHLDH antibodies were purified from the antiserum by ammonium 
sulphate precipitation and affinity chromatography as described in sections 2.4.1 and
2.4.2. A sepharose affinity column was prepared by linking CHLDH to CNBr-activated 
sepharose. Only antibodies specific for CHLDH, bound to the immobilised antigen. 
Unbound proteins were removed by washing the column with binding buffer and the 
specific antibodies were eluted by changing the pH of the elution buffer. Both IgG and 
IgM classes of antibody are isolated by affinity chromatography, as the purification is 
based on specificity alone. The titre of the purified antibody was determined as for the 
unpurified antiserum (Figure 3.8.1), and was found to be 1:32,000.
3.8.3 Characterisation of purified anti-CHLDH antibody by HPLC
A sample of the purified antibody and a commercially available, affinity-purified goat 
anti-mouse IgG antibody, were analysed and compared by HPLC, as described in section
2.9.1 (Figure 3.8.2). The retention times of the purified anti-CHLDH antibody and the 
commercial antibody preparation were 15.07 and 15.09 minutes, respectively. The 
smaller peaks found at retention times between 18-20 min, were shown to be due to the 
preservative thiomersal and glycine salts. The commercial preparation has an extra peak 
at 13.91 min, which is probably due to slight antibody aggregation during storage.
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Figure 3.8.1
Production of anti-CHLDH antibodies. Serial dilutions (1:100 - 1:128000) of normal 
rabbit serum (0), unpurified antiserum (■) and affinity-purified anti-CHLDH antibodies 
(□) were prepared in 0 .15M PBS, pH 7.4 and the titre determined as outlined in section
2.5.1. The antiserum and purified antibody preparations have a titre of 1:32000, which 
is an indication that there is a large quantity of specific antibody present.
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Figure 3.8.2
HPLC chromatograms of a) affinity-purified anti-CHLDH antibody and b) a 
commercially available affinity-purified antibody, anti-mouse IgG (Sigma), using a 
Phenomenex Biosep-Sec S4000 10 pm column (section 2.9.1). The mobile phase was 
0.1M sodium phosphate buffer, pH 7.0, at a flow rate of 0.75 ml/min. Proteins were 
detected at 280 nm. The retention times of both antibodies was 15.08 min. The purity 
of the anti-CHLDH antibody compares favourably with the commercial antibody.
a)
b)
3.8.4 Characterisation of purified anti-CHLDH antibody by SDS-PAGE
The purified antibody was also characterised by SDS-PAGE electrophoresis, as outlined 
in section 2.8. The affinity-purified anti-CHLDH antibody and a commercially available 
affinity-purified goat anti-human IgG antibody, were electrophoresed under non-reducing 
conditions using a 5-20% gradient gel, and stained using Coomassie Brilliant Blue. The 
molecular weight markers are shown in lane 1 (Figure 3.8.3). Affinity-purified anti- 
CHLDH and affinity-purified anti-human IgG (M.W. 150000-180000 Da) are shown in 
lanes 3 and 4, respectively. BSA (M.W. -66000 Da) was run in lane 2. The single band 
for the anti-CHLDH IgG indicates a highly purified preparation of IgG alone, which 
compares favourably with the commercial preparation. The higher molecular weight of 
the goat antibody over the rabbit antibody could be due to some species variability.
3.9 Conjugation of horse radish peroxidase (HRP) to anti-CHLDH antibody.
Affinity-purified anti-CHLDH antibody was conjugated to the enzyme, HRP, as 
described in section 2.5.2. The HRP-anti-CHLDH antibody conjugate and the 
unconjugated antibody were purified from the unconjugated enzyme by ammonium 
sulphate precipitation and diluted 1:1 with glycerol. The glycerol stabilises the conjugate 
during storage at -20°C, as it prevents ice formation.
3.9.1 Characterisation of HRP-anti-CHLDH antibody by HPLC
The HRP-labelled anti-CHLDH antibody was characterised by HPLC as described in 
section 2.9.1. A peak was obtained at a retention time of 9.49 min, indicating that a 
substance of molecular weight greater than IgG (which was shown to be represented by 
the peak at 15.10 min), was present (Figure 3.9.1). The molecular weight of the HRP- 
anti-CHLDH antibody conjugate will vary depending on the number of peroxidase 
molecules coupled to the antibody. Different levels of conjugation were observed 
between 9.49 and 15.10 min., indicated by the fact that the absorbance reading does not 
return to the baseline. The large peak seen at 19.63 min was shown to be due to the 
glycerol added, to stabilise the conjugate during storage. No free peroxidase was found 
in the sample. If any peroxidase was present, one would expect to find a peak between
15.10 (IgG, m.w. -150,000 Da) and 19.63 (glycerol, m.w. -80  Da) min, since the 
molecular weight of peroxidase is -44,000 Da.
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Figure 3.8.3
Analysis of the purity of the affinity-purified anti-CHLDH antibody by SDS-PAGE (5- 
20% gradient gel), under non-reducing conditions, and stained with Coomassie Brilliant 
Blue (section 2.8). Prestained molecular weight markers (Sigma SDS-7B), with 
molecular weights ranging from 32,000 - 195,000, were electrophoresed in lane 1. The 
molecular weight markers were triosephosphate isomerase (32,000), lactic dehydrogenase
(35.000), fumarase (52,500), pyruvate kinase (63,000), fructose 6-phosphate kinase
(84.000), P-galactosidase (112,000) and c^-macroglobulin (195,000). Affinity-purified 
anti-CHLDH antibody and affinity-purified anti-human IgG antibody were 
electrophoresed in lanes 3 and 4, respectively. BSA was run in lane 2. The purity of the 
anti-CHLDH antibody (band found at molecular weight between 112 kDa and 195 kDa), 
compares favourably with the commercial preparation, indicated by the lack of 
contaminating protein bands.
1 2 3 4
Figure 3.9.1
HPLC chromatogram of HRP-labelled anti-CHLDH antibody using a Phenomenex 
Biosep-Sec S4000 10 pm column. The mobile phase was 0.1M sodium phosphate buffer, 
pH 7.0, at a flowrate of 0.75 ml/min. Protein was detected at 280 nm. The presence of 
HRP-labelled anti-CHLDH antibody is indicated by the large protein peak at 9.49 min. 
Unconjugated anti-CHLDH antibody is also present in the sample, as indicated by the 
peak at 15.10 min. The large peak seen at 19.63 min was shown to be due to the 
glycerol added to stabilise the conjugate during storage.
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3.9.2 Determination of the working dilution of HRP-Iabelled anti-CHLDH 
antibody
The working dilution of the HRP-anti-CHLDH antibody was determined, for use in an 
ELISA, as described in section 2.5.3. Serial dilutions (1:50 - 1:25600) were prepared in 
0.15M PBS, pH 7.4. The working dilution of the conjugate was determined to be 1:4000
(Figure 3.9.2).
3.10 Determination of CHLDH by two-site sandwich ELISA
Samples of CHLDH were prepared at concentrations ranging from 0.005-10 pg/ml, in 
0.15M PBS, pH 7.4 and used in the ELISA. The optimal coating antibody concentration 
was determined to be 5 pg/ml, as higher antibody concentrations did not give increased 
binding to the plate. The HRP-anti-CHLDH second antibody was used at its working 
dilution of 1:4000. Negative controls (heart LDH from rabbit, porcine and bovine 
sources) were included. PBS alone was added to some control wells.
The ELISA was carried out as described in section 2.5.4 and the results plotted on a 
linear/log scale. The standard curve shown in Figure 3.10.1. The curve is linear between 
0.020-0.625 pg/ml (Figure 3.10.2).
3.11 Labelling of anti-CHLDH antibody with fluorescein
Affinity-purified anti-CHLDH antibodies were conjugated with fluorescein 
isothiocyanate, a functionalised derivative of fluorescein according to the method of' 
Goding (1984), as outlined in section 2.6.1. The conjugate was purified by gel filtration 
on a Sephadex-G25 column. The fluorophore to protein ratio, F/P, (i.e. the number of 
FITC molecules per antibody molecule), was estimated by the absorbance method using 
the formula given in section 2.6.1. (The and Feltkamp, 1970). The F/P was determined 
to be between 3-5, for all the conjugate preparations undertaken.
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Figure 3.9.2
Determination of the working dilution of HRP-anti-CHLDH antibodies. Serial dilutions 
(1:50 - 1:25600) of the conjugate were prepared in 0.15M PBS, pH 7.4 and titred as 
outlined in section 2.5.3. The working dilution was determined to be 1:4000, as this was 
the dilution which gave an absorbance value of half of the lowest dilution (1:50) 
absorbance value.
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Figure 3.10.1
Determination of the linear range of the two-site sandwich ELISA for CHLDH. Samples 
(0.005 - 10 pg/ml CHLDH) were prepared in 0.15M PBS, pH 7.4, and the ELISA was 
performed as outlined in section 2.5.4. The second antibody, HRP-labelled anti-CHLDH 
antibody, was used at its working dilution of 1:4000. Absorbance values were plotted 
against the log CHLDH concentration. The linear range was determined to be between 
0.0200 - 0.625 pg/ml (see figure 3.10.2).
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Figure 3.10.2
Linear range of two-site sandwich ELISA for CHLDH. Absorbance values were plotted 
against the log CHLDH concentration. The linear range is between 0.020 and 0.625 
pg/ml (r=0.999).
log CHLDH concentration (ug/ml)
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3.11.1 Characterisation of FITC-anti-CHLDH antibody by spectral analysis
Unconjugated IgG (anti-CHLDH antibody), i.e. IgG sample which was subjected to the 
conjugation procedure in the absence of FITC, and FITC-anti-CHLDH antibody were 
diluted in 0 .15M PBS, pH 7.4, and scanned from 250-550 nm using the Shimadzu 
UV/vis spectrophotometer. The resulting scans are shown in Figure 3.11.1. The IgG 
spectra has an absorbance peak with a maximum at 280 nm, whereas the FITC-IgG 
conjugate has the same absorbance peak at 280 nm but also an absorbance peak at 495 
nm, the absorbance maximum of fluorescein.
3.11.2 Characterisation of FITC-anti-CHLDH antibody by HPLC with PDA 
detection
The FITC-IgG conjugate and unconjugated IgG were characterised by gel permeation 
HPLC with photodiode array (PDA) detection, as outlined in section 2.9.2. The peak 
retention time of IgG using the protein Pak SW 300, 10 pm column, was found to be 
approximately 15.5 min. All the peaks which were initially detected at 280 nm, were 
scanned from 220-600 nm, and the resulting contour pattern recorded (Figure 3.11.2). 
The IgG sample produced a single absorption peak centred at 280 nm. Absorbances 
below 250 nm are due to buffer solutions. The peak found at 22.5 min is due to the 
added preservative, thiomerosal. The contour plot for the conjugate sample shows an 
extra absorbance peak centred at 495 nm, at the same retention time as IgG. This proves 
that the FITC is conjugated to the protein. FITC has a very low molecular weight, 389.4 
Da, so if it was not conjugated to the protein one would expect it to have a retention 
time >22 min.
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Figure 3.11.1
UV/visible scans of a) unconjugated anti-CHLDH antibody b) unconjugated FITC and 
c) FITC-anti-CHLDH antibody. The samples were prepared in 0.15M PBS, pH 7.4 and 
scanned from 250-550 nm, using the Shimadzu UV/vis spectrophotometer. The scan of 
unconjugated anti-CHLDH antibody shows a protein absorbance peak at 280 nm, while 
the FITC-labelled anti-CHLDH antibody shows a protein peak at 280 nm and the 
appearance of a new peak at 495 nm. This peak at 495 nm was shown to be due to
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HPLC chromatogram contour pattern of a) unconjugated anti-CHLDH antibody and b) 
FITC-anti-CHLDH antibody, with PDA detection (section 2.9.2). All the peaks detected 
initially at 280 nm were scanned from 220-600 nm. The unconjugated antibody sample 
produced a single absorption peak at 15.5 min, while the FITC-labelled anti-CHLDH 
antibody produced two peaks at the same retention time, one at 280 nm and the other 
centred at 495 nm. This proves that the FITC is conjugated to the antibody.
Figure 3.11.2
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3.11.3 Determination of the working dilution of FITC-anti-CHLDH antibody
The working dilution of the conjugate for use in immunoassays, was determined as 
described in sections, 2.6.3 and 2.5.3. Serial dilutions 1:25-1:6400 were prepared in 
0.15M PBS, pH 7.4, and added to CHLDH-coated fluorimeter microtitre plates 
(Dynatech). The fluorescence intensity of the contents of each well was read using the 
microtitre plate reader facility of the Perkin-Elmer fluorimeter, with the excitation and 
emission wavelengths set at 488 nm and 520 nm, respectively. The excitation and 
emission slit widths were set at 10 nm. Unconjugated antibody (anti-CHLDH antibody) 
and FITC-labelled non-specific antibody (FITC-anti-mouse IgG) were included as 
controls. The working dilution of the FITC-anti-CHLDH antibody was determined to be 
between 1:100-1:150, as this was the dilution which gave a fluorescence intensity of half 
the lowest dilution (1:25), fluorescence intensity value (Figure 3.11.3).
3.11.4 Fluorescence-linked immunosorbent assays
One-step (antigen and labelled-antibody premixed before adding to the immobilised 
antibody) and two-step (antigen and labelled-antibody added at separate times to the 
immobilised antibody) fluorescence-linked immunosorbent assays were performed in 
Dynatech fluorimeter microtitre plates. These assays were performed to assess the 
labelled antibodies in the immunoassays, and to compare the one-step and two-step 
assays in terms of sensitivity and range.
3.11.4.1 One-step fluoroimmunoassay
Antigen (CHLDH) concentrations in the range 0.015 - 10.0 pg/ml, were premixed with 
a 1:100 dilution of FITC-anti-CHLDH antibody (working dilution as determined in 
section 3.11.3), and added to the anti-CHLDH antibody coated plate (section 2.6.3.1), 
in triplicate. Following a washing step, the fluorescence was determined, as outlined in 
section 3.11.3. The standard curve is shown in Figure 3.11.4. The curve is linear 
between 0.5 - 2.0 pg/ml (r=0.970). Above 2.0 pg/ml, the second labelled antibody is no 
longer in excess, and so a decrease in fluorescence is observed.
3.11.4.2 Two-step fluoroimmunoassay
The two step fluoroimmunoassay was performed under the same conditions as the one 
step assay, except that the CHLDH and the anti-CHLDH antibody were incubated with
9 2
the plate separately, with a washing step between each incubation (section 2.6.3.2). The 
standard curve is shown in Figure 3.11.4. The curve is linear between 0.125 - 4.0 pg/ml 
(r=0.993). Above 4.0 pg/ml, the curve levels off, indicating that the capture antibody is 
saturated with antigen.
I
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Figure 3.11.3
Determination of the working dilution of FITC-labelled anti-CHLDH antibody. Serial 
dilutions of the labelled antibody were prepared in 0.15M PBS, pH 7.4, and titred as 
outlined in sections 2.6.3 and 2.5.3. The fluorescence intensity was read at excitation 
and emission wavelengths of 488 nm and 520 nm, respectively, with the excitation and 
emission slit widths set at 10 nm and 10 nm, respectively. The fluorescence intensity 
was plotted against the log FITC-anti-CHLDH antibody dilution. The working range was 
determined to be 1:100 - 1:150, as this was the dilution range which gave a fluorescence 
intensity value of half the lowest dilution (1:25) fluorescence intensity value.
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Figure 3.11.4
One-step (■) and two-step (□) fluorescence-linked immunosorbent assays (section 
3.11.4), performed on fluorimeter microtitre plates. Antigen (CHLDH) samples, in the 
range 0.015 - 10.000 pg/ml, were prepared in 0.15M PBS, pH 7.4, and the assays 
performed as outlined in section 2.6.3.1 and 2.6.3.2., using a 1:100 dilution of FITC- 
anti-CHLDH antibody. Fluorescence intensity values were read at excitation and 
emission wavelengths of 488 nm and 520 nm, respectively, with the slit widths set at 
10 nm. The intensity values were plotted against log CHLDH concentration. The linear 
range of the one-step assay was 0.5 - 2.0 pg/ml (r=0.970) and 0.125 - 4.000 pg/ml 
(r=0.993) for the two-step assay.
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3.12 Discussion
This chapter outlines the production, purification and characterisation of polyclonal 
antibodies against LDH, isolated from chicken heart muscle. The purified antibodies 
were subsequently labelled with HRP, for enzyme-linked immunosorbent assay 
development, and labelled with FITC, for use in the development of a model evanescent 
wave fibre optical immunosensor (Chapter 4).
The antigen, CHLDH, is a large molecular weight protein (Cahn et al., 1962), and so 
does not require crosslinking to a carrier molecule for production of an immune 
response. A high titre polyclonal sera was obtained, 1:32000, after repeated 
immunisations. The antiserum contains antibodies of different affinities against different 
epitopes on the CHLDH surface. The antibodies were purified by immunospecific 
affinity chromatography, resulting in specific antibodies only, against the CHLDH. This 
method of purification was feasible as the CHLDH is inexpensive, and commercially 
available in a purified form. Immunospecific affinity chromatography (Eveleigh and 
Levy, 1977) requires large quantities of purified antigen and so preparation of an affinity 
column is not feasible for all antigens. Other methods of purification such as affinity 
chromatography using protein A, which binds to the Fc portion of class G 
immunoglobulin (Underwood et al., 1983), or Affi-T columns, a matrix with an 
immobilised thiophilic ligand which binds to the disulphide linkages in the IgG molecule 
(Yurov et al., 1994), isolate the immunoglobulin fraction of an antiserum, which 
contains both specific and non-specific (host) antibody.
A two-site Sandwich enzyme-linked immunosorbent assay (ELISA), was developed using 
HRP-labelled anti-CHLDH antibody as the second antibody. The sandwich assay system 
is simple, specific and sensitive (Catty and Raykundalia, 1988). The linear range scans 
two orders of magnitude (0.020 - 0.625 pg/ml), but the absorbance change was large for 
small changes in concentration. The sensitivity of a two-site ELISA depends on the 
surface concentration of the immobilised antibody, the purity of the immunoreactants 
and the concentration of the labelled species. The fact that the antibodies are 
immunospecifically affinity-purified ensures that the surface density of specific antibody 
is high.
Often two-site sandwich ELISAs are performed employing high affinity monoclonal 
antibodies as the solid phase immobilised antibody. After exposing the immobilised 
antibody to the test sample, and following washing, the immunocomplex is exposed to
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another monoclonal antibody which binds a different (Corti et al., 1994) or repeated but 
spatially distant epitope on the same antigen (Wang et al., 1994). Monoclonal antibodies 
are expensive and time-consuming to produce, however the sensitivity and specificity 
of immunoassays using monoclonal antibodies is very high. The disadvantage of the 
double monoclonal system is that there must be two target epitopes on opposite sites of 
the antigen, to facilitate detection. Alternatively, the second antibody can be polyclonal 
and so bind to several epitopes on the antigen surface (Akhoundi et al., 1994), thereby 
increasing sensitivity. The ELISA developed here however, employed the same 
polyclonal preparation as the capture and labelled antibody. The antigen is large and so 
has several epitopes spatially separated over its surface. The fact that the antibody was 
affinity purified increases the sensitivity of the assay, as all of the capture antibody is 
specific for the CHLDH. It is difficult however to purify the high avidity fraction of the 
antibody, without denaturing the binding sites.
The purified antibodies were assessed for purity by HPLC using a gel permeation 
column and SDS-PAGE. Both methods separate the molecules in a sample on the basis 
of size, and the number of peaks (HPLC) or bands (SDS-PAGE) detected gives 
information on the relative purity of the sample. The largest molecular weight molecule 
elutes first from the HPLC gel permeation column, and so high molecular weight 
molecules have shorter retention times than low molecular weight molecules (Carty and 
O ’Kennedy, 1988). The affinity-purified anti-CHLDH antibody was shown to be 
relatively pure since only one strong peak was visible at a retention time of 15.08 min. 
The smaller peaks were shown to be due to the added preservative, thiomerosal and 
glycine salts. Glycine buffer was used to elute the specific antibody from the affinity 
column. The preparation was not dialysed sufficiently to remove all the glycine salts. 
SDS-PAGE allows visualisation of the purity of the antibody preparation, by staining 
the separated proteins, with a protein specific dye, Coomassie Blue. The proteins are 
separated in the gel on the basis of size, by molecular sieving through the pores in the 
gel (Laemmli, 1970). The smaller molecules move further through the gel. The 
separation can be improved by varying the % acrylamide in the gel, which varies the 
pore size of the gel matrix. Only one blue band was visualised on the gel indicating that 
the purification yielded only immunoglobulin. There is a slight difference in molecular 
weight of the immunoglobulin from the rabbit and goat (commercial) sources. This was 
not unexpected, since the molecular weight of IgG from different animal species is
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slightly different. This is probably due to the different ratios of the K and X light chain
types in different animal species (chapter 6, Tijssen, 1985).
The anti-CHLDH antibody was labelled with a derivative of fluorescein (FITC) for use 
in the development of the evanescent wave fibre-optic immunosensor. The conjugate 
was characterised by gel permeation HPLC with photodiode array detection (Escribano 
et al., 1988). The photodiode array generates an absorption spectrum over a range of 
wavelengths at specified time intervals (typically every 0.5 second). Unlabelled anti- 
CHLDH antibody and FITC-labelled antibody was passed through the column and the 
contour plots reveal an extra absorption peak between 460 - 510 nm, for the FITC- 
labelled antibody.
One-step and two-step two-site sandwich fluoroimmunoassays were performed using the 
FITC-labelled anti-CHLDH antibody at its working dilution of 1:100. In the one-step 
assay, the CHLDH and FITC-anti-CHLDH antibody were premixed, allowing the antigen 
and labelled antibody to bind in solution, before incubating with the capture antibody. 
The one-step assay is simpler and quicker to perform as the analyte and labelled 
antibody are added in one step. Corti et al., (1994), performed a one-step immunoassay 
for the quantitation of tumour necrosis factor (TNF) a . The immunoassay, however, 
employed monoclonal antibodies against different epitopes. The anti-CHLDH antibody 
is polyclonal in nature and therefore binds to several epitopes on the antigen surface. 
The antigen is a large molecule and so for a limited concentration range there are 
enough epitopes left free to bind to the capture antibody. The rate at which the ■ 
immunocomplex binds to the immobilised antibody would be reduced, however, due to 
steric hindrance and diffusional effects.
The linear range of the two-step assay is wider than that of the one-step assay. It is clear 
from Figure 3.11.4, that the one-step assay is sensitive within a very limited linear 
range. At high concentrations of antigen, the labelled antibody is no longer in excess and 
so a decrease in the fluorescence is observed. This ‘high-dose hook effect’ can be 
shifted to higher antigen concentrations by using a lower dilution of labelled antibody. 
This may result in higher background fluorescence and reduce the sensitivity at the 
lower end of the antigen concentration scale, as the number of free epitopes for low 
concentrations would be reduced.
In conclusion, antibodies against the CHLDH were produced, immunospecifically 
purified and labelled with FITC, for the development of the evanescent wave fibre optic
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immunosensor described in chapter 4. An ELISA system was developed and was used 
for model fibre ELISAs (chapter 4), to assess the optimal coating concentration etc. of 
the fibre probes. The feasibility of performing one-step and two-step 
fluoroimmunoassays with the same batch of polyclonal antibodies was also investigated.
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CHAPTER 4
DEVELOPMENT OF A FIBRE OPTICAL 
FLUOROIMMUNOSENSOR BASED ON THE 
EVANESCENT WAVE TECHNIQUE
4.1 Introduction
This chapter decribes the development of an antibody-based optical biosensor. Chicken 
heart LDH was used as the analyte in this model system. The fluorescently-labelled 
immunoassay system was performed on the exposed core of optical fibres, and the 
evanescent wave was used to probe the reaction. The binding of antibody and antigen 
was monitored in ‘real-time’. The fibre-based immunoassay was optimised using ELISA 
techniques. The evanescent wave optical biosensor was compared to a commercially 
available biosensor based on surface plasmon resonance, the BIAcore™.
4.2 The evanescent wave
When an electromagnetic wave (light ray), is incident on the interface between two 
dielectric media, having refractive indices, nj and n2, such that n ^ n ^  and when the 
light ray angle, a , is greater than the critical angle, a c, total internal reflection results, 
with no refracted light entering the lower refractive index medium (Figure 4.1(a)). The 
critical angle of the waveguide is determined by the refractive indices of the two media, 
according to the following formula (Love et al., 1991):
o  = s i n _1 ( — ) (4.1)
An electromagnetic wave analysis of this situation yields a more complete picture. In 
the denser medium, the superposition of the incident and the reflected light wave, results 
in the generation of an electromagnetic standing wave (Figure 4.1(b)). In addition, an 
electromagnetic wave extends a short distance, typically 0.1 - 1.0 pm (<^0, the 
wavelength of the incident light in a vacuum), into the lower refractive index medium 
(n2). This non-propagating electromagnetic radiation is called the ‘evanescent wave’. The 
amplitude of the evanescent wave is non-zero for distances close to the interface surface, 
but decays exponentially to zero with distance, 8, from the waveguide surface, although 
there is no net flow of energy across the interface.
The exponential decay is depicted in Figure 4.1(b). The distance, dp, the penetration 
depth, is the distance for the electric field amplitude of the evanescent wave to fall to 
1/e or 37% of its value at the waveguide surface. It is defined by the following formula:
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The penetration depth is dependent on the vacuum wavelength (X^ ), of the totally 
internally reflected light, the refractive indices of the two media, and n2, and the 
incident light angle, a x (Love et ah, 1991). From the formulas, 4.1 and 4.2, it is clear 
that the penetration depth rises sharply as approaches the critical angle, a*.
Figure 4.1(a): Plane wave total internal reflection and refraction at a dielectric interface
Plane
Interface
Figure 4.1(b): Diagrammatic representation of the standing wave generated as a result 
of incident and reflected light interference and its associated evanescent wave
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4.3 Fluorescence
A molecule in its ground state may be raised to a higher energy level or excited state 
by absorption of photons at particular wavelengths. When a molecule is in this excited 
state, it is unstable and returns to the ground state by spontaneous emission of a photon. 
The emitted photon, called fluorescence, is generally of a lower energy than that of the 
absorbed photon, due to the energy loss (e.g. release of heat), encountered during 
internal conversion. The nature of fluorescence, which is a property of relatively few 
molecules, termed fluorophores, is discussed in Ward and Fothergill (1976). The 
excitation and emission scans for fluorescein isothiocyanate (FITC), are shown in Figure
4.2.
Fluorescence intensity can be related to fluorophore concentration as follows;
If=<bI0( l - l O eU) (4-3)
where
<]) = fluorescence quantum efficiency
I0 = incident radiation intensity
e = molar extinction coefficient
L  =  optical path length
c =  fluorophore concentration
The fluorescence quantum efficiency, <J>, is a property of the fluorophore and is a, 
measure o f the ratio o f photons emitted to those absorbed, and is always <1.0, but more 
usually <0.1. Fluorescein has a high quantum efficiency, -0.9, in its natural state, but 
this is somewhat reduced on conjugation to proteins, -0.4. The molar extinction 
coefficient, e, is a measure of the strength of absorption at the maximum absorbance 
wavelength of the fluorophore, e.g. fluorescein has a high molar extinction coefficient 
of 80,000 cm ^M 1. Exciting a fluorophore at a wavelength away from the maximum 
absorbance wavelength, has the same effect as using a more weakly absorbing 
fluorophore. The maximum fluorescence peak wavelength is a characteristic of the 
fluorophore and remains the same regardless o f the excitation wavelength.
The environment which surrounds the fluorophore can effect its fluorescence intensity, 
by changing the stability of the excited state. Environmental factors include the nature 
of the solvent i.e. ionic composition, pH and temperature. The loss of energy in the
103
excited state through vibrational energy transfer to the environment before emission 
results in the Stoke’s shift, which is an intrinsic property of the fluorophore. It is defined 
as the difference in wavelength between the excitation and emission maxima, and for 
fluorescein is approximately 30nm. The longer the Stoke’s shift of a fluorophore, the 
less overlap there is between the excitation and emission spectra. This is important for 
evanescent wave sensing where the excitation radiation must be separated from the 
fluorescence (Haugland, -1991).-------------
Reduction of fluorescence emission results from different physical and chemical 
phenomena such as the inner filter effect, photobleaching and quenching. The inner filter 
effect occurs at high concentrations of fluorophore, where part o f the emission intensity 
is reabsorbed by other fluorophore molecules, resulting in a plateau effect. 
Photobleaching is not a completely understood phenomenon. It is believed that the 
absorption o f high intensity light results in the irreversible destruction of the chemical 
structure o f the fluorophore. Schauenstein et al. (1982), studied the effect o f high 
intensity radiation on FITC-antibody conjugates, and showed increased photobleaching 
of fluorescein on conjugation to proteins.
Quenching is a phenomena resulting from an extrinsic process, which depopulates the 
excited state without the emission of a photon. The reduction of fluorescence results 
from the interaction of the fluorophore with other factors present in the system, such as 
temperature, solvent, concentration of fluorophore, impurities and oxygen. This property 
of fluorescent molecules has been exploited for the development of sensors, e.g. 0 2 
quenches the fluorescence of some ruthenium derivatives (O’Keeffe et al., 1995)
4.4 Evanescent wave interactions
Normally there is no net flow of evanescent wave energy across the interface between 
two dielectric media such as the core/cladding interface of an optical fibre. However, 
if the optically less dense medium contains an absorbing species, within the penetration 
depth o f the evanescent wave, a net energy loss from the reflecting wave, through 
interaction with the evanescent wave results. This is referred to as attenuated total 
reflection or ATR (Place et al., 1985). The light beam does not pass directly into the 
absorbing species matrix, as the interaction takes place at the point of total internal 
reflection in the denser medium.
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Figure 4.2: Excitation and emission profile for FITC. FITC has a maximum absorbance
peak at 488 nm (....) and a maximum fluorescence peak at 520 nm (___). The Stoke’s
shift, the difference between the excitation and emission maxima is -3 0  nm, and the 
quantum yield, the ratio of the emission to absorbance peak intensity, is -0.9.
I
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As the magnitude of the penetration depth of the evanescent wave is less than 1 pm, and 
the electrical intensity decreases exponentially with depth, the evanescent wave only 
interacts with molecules close to the interface surface, and those in the bulk solution 
remain relatively unaffected. If the absorbing species dissipates the absorbed energy as 
fluorescence, then the evanescent wave may be employed as an excitation source. A 
fraction of the fluorescent radiation emitted in the less dense medium, is coupled back 
into the optically denser medium, according to the principle of optical reciprocity. This 
principle states that the fluorescent radiation is coupled back into the waveguide in the 
same way as the inverse process, and has the same angular distribution and dependence 
on index, wavelength and distance, as the plane wave which generates an evanescent 
wave. The coupled fluorescence will propagate as a plane wave above the critical angle, 
within the higher refractive index medium. Love and Button (1988), showed 
experimentally and theoretically, that the total fluorescent signal obtained from one end 
of a short length of fibre surrounded with fluorescent material can be described by;
I n i '/ M ^ ) ( 4 4 )
J CL
e =  extinction coefficient of the fluorophore
I0 =  excitation intensity of launched light
L  =  fibre sensing length
rm„  =  radius of the launch spot
0mM= maximum external angle of the launch and acceptance 
cone
a =  fibre core radius
NA =  numerical aperture of the fibre
This expression emphasis the critical effect of high angle light in a fibre or waveguide 
(sin80).
4.5 Optical fibres and evanescent wave sensing
A plastic clad optical fibre is a thin rod which typically consists o f a transparent silica- 
based fibre core, o f refractive index, n1; surrounded by a plastic cladding of lower 
refractive index, n2. Light launched down the optical fibre at angles greater than the
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critical angle, a c , of the waveguide, is propagated through the core by total internal 
reflection, as described in section 4.2. An evanescent wave is generated at the dielectric 
interface which extends into the plastic cladding. Optical fibres are used widely in the 
communications industry, as they allow transmittance of light over long distances, with 
very high efficiency.
If the cladding of the optical fibre is removed, we have a situation where a molecular 
species in solution can interact with the evanescent wave, as the sample solution now 
acts as the ‘cladding’ . Exposed core optical fibres can therefore be used for sensing. 
Most evanescent wave sensors cited in the literature are based on fluorescence detection. 
The evanescent wave radiation at the appropriate wavelength, excites fluorescent 
molecules either immobilised on or very close to the fibre core surface, thus optically 
separating the fluorescent molecules within the penetration depth from those in the bulk 
solution. The resulting fluorescence is coupled back into and propagated by the same 
optical fibre in higher order modes, and can be detected at the distal (Sutherland et al.,
1984), or proximal end (Hirschfeld and Block, 1984), of the fibre using appropriate 
filters and detectors. This effectively means that the fluorescence can be monitored at 
the output o f the waveguide in the same optical plane as the excitation light. The 
separation of the fluorescence in the ‘ sensing volume’ from that in the bulk solution is 
further enhanced by the efficiency of coupling the fluorescence back into the fibre, 
which also decreases with distance from the interface.
The geometry of optical fibres offers an advantage in terms of sensitivity in that the 
high number of internal reflections of a light ray propagating down an optical fibre are 
confined to two of the three dimensions instead of one, as for a planar waveguide. The 
total number of reflections (N) along a fibre is given by the formula;
N=(— )cota (4.5)
2a
where 
L  =  fibre length
a =  fibre core radius
a  =  incident wave angle to the normal to the interface
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Since the interrogating light remains guided, no coupling optics are required in the 
sensor region and this allows considerable miniaturisation. Optical fibres also allow the 
transmission of light over long distances, facilitating remote sensing (Andrade et al.,
1985).
Some fluorescent molecules respond optically to changes in their environment, and this 
property can be exploited for the development of chemical sensors. The fluorescent 
intensity of fluorescein shows sensitivity to pH (Badini et al., 1989) and certain 
derivatives o f ruthenium have their fluorescence quenched by Oz (Mac Craith et al.,
1993).
Evanescent wave sensors, based on non-fluorescent compounds have been reported. The 
wavelength of the propagating light is chosen so that it coincides with the absorbance 
wavelength of the analyte. The decrease in transmission of the propagated light (ATR), 
can be related to the concentration of the absorbing analyte. In 1992, Carlyon et al. 
reported a single mode fibre optic evanescent wave biosensor for the detection of a blue 
dye at 633 nm. The sensor was used for the determination of Penicillin G and was based 
on a colorimetric assay system.
4.6 Evanescent wave fibre optic immunosensors
Immunosensors require that the change induced by antibody-antigen binding is 
immediately convertible to an electrical signal that can be amplified, stored and 
displayed, so that as the primary bioreaction occurs, there is an immediate detectable, 
signal output. Fluorophore-labelled antibodies (or antigens) can be used to detect analyte 
concentration, because the recognition event can be transduced indirectly, as a change 
in the fluorescence intensity, and detected via fibre optic evanescent wave technology. 
One of the first fluoroimmunosensors based on evanescent wave excitation and detection 
was developed by Sutherland et al. (1984).
Antibodies specific for the analyte of interest are immobilised on the exposed core silica 
of an optical fibre (Figure 4.3). The antibodies biospecifically bind analyte molecules, 
removing them from the bulk solution. Fluorophore-labelled antibodies with specificities 
for different epitopes on the analyte (antigen) surface, can simultaneously bind with the 
antigen to the antibodies bound to the fibre core surface. Fluorescent molecules, 
therefore, move into the evanescent ‘ sensing zone’ of the fibre, in direct proportion to 
the analyte concentration, and are detected due to their interaction with the evanescent
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wave. No separation step is required as with conventional plate immunoassays, since the 
evanescent wave only interacts with molecules within its penetration depth.
4.7 Immobilisation of antibodies to silica surfaces
The sensing surface, made up of antibodies immobilised on an optical substrate, e.g. an 
exposed core optical fibre, is fundamental to an immunosensor based on the evanescent 
wave technique. Methods for immobilisation include entrapment, adsorption, 
crosslinking, biological immobilisation (via Protein A or avidin-biotin) and covalent 
attachment and are discussed in detail in Taylor (1991).
The requirements for an efficient immunosensing surface include:
(1) high monolayer surface density of functionally active antibodies
(2) the absence o f non-specific binding
(3) stability during storage and use
(4) linkage must be inert to dissociation conditions if sensor is to be reusable
(5) negligible denaturation of the immobilised antibody during the immobilisation 
procedure
The method o f immobilisation must be simple (facilitating mass production), 
reproducible and should not require large amounts of antibody. Immobilisation via 
physical attraction i.e. adsorption, is not reliable because of problems concerning 
leaching and washing o ff the immunoglobulin during use. Jonsson et al. (1985), showed 
that covalently bound IgG has a superior stability compared to adsorbed IgG, when the 
pH was lowered or on incubation with detergents, urea or ethylene glycol. Adsorption 
followed by crosslinking with a bifunctional crosslinker, such as glutaraldehyde, has 
been shown to improve the stability of the adsorbed surface. However, protein-protein 
crosslinking generally results in some inactivation of the antibodies due to incorrect 
orientation and masking of the binding sites.
Directional orientation of antibodies with biological molecules, such as Protein A, which 
binds the Fc portion of the antibody, has shown increased activity per mole of protein 
immobilised. However, such reagents are extremely expensive and are prone to leaching 
(Alaire et al., 1990).
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NOT TO SCALE
Figure 4.3: Evanescent wave fibre optic fluoroimmunosensing
Figure 4.4: Fibre probe and flowcell apparatus for evanescent wave
fluoroimmunosensing experiments
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Several methods for covalent immobilisation of immunoglobulins onto silica surfaces 
have been reported. Surface derivatisation using silanes is a common way to impart a 
particular chemical reactivity to solid substrates which have hydroxyl groups on their 
surfaces, such as silica. Silane coupling reagents have one end which react with glass 
via one or more reactive groups and one end which gives the glass a new functionality. 
Initially developed methods utilised glutaraldehyde as a homobifunctional crosslinker, 
crosslinking the amino group of the immunoglobulin molecule to the silica substrate 
silanised with aminopropyltrimethoxysilane, APTS, (Weetall, 1976). As before, the use 
of homobifunctional crosslinkers suffers from multi-layer protein complex formation, 
thus, masking the activity of the antibody. Some silanes such as APTS are prone to 
hydrolysis and cyclisation (Cass, personal communication).
Briining and Grobe (1992), synthesised several immobilisation reagents based on silanes 
with aldehyde functions. These compounds avoid the use of bifunctional crosslinkers, 
because the biomolecule reacts directly with the aldehyde groups, thus simplifying the 
procedure. Build up of polymer layers due to crosslinking of proteins, is also avoided. 
Zull et al. (1994), suggested that using long chain silane compounds for protein 
immobilisation results in more stable linkages as short chain silanes are subject to 
hydrolysis. They also suggested that exploiting the less common functional groups of 
the protein, such as the thiol groups of cysteine residues, will result in more reproducible 
site-directed coupling. Ahluwalia et al. (1992) and Baldini and Bracci (1993), compared 
several silanisation reagents under different conditions for IgG immobilisation.
The method used for antibody immobilisation in this thesis was that of Bhatia et al. 
(1989). A thiol terminal silane, MTS, was used to functionalise the glass surface. The 
thiol group reacts specificially with the maleiimide region of the heterobifunctional 
crosslinker, GM BS, leaving the succinimide residue of the GMBS available for protein 
attachment (Figure 4.5). This non-directional method of immobilisation was shown to 
retain the high antibody functionality. It was 3-5 times better than other investigators. 
No multilayer protein build-up occurs, due to the use of a heterobifunctional crosslinker. 
A very new and novel approach to immobilising biological molecules on silica surfaces 
is via the sol-gel process. Porous glass coatings (sol-gels), on unclad fibres have been 
utilised to enhance the performance of evanescent wave sensors (Mac Craith, 1993). 
Initially, the sol-gel preparation methods were too harsh to allow immobilisation of 
organic molecules. However, more ambient preparation methods, described by Dunn et
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al. (1991), facilitated the encapsulation of proteins such as enzymes (Shtelzer and Braun,
1994) and antibodies (Wang et al., 1993) into sol-gel matrices while still retaining their 
biological activity. This technology is as yet in the early stages of development.
Figure 4.5: Immobilisation procedure for covalent attachment of antibodies to silica 
surfaces (Bhatia et al., 1989). The thiol terminal silane, mercaptopropyltrimethoxysilane 
(MTS), reacts with the acid-cleaned silica surface followed by the heterobifunctional 
crosslinker, N-y-maleimidobutyryloxy succinimide ester (GMBS). The amino groups on 
the antibody then react with the succinimide ester group of the GMBS, forming stable 
amide bonds.
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Results
4.8 Antibody immobilisation to exposed core optical fibres.
The procedure used for immobilising antibodies onto the exposed core of optical fibres, 
was that o f Bhatia et al. (1989), as described in section 2.10.2. This method was chosen 
because it reported the ability to immobilise a high density of functional antibodies onto 
silica surfaces.
4.8.1 Optimisation of coating antibody concentration by ELISA techniques
The sensitivity of immunoassays is partially dependent on the amount of antibody 
immobilised onto the solid surface, in this case, the fibre core surface. In order to ensure 
that the maximum amount of antibody was immobilised to the substrate, without 
wastage o f antibody, different coating antibody (rabbit anti-CHLDH antibody) 
concentrations were prepared (0, 0.5, 2.5, 5, 10, 40 and 80 pg/ml). Goat anti-mouse IgG 
(50 pg/ml), was immobilised on control fibres. Test tube ELISA ’s employing HRP-anti- 
rabbit IgG were performed on the fibres, as described in section 2.11.2.
From Figure 4.8.1, it can be seen that the absolute coating capacity of the fibres occurs 
for antibody coating concentrations of 40 pg/ml or greater. A coating antibody 
concentration of 50 pg/ml was used for all further immobilisations, to ensure maximum 
antibody immobilisation. The control fibres coated with goat antibodies, gave absorbance 
values similar to those not coated with antibody (0 pg/ml). Since it is generally accepted 
that less than 10% of the antibody in solution actually binds to the fibres, the antibody 
solution was reused 2-3 times. Theoretically, it could be reused more times. However, 
since no sodium azide (NaN3) preservative could be added, as it inhibits the coupling 
reaction between IgG and ester groups, diluted antibody solutions were discarded after 
2 weeks.
4.8.2 Reproducibility of antibody immobilisation using ELISA techniques
In order to ensure that the sensor system gave reproducible results, it was necessary to 
ensure that the same amount of antibody was immobilised onto each fibre in a batch, 
at a given coating antibody concentration. A different fibre was used for each sample 
reading in the evanescent wave immunosensor system, and so fibre-to-fibre variation 
would result in inter-assay error. Eight fibres were incubated with each coating antibody 
(0 - 80 pg/ml rabbit anti-CHLDH antibody) concentration and probed with HRP-anti-
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rabbit IgG, as outlined in section 2.11.2. Control fibres (50 pg/ml goat anti-mouse IgG) 
were also included. The absorbance at 405 nm was recorded for each fibre, and the 
%CV for each antibody concentration determined, where n=8.
From the graph (Figure 4.8.2), the immobilisation method was shown to give good 
‘inter-batch’ reproducibility. The data for concentrations 60 and 80 pg/ml showed some 
overlap as they are on the saturation part of the curve (see Figure 4.8.1). The %CV for 
all sets of data points was <4%, indicating reproducible immobilisation of antibodies.
4.9 Fibre blocking to reduce non-specific binding
Another factor which must be taken into account is non-specific binding. Non-specific 
binding occurs due to interactions of the antigen or second labelled antibody with the 
fibre core surface, rather than the immobilised antibody, and can be dependent to some 
degree on the immobilisation chemistry used. Blocking all available binding sites on the 
fibre core surface helps reduce non-specific binding. Bovine serum albumin (1%, w/v) 
and gelatin (1%, w/v) were tested as blocking agents in fibre ELISA systems, and it was 
concluded that bovine serum albumin (1%, w/v) effectively blocks non-specific binding 
to less that 8% (data not shown).
4.10 Working range of anti-CHLDH antibody coated fibres by ELISA techniques
The sensitivity range (i.e. the range o f antigen concentrations that can be detected), of 
the evanescent wave immunosensor will partially depend on the amount of immobilised 
active antibody on the fibre surface. The approximate sensitivity range was determined 
by fibre ELISAs, as outlined in section 2.11.1. It was determined to be 0.125 - 1.000 
pg/ml, for the two-step immunoassay (Figure 4.10.1).
A one-step immunoassay was also performed on the fibres (Figure 4.10.2), as outlined 
in section 2.11.1, and a wider linear range for the ELISA was obtained, 0.05 - 1.00 
pg/ml.
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Figure 4.8.1
Optimal coating concentration for immobilisation of affinity-purified anti-CHLDH 
antibodies to the exposed core fibre surface, using the method of Bhatia et al. (1989). 
Different concentrations (0-80 pg/ml) o f coating antibody were immobilised to the fibre 
surface and the optimal coating concentration determined by ELISA, as outlined in 
section 2.11.2. Above 40 pg/ml, the fibre is saturated with antibody and increasing the 
coating antibody concentration has no effect.
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Figure 4.8.2
Inter-batch reproducibility of the immobilisation of affinity purified anti-CHLDH 
antibodies to exposed core fibre surface using the method of Bhatia et al. (1989). Fibres 
(n=8) were coated with different concentrations of the antibodies (0 (o), 5 (4), 20(D), 
30(B), 60(x) and 80(+) pg/ml), and the reproducibility assessed qualitatively by fibre 
ELISA  as outlined in section 2.11.2. The coefficient of variation was determined to be 
<  4%, indicating good inter-batch reproducibility for the immobilisation procedure.
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Figure 4.10.1
Sensitivity range of anti-CHLDH antibody-coated fibres as determined using a two-step 
fibre ELISA (section 2.11.1). The fibre sensitivity range was determined to be linear 
between 0.05-1.00 pg/ml. All sample estimations were performed in triplicate, and the 
HRP-anti-CHLDH was diluted to 1:4000.
log CHLDH concentration (ug/ml)
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Figure 4.10.2
Linear working range of anti-CHLDH antibody-coated fibres as determined using a one- 
step fibre ELISA (section 2.11.1). The fibre working range was determined to be 0.05-
1.00 pg/ml (r=0.990). All sample estimations were performed in triplicate, and the HRP- 
anti-CHLDH antibody was diluted to 1:4000.
log CHLDH concentration (ug/ml)
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4.11 Evanescent wave i mm u nosen sing
The system used to carry out this work is described in section 2.12.1 and Figure 2.3. 
The argon-ion laser has a 488 nm line and so is suitable for excitation of FITC which 
absorbs strongly at 488 nm for fluorescence emission at 520 nm (Figure 4.2).
A glass flow cell with both ends threaded, to facilitate screw-on caps, was designedly-, 
the author and manufactured by AGB Scientific, Ireland (Figure 4.4). It is essential that 
the fibre is held firmly in place in the flow cell, so that it does not move out of position 
when liquids are being pumped through the flow cell. The fibre is threaded through 
rubber septa at either end of the cell, and held along the central axis of the flow cell, 
using the screw-on caps. The flow cell was filled with BSA (1%, w/v), to obtain a 
baseline signal, prior to adding the sample. Samples were passed through the flow cell 
using a peristaltic pump in such a way that no air bubbles entered the sample flow 
stream. A new fibre was used for each sample (except for the regeneration 
experiments). The flow cell was mounted in an X-Y-Z micropositioner to enable 
adjustment of the fibre launching position.
4.11.1 Specificity of fibre probe
The fibre was aligned in the optical system (Figure 2.3), and a baseline recorded after 
filling the flow chamber with 1% (w/v) BSA. D.C. background signals, due to excitation 
light breaking through the emission filters and back reflections from the proximal end 
o f the fibre, were nulled by using the ‘offset’ feature of the lock-in amplifier. Non­
specific antigen, 1 pg/ml rabbit muscle LDH (RMLDH), was premixed with 20 pg/ml 
FITC-labelled anti-CHLDH antibody prepared in 1% (w/v) BSA, and passed over the 
fibre using the peristaltic pump at a flow rate of 5 ml/min. No increase in signal over 
the baseline was recorded, indicating that there was no non-specific binding o f antigen 
and antibody (Figure 4.11.1). A  slight decrease in signal was actually observed. When 
the fibre was exposed to excitation light continuously, the innate fibre fluorescence 
slowly decays and leads to a changing background signal. For quantitation experiments 
the baseline was allowed to stabilise before measurements were taken.
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Figure 4.11.1
Specificity of fibre probe for CHLDH. Rabbit muscle LDH, RMLDH (1 pg/ml), 
premixed with 20 pg/ml FITC-anti-CHLDH antibody and injected into the flow cell 
containing the fibre probe. No increase in fluorescence signal by evanescent wave 
sensing was observed. CHLDH (1 pg/ml), premixed with 20 pg/ml FITC-anti-CHLDH 
antibody was then passed over the fibre probe. An increase in the fluorescent signal was 
observed due to the specific binding of CHLDH/FITC-anti-CHLDH antibody 
immunocomplex with the fibre-immobilised antibody.
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A sample consisting of 1 pg/ml specific antigen, chicken heart LDH (CHLDH) premixed 
with 20 pg/ml FITC-labelled anti-CHLDH antibody prepared in 1% (w/v) BSA, was 
then passed over the fibre. An immediate signal increase was observed. This 
fluorescence intensity increase was attributed to the specific binding of the FITC-anti- 
CHLDH/CHLDH immunocomplex to the fibre core immobilised anti-CHLDH antibody, 
and interaction of the FITC with the evanescent wave. This experiment shows that the 
increase in fluorescence signal is due to the immunoreaction and not non-specific 
binding.
The small increase in signal observed between the non-specific and specific antigen 
samples, was due to vibrations in the fibre during liquid flow, and is not a fluorescence 
signal.
4.11.2 Regeneration of fibre probe
Many antibody-antigen reactions have high affinity constants of the order of 1010 - 1012 
M'1, which confer high sensitivity on immunoassays. The price to be paid, however, is 
irreversibility, and hence most immunosensing systems are considered single use with 
irreversible binding. However, if the fibre immunosensing surface can be regenerated 
for reuse, several measurements may be made with one fibre.
The fibre probe was aligned in the optical system and a one-step immunoassay (2 pg/ml 
CHLDH premixed with 20 pg/ml FITC-anti-CHLDH antibody) performed on the fibre, 
7 times, with regeneration in between each sample. Glycine-HCl (0.1M), pH 2.5, for 1.5 , 
min was used for the regeneration of the fibre probe, as this buffer was found to 
successfully break the antibody-antigen complex in question, when purifying the 
antibody by affinity chromatography (section 2.4.2.2). A typical signal curve with 
regeneration is shown in Figure 4.11.2.1. The fluorescence signal generated by the 
immunoreaction, was monitored for approximately 2 minutes, and the initial linear slope 
(over a time period of 0.5 min) of the curve determined using linear regression.
The initial slope of the immunoreaction curve is plotted against the number of 
regenerations, in Figure 4.11.2.2. For the 7 regenerations carried out, is does not appear 
that the dissociating conditions used, had any adverse effect on the antigen binding 
ability of the immobilised antibody. The %CV of the 7 samples was 5.3%. No further 
regenerations were carried out, as it was impossible to keep air bubbles out of the flow 
cell, without removing the fibre and flow-cell apparatus from the X-Y-Z micropositioner,
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filling the flow cell and realigning the fibre. Realignment has been shown to induce 
some variability (see section 4.11.3).
It was observed that after the dissociating solution was pumped out o f the flow cell and 
baseline solution (1% (w/v), BSA), pumped in, the new baseline signal was slightly 
higher than the initial baseline signal, indicating that not all of the immunocomplexes 
had been removed from the surface. With further regenerations, the kinetics of the 
immunoassay would be changed, due to their being progressively less solid-phase 
immobilised antibody available for binding (Place et a l ,  1991). For this reason, it was 
decided to use a new fibre for each new sample.
4.11.3 Realignment reproducibility of fibre probe
For every new sample assayed, a new fibre probe had to be aligned in the optical 
system. This proved difficult because unlike other evanescent wave sensors, such as 
those based on the quenching of fluorescence, there was no initial fluorescence signal 
(O’Keeffe et al., 1995). Fluorescence allows easier optical alignment, as the light spot 
can be visually focused on the detector, and the monitored signal maximised. For this 
system, the fluorescence was generated after optical alignment, due to the fluorescently 
labelled antibodies in the immunoreaction. Exact alignment is crucial, to ensure all the 
angles of the fibre are filled.
The fibre probe was realigned in the system each time using the X-Y-Z micropositioner 
and judged by eye, using the light spot emerging from the distal end of the fibre as a 
guide. For evanescent wave sensing at the proximal end of the fibre, there is normally 
no need to polish the distal end of the fibre. However, in this case the distal end of the 
fibre was polished, because it allowed a circular light spot to be focused on the back of 
the hand. When this light spot was symmetrical and perfecdy circular, the fibre was 
considered aligned.
A one-step immunoassay was performed (2 pg/ml CHLDH premixed with 20 jig/ml 
FITC-anti-CHLDH antibody), eight times using a new fibre probe for each reading. The 
initial signal was monitored and the slope (mV/sec) determined. The %CV for the eight 
probes was determined to be 14.4% (Figure 4.11.3). This error was attributed to the 
difficulty in aligning the fibre accurately. There is also the possibility of other variables 
in the system, such as fibre-to-fibre variation in optical transmission properties and 
polishing defects, although care was taken to reduce these.
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Figure 4.11.2.1
FITC-anti-CHLDH antibody/CHLDH immunocomplex binding to immobilised anti- 
CHLDH antibody (i.e. one-step assay) and detection by evanescent wave sensing, 
followed by regeneration of the fibre probe surface with 0.1M glycine, pH 2.5. The 
rapid drop in fluorescence after addition of the acidic solution is due to the quenching 
of the fluorescence o f fluorescein at low pH and dissociation of some of the 
immunocomplexes from the fibre probe. On filling the flow-cell again with baseline 
solution (1% (w/v) BSA ), the fluorescence intensity was higher than that of the original 
baseline solution, indicating that not all of the immunocomplexes had been dissociated 
from the fibre surface.
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Figure 4.11.2.2
Effect of repeated regenerations with 0.1M glycine, pH 2.5 on the binding ability of 
fibre probe. The effect of repeated regeneration on the signal measured by evanescent 
wave sensing for a one-step immunoassay (2 pg/ml CHLDH premixed with 20 pg/ml 
FITC-anti-CHLDH antibody) was determined (n=7). The sensitivity of the optical system 
was set at lOOmV. The same fibre was used for all experiments and the fibre probe was 
not realigned between samples. The coefficient of variation for n=7 was 5.3%.
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Figure 4.11.3
Effect of fibre realignment on the reproducibility of the signal measured by evanescent 
wave sensing for a one-step immunoassay (2 pg/ml CHLDH premixed with 20 pg/ml 
FITC-anti-CHLDH antibody). The sensitivity of the optical system was set at lOOmV. 
A new fibre was used for each sample concentration (n=8), and the coefficient of 
variation was 14.4%, indicating that there is some variability in realigning the fibre 
probes.
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4.11.4 Kinetic response of fibre-optic immunoassay
The slope of the signal response curve, which corresponds to the initial rise of the 
number of labelled antigen molecules (FITC-CHLDH) on the fibre surface, should be 
strictly proportional to the concentration of antigen in solution, for a diffusion-limited 
process (Feldman and Uzgiris, 1993). Antigen (FITC-CHLDH) was prepared at 
concentrations ranging from 0.125-5.00 pg/ml (1.12-35.7 nM), in 1% (w/v) BSA and 
injected into the flow cell. The increase in fluorescence intensity was recorded and the 
initial slope of the binding curve determined. The results are plotted in Figure 4.11.4. 
The results show that there is an excellent linear dependence for all data points except 
for the high concentration, 5 pg/ml. The reason for this is not clear. It is possible that 
at high concentrations o f antigen, convectional effects and not diffusion through the 
‘dead layer’ , are the limiting factors in the mass transport process to the surface.
4.11.5 Two-step and one-step immunoassays
A two-step immunoassay was performed on the fibres as described in section 2.12.2.1. 
The fibres were incubated with CHLDH (0.03 - 10.0 pg/ml) for 15 mins, followed by 
20 pg/ml FITC-anti-CHLDH antibody. The fluorescence signal was recorded for 4.5 min 
and the initial slope (over 0.5 min), calculated by linear regression (4.11.5.1). The 
sensitivity of the optical system was set at 300 mV, with the ‘expand X10’ function 
turned off. The linear range for the two-step assay was from between approximately 0.1 
- 10.0 pg/ml (r=0.995), as shown in Figure 4.11.5.2. This is similar to results obtained 
with the fibre ELISA  (Figure 4.10.1).
A one-step assay was also performed, where the antigen, CHLDH (0.03 - 10.0 pg/ml), 
was premixed with 20 pg/ml FITC-anti-CHLDH antibody(section 2.12.2.2), and injected 
into the flow cell immediately. The initial binding slope was calculated as before. The 
sensitivity o f the optical system was lOOmV, with the ‘expand X 10 ’ function turned on. 
The results are shown in Figure 4.11.5.3. The linear range for the one-step assay was 
approximately 0.156 - 5.0 pg/ml (r=0.990), again giving similar results to the one-step 
fibre ELISA  (Figure 4.10.2).
It is clear from Figures 4.11.5.2 and 4.11.5.3, that the two-step assay is more sensitive 
than the one-step assay. The optical system sensitivity was set 30-fold less for the two- 
step assay compared to the one-step assay, and yet the initial slope was 3-4 times higher 
for the two-step assay.
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Figure 4.11.4
Kinetic response o f fibre probe using FITC-CHLDH, showing pseudo-first order reaction 
kinetics. The slope o f the signal response curve is strictly proportional to the 
concentration of antigen in solution, for a diffusion-limited process. There is a deviation 
from linearity at high antigen concentrations.
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Figure 4.11.5.1
Typical one-step or two-step binding curve for evanescent wave immunosensing 
experiments. The rate o f binding follows pseudo-first order reaction kinetics and, hence, 
linear regression was carried out on the initial part of the binding curve, which is 
directly proportional to the antigen concentration. The sample was injected into the flow 
cell at the point marked A, however the slope was determined from B-C. The first part 
of the curve was ignored (A-B), to eliminate any background fluorescence effects and 
fluorescence due to non-specific binding.
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Figure 4.11.5.2
Standard curve for two-step immunoassay for CHLDH using evanescent wave 
immunosensing. The slope of the binding curve was determined by linear regression on 
the initial part of the curve, over 1 min. The linear range is between 0.1 - 10.0 pg/ml 
(r=0.995). The sensitivity of the optical system was set at 300mV, and the ‘expand xlO’ 
function was off.
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Figure 4.11.5.3
Standard curve for one-step immunoassay for CHLDH using evanescent wave 
immunosensing. The slope of the binding curve was determined by linear regression on 
the initial part of the curve, over 1 min. The linear range is between 0.156 - 5.0 pg/ml 
(r=0.990). A ‘high-dose hook effect’ for high CHLDH concentrations has occurred 
because the FITC-labelled anti-CHLDH antibody was no longer in excess. The 
sensitivity o f the optical system was set at lOOmV and the ‘expand xlO’ function was
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4.11.6 Competitive immunoassay
A competitive one-step immunoassay was performed for CHLDH concentrations ranging 
from 0.156 - 10.0 pg/ml. An excess of FITC-labelled CHLDH (-20 pg/ml), and standard 
CHLDH competed for the limited number of immobilised antibody binding sites. The 
signal was inversely proportional to the concentration of unlabelled CHLDH, as the 
more unlabelled CHLDH in the sample, the less sites available for the labelled CHLDH 
to bind.
The initial slope of the signal was calculated and the results are shown in Figure 4.11.6. 
The graph is linear for concentrations ranging from 1.0 -10.0 fig/ml (r=0.992).
4.11.7 Effect of sample viscosity on signal accumulation
All the samples assayed by the evanescent wave immunosensor were prepared in 1% 
(w/v) BSA. Serum has a viscosity similar to 8% (w/v) BSA. Sample matrices; 0.15M 
PBS, pH 7.4, 1% (w/v) BSA, 3% (w/v) BSA, 8% (w/v) BSA  and a 1:2 dilution of 
normal human serum, were prepared in 0.15M PBS, and a one-step immunoassay 
performed (2 pg/ml CHLDH + 20 pg/ml FITC-anti-CHLDH antibody), in duplicate for 
each sample matrix. The aim of this experiment was to check whether the viscosity of 
the sample matrix effects the rate of accumulation of fluorescence intensity signal. The 
results are shown in Figure 4.11.7. It was expected that for higher viscosity solutions, 
the rate of signal accumulation would be less than for lower viscosity solutions. The 
opposite result was found. The reason for this is unclear, but may be an effect due to , 
a change in the numerical aperture of the sensor, resulting in more efficient coupling of 
fluorescence back into the fibre, rather than a viscosity effect.
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Figure 4.11.6
Standard curve for competitive immunoassay for CHLDH using evanescent wave 
immunosensing. The slope of the binding curve was determined by linear regression on 
the initial part o f the curve, over 1 min. The linear range is between 1.0 - 10.0 pg/ml 
(r=0.992). The sensitivity of the optical system was set at lOOmV and the ‘expand xlO’ 
function was on.
log CHLDH concentration (ug/ml)
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Figure 4.11.7
Effect o f sample matrix viscosity on signal accumulation. A one-step immunoassay (2 
pg/ml CHLDH premixed with 20 pg/ml FITC-anti-CHLDH antibody) was performed in 
duplicate in matrices o f different viscosities and the effect on the rate of signal 
accumulation determined by linear regression on the initial part of the binding curve.
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4.12 Determination of CHLDH concentration using the BIAcore™
The BIAcore™ uses the optical phenomenon of surface plasmon resonance (SPR), to 
measure the surface concentration of analyte biospecifically bound to the sensor chip 
surface. The principle of SPR is described in section 4.7.
Anti-CHLDH antibodies were covalently immobilised to the sensor chip surface as 
outlined in section 2.13.1. A typical immobilisation sensorgram is shown in Figure 
4.12.1. Direct (no second antibody), one-step and two-step immunoassays were 
performed on the sensor chip surface coated with anti-CHLDH antibody. A typical 
antibody-antigen sensorgram curve is shown in Figure 4.12.2. Different combinations 
of regeneration solutions were tested (O-lOOmM HC1; O-lOOmM NaOH; 0.1M glycine, 
pH 2.5), to evaluate how the immunosensing surface could be most effectively 
regenerated, for multiple immunoassays. For these experiments, two 1 min pulses of 
lOmM HC1 and one 1 min pulse of 5mM NaOH, was found to regenerate the surface 
reproducibly to within 10 RU of the original baseline value.
4.12.1 Direct immunoassay for CHLDH
Affinity-purified polyclonal anti-CHLDH antibody was immobilised to the sensor chip 
surface, as outlined in section 2.13.1. The amount of antibody immobilised in terms of 
response units (RU) was 6879 RU. CHLDH samples, prepared in 0.15M PBS, pH 7.4 
(0.009 - 5.000 pg/ml), were injected over the immobilised antibody, as outlined in 
section 2.13.2.1. A standard curve for the known concentrations of CHLDH is shown, 
in Figure 4.12.3. The graph appears linear for the concentration range 0.312 - 5.000 
pg/ml (r=0.997). The Y-error bars are shown on the graph but in most cases are too 
small to be seen. The CV was less than 4%, over the whole measuring range.
4.12.2 Two-step immunoassay for CHLDH
CHLDH samples prepared as in the previous section, were injected over the immobilised 
antibody (7531 RU), followed by the same polyclonal anti-CHLDH antibody, to amplify 
the signal and improve sensitivity, as outlined in section 2.13.2.2. A standard curve for 
the two-step assay is shown in Figure 4.12.4. Clearly, the standard curve has the same 
linear range (0.312 - 5.000 pg/ml), as the direct assay (r=0.998), but the response units 
are approximately 2.8 times higher, due to amplification of the response by the second 
antibody.
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Figure 4.12.1
Sensorgram of typical immobilisation of antibody/antigen to sensor chip surface, as 
outlined in section 2.13.1. HEPES-buffered saline is allowed to flow over the surface 
(a-b). The surface is activated with 50mM NHS/ 200mM EDC (b-c) and the 
antibody/antigen solution in lOmM sodium acetate, pH 5.5, allowed to immobilised to 
the surface (c-d). Excess reactive groups are inactivated with 1M ethanolamine 
hydrochloride, pH 8.5 (d-e). A pulse of acid (typically lOOmM HC1) is then passed over 
the chip surface to remove any non-covalently bound material (e-f) and the amount of 
antibody/antigen immobilised determined in terms of response units, (4317 RU for this 
sensorgram).
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Figure 4.12.2
Sensorgram of typical antibody-antigen binding curve. The baseline is established in 
HEPES buffered saline (a) and then the antibody (or antigen) passed over the chip 
surface. The dip from (a-b) is due to the change in refractive index due to the buffer 
change from HEPES to PBS. The antibody binds to the antigen (b-c) for 20 mins and 
the total binding determined on returning to HEPES buffer (d). The sensor chip is 
regenerated using a 1 min pulse of lOmM HC1 (d-e), 1 min pulse of 0.1M glycine, pH
2.5 (e-f) and finally a 1 min pulse of lOmM HC1 (f-g). A 1 min pulse of HEPES- 
buffered saline was passed over the chip between regenerations.
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Figure 4.12.3
Standard curve for direct assay for CHLDH using the BIAcore™. The response units 
for each antigen concentration was determined as the total binding after two minutes 
(end-point method). The graph is linear for CHLDH concentrations ranging from 0.312 -
5.000 (jg/ml (r=0.997). The samples were injected over the immobilised anti-CHLDH 
antibody, randomly and in triplicate. The coefficient of variation is <4% for all sample 
concentrations.
log CHLDH concentration (ug/ml)
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Figure 4.12.4
Standard curve for two-step assay for CHLDH using the BIAcore™. The response signal 
for each antigen concentration was determined as the total binding after 2 min CHLDH 
followed by 2 min anti-CHLDH antibody (end point method). The graph is linear for 
CHLDH concentrations ranging from 0.312 - 10.000 pg/ml (r=0.998). The samples were 
injected randomly and in triplicate. The coefficient o f variation for all the samples was 
<4%.
log CHLDH concentration (ug/ml)
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4.12.3 One-step assay for CHLDH
CHLDH samples (0.009 - 10.000 pg/ml) were premixed with 20 pg/ml polyclonal anti- 
CHLDH antibody, and incubated for 1 minute at room temperature, before injecting over 
the immobilised anti-CHLDH antibody (4253 RU). This process was controlled 
automatically by the BIAcore™ autosampler and microfluidics system. A standard curve 
for the one-step assay is shown in Figure 4.12.5. The one-step assay is not as sensitive 
as the direct and two-step assay. The graph is linear between 1.25 - 10.00 pg/ml 
(r=0.979), for the range of CHLDH concentrations assayed.
4.13 Effect of increased FITC labelling on antibody affinity, as determined using 
the BIAcore™ and the evanescent wave immunosensor
Protein A-purified anti-CHLDH antibody, at a concentration of 1.8 mg/ml, was labelled 
with increasing concentrations of FITC (50, 100, 200, 400, 1600 pg FITC per mg of 
protein) as outlined in section 2.6.3. The molecular fluorophore to protein ratio was 
estimated using the formula given in The and Feltkamp (1970), and the results are given 
in Table 4.13.1. The protein concentrations of all the conjugates was determined using 
the Bio-Rad protein assay (section 2.7.2), as the FITC appeared to interfere with the 
BCA protein assay (section 2.7.1). All the FITC-antibody samples were diluted in 0.15M 
PBS, pH 7.4, to give a final protein concentration of 100 pg/ml. The effect of increased 
labelling on the affinity of the FITC-anti-CHLDH antibody was assessed using the 
BIAcore™ and the evanescent wave immunosensor.
4.13.1 Effect of FITC-labelling on anti-CHLDH antibody affinity using the 
BIAcore™
Antigen (CHLDH) was immobilised to the sensor chip surface, using the immobilisation 
method outlined in section 2.13.1. The amount of CHLDH immobilised in terms of 
response units was 4317 RU. FITC-labelled anti-CHLDH antibody (100 pg/ml) was 
injected over the immobilised antigen as outlined in section 2.13.3, and the resulting 
sensorgram recorded. The absolute amount of FITC-antibody bound after 20 minutes 
was plotted against the molecular F/P ratio, and is shown in Figure 4.13.2. With 
increasing labelling (F/P ratio), the amount of antibody bound to the immobilised 
antigen decreases.
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Figure 4.12.5
Standard curve for one-step assay for CHLDH using the BIAcore™. The response signal 
was determined after premixing CHLDH with 20 jig/ml anti-CHLDH antibody for 1 min 
and determining the total binding to the chip after 2 min (end-point method). The graph 
is linear for CHLDH concentrations ranging from 1.25 - 10.00 pg/ml (r=0.979). The 
samples were injected over the immobilised antibody randomly and in duplicate. The 
coefficient of variation for the linear range was <20%.
log CHLDH concentration (ug/ml)
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Table 4.13.1
FITC-labelling of protein A-purified anti-CHLDH antibodies using the method as 
outlined in section 2.6.3. Anti-CHLDH antibody (1.8 mg/ml) was labelled with 50 - 
1600 pg FITC per mg protein, and the molecular fluorophore to protein ratio determined 
using the formula given in The and Feltkamp (1970).
fig FITC per mg protein Abs 495 nm / Abs 280 nm Molecular F/P ratio
50 0.540 1.91
100 0.797 3.42
200 0.992 5.19
400 1.327 7.10
1600 1.436 8.26
control 0.079 0.00
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Figure 4.13.2
Effect o f increased fluorophore-to-protein ratio on anti-CHLDH antibody binding, as 
determined using the BIAcore™. The binding was measured in terms of the total 
response units (i.e. antibody bound) after 20 minutes, to the CHLDH coated sensor chip 
surface.
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4.13.2 Effect of FITC-labelling on anti-CHLDH antibody affinity using the 
evanescent wave sensor
Fibres were coated with CHLDH, in the same manner as antibody immobilisation (as 
outlined in section 2.10.2). FITC-anti-CHLDH antibody (100 pg/ml) was injected into 
the flow cell and 8.75 minute scans recorded. The scans were overlaid and are shown 
in Figure 4.13.3. The affinity of the antibody appears to be adversely affected, with high 
levels o f labelling (i.e. greater than 6 FITC molecules per antibody molecule). Very 
little, if any, binding, to the CHLDH coated fibres, was observed for these antibodies. 
FITC does not suffer seriously from fluorescence quenching at high fluorophore to 
protein ratios, as is found with other fluorophores, such as rhodamines (Haugland, 1991). 
It was concluded, therefore, that the absence of a signal for overconjugated antibodies 
was due to denaturation of the antibody and not due to quenching at high F/P ratios. The 
control antibody samples produced no signal, due to the fact that the antibody was not 
labelled with FITC, and so the binding reaction cannot be transduced and detected. 
With lower levels of FITC labelling, i.e. less than 6 FITC molecules per antibody 
molecule, the antibody retains its ability to bind to its antigen. From the BIAcore™ 
results, it is clear that the affinity of the antibody decreases with increased F/P ratio. 
However, the loss in binding affinity is compensated for by the increased amount of 
FITC available for detection. The signal progressively increases with increased FITC 
labelling up to 5 fluorophores per antibody molecule.
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Figure 4.13.3
Effect o f increased FITC labelling on anti-CHLDH antibodies as determined in an 
evanescent wave fluoroimmunoassay. Anti-CHLDH antibody samples labelled with 
various levels of FITC (fluorophore-to-protein ratios of 0.00, 1.91, 3.42, 5.19, 7.10, 
8.26), as oudined in section 2.6.3, and the effect of increased labelling on the affinity 
and fluorescence o f the conjugates was determined in an evanescent wave 
fluoroimmunoassay.
(=!
iif—CO
GO
CD
CDOG
CDO(73
CD
O
Time (seconds)
144
4.14 Discussion
Model immunoassay experiments were performed on the surfaces of the fibres, 
employing HRP-labelled antibodies. These model E LISA ’s were used to evaluate the 
optimum coating antibody concentration, the reproducibility of the immobilisation 
procedure and the activity of the immobilised antibodies. The ELISA assay parameters 
were chosen where possible, to correspond as closely as possible to the conditions used 
in the evanescent wave immunosensing experiments. The ELISA employs an end-point 
method for determination of concentrations whereas the EWS measures concentrations 
on initial binding slope determinations.
The method of Bhatia et al. (1989), was used to covalently immobilise anti-CHLDH 
antibodies to the silica surface of exposed core optical fibres. Covalent immobilisation 
was preferred as covalently immobilised antibodies are more stable than adsorbed 
antibodies (Jdnsson et al., 1985). This method was chosen because although it does not 
allow directional orientation of antibody molecules, crosslinking of antibody molecules 
to each other is prevented. The heterobifunctional crosslinker has a different 
functionality at either end of the molecule, one which reacts with the thiol-terminal 
silane and one which reacts with the protein. The heterobifunctional crosslinker was 
allowed to react with the silylated fibre first, and then the antibody solution was added. 
This ensures that the crosslinker does not react with thiol groups on the protein. Bhatia 
et al. (1989), reported that the amount of immobilised antibody on the fibre was 0.96 
ng/mm2, and that the antibody retained its ability to bind 0.37 - 0.55 mole antigen per, 
mole of antibody, as determined by radioisometric immunoassays. This was 3 - 5  times 
greater than reported by other investigators where the retention of antibody binding 
activity was less than 10% (Sportsman and Wilson, 1980).
A ratio of 1 fibre per 1 ml of solution was maintained throughout the immobilisation 
procedure, i.e. for 20 fibres the volume of the silylating, crosslinking and antibody 
solutions was 20 ml. The vessel geometry was chosen to ensure that the entire exposed 
core surface of the fibre was immersed in liquid.
The concentration of immobilising antibody to use was assessed by ELISA, so as to be 
certain that the maximum amount of antibody possible was immobilised to the surface, 
without wasting the antibody preparation. The actual concentration of antibody 
immobilised to the surface was not determined as this would involve the use of 
radioisometric assays, where the specific activity of the radiolabelled conjugates, in
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jjCi/pg protein, is known (Bluestein et al., 1991). A method which does not require the 
use of radioactivity was described by Feldman and Uzgiris (1993). They used citric acid 
to remove bound FITC-labelled antigen from fibre immobilised antibody, and after 
readjustment of the pH to neutral, determined the equilibrium binding capacity of the 
fibres.
All EWS experiments were performed under first-order reaction kinetics, and so the 
fractional occupancy of the immobilised antibody is low during the initial stages of the 
diffusion-limited process. The antibody surface density does not affect the signal within 
a certain range of antigen concentrations (Lin et al., 1994), and so the actual 
concentration of immobilised antibody is not important for these experiments. The 
maximum amount of protein was immobilised to the fibre, at antibody concentrations 
of 40 pg/ml or greater. Using concentrations much greater than 40 pg/ml, would result 
in wastage of the antibody solution. It would also increase the risk of protein-protein 
interactions and adsorption to the fibre surface rather than covalent interactions 
(Porstmann and Kiessig, 1992). The use of lower concentrations of antibody and longer 
incubation times, could attain the same level of immobilisation. However, the GMBS 
crosslinker is only known to be stable in solution for 1 hour. This was determined by 
Bhatia et al. (1989), using nuclear magnetic resonance.
The ‘inter-batch’ reproducibility of the immobilisation procedure was also assessed 
qualitatively by ELISA . The fibre-to-fibre variability as regards the amount of protein 
immobilised was shown to be less than 4%. Intra-batch variability was not determined, 
but all the batches were prepared under the exact same experimental conditions and all 
fibres prepared in a single batch were used for a single experiment.
The activity of the immobilised antibody was also assessed by ELISA, under non­
equilibrium conditions. The ELISA  performed on the fibres, employed the same 
incubations times and antigen concentrations as the EWS experiments. One-step and 
two-step E LISA ’s were performed and compared. For biosensing applications, two-step 
assay protocols cannot be considered to fulfil the criteria for direct signal readout. Two- 
step immunoassays require multiple reagent addition steps and user-mediated separation 
of bound from unbound moieties. Ideally, biosensors should not require any assay 
manipulation once the sample has been added to the system, resulting in direct sample 
signal readout (Robinson, 1991). Both immunoassays showed that the antibody retained 
its biological activity once immobilised to the fibre. The amount of antigen bound
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increased exponentially over the range. The linear range for the two-step assay (0.125 -
1.000 pg/ml) was similar to that of the one-step assay (0.05 - 1.00 pg/ml). A decrease 
in signal was observed (data not shown), for the one-step immunoassay, at higher 
antigen concentrations. This can be explained by the fact that the free antigen in solution 
and the antigen in the HRP-antibody/antigen complex compete for binding sites on the 
immobilised antibody. At high antigen concentrations, the amount of antigen exceeds 
the amount of labelled antibody and so the amount of free antigen in solution 
progressively increases over that in the HRP-antibody/antigen complex. The proportion 
of untagged antigen bound to the fibre increases, and a progressive decrease in the 
signal results. The linear range of the one-step assay can be increased by either 
increasing the concentration of immobilised antibody on the fibre, using more highly 
purified antibodies or increasing the concentration of the labelled antibody. The 
concentration of immobilised antibody is limited by the surface area of the fibre and the 
antibodies used here were affinity-purified, and therefore only specific antibodies are 
present. The only parameter which can be adjusted to improve sensitivity is the 
concentration of the HRP-labelled antibody. In summary, the concentration of the 
labelled antibody must be greater than the highest antigen concentration in a one-step 
assay, to prevent a ‘high-dose hook effect’ . The effect of increasing the concentration 
of the labelled antibody is illustrated in Figure 4.14. Walczak et al. (1992) stated that 
at least a five-fold excess o f labelled antibody is required to minimize the reaction 
dependence upon the secondary labelled antibody. The linear range of the assay can be, 
expanded by controlling the labelled antibody concentration.
All the fibre ELISA s were performed in order to characterise the fibre probe surface and 
to optimise the parameters for the evanescent wave sensing experiments, as much as 
possible. No direct comparison can be made between the ELISAs and evanescent wave 
immunosensing since the labelled antibody is different for both, HRP-labelled and FITC- 
labelled antibody, respectively. The affinity of these antibodies may be different, due to 
the presence of the label. However, the ELISA experiments are simple to perform and 
give valuable information about quantity and activity of the immobilised antibody.
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Figure 4.14
Illustration of the ‘high-dose hook effect’ . A one-step fluoroimmunoassay was performed 
in microtitre plates, using CHLDH at concentrations ranging from 0.019 - 5.000 pg/ml 
CHLDH and 10 (■ ), 5 (□ ) and 2.5 (0) pg/ml FITC-labelled anti-CHLDH antibody. The 
fluorescence intensity was measured using the microtitre plate reader facility of the 
Perkin-Elmer fluorimeter.
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Evanescent wave immunosensing experiments were carried out as described in section
2.12.2 with proximal end detection of fluorescence, as outlined in section 2.12.1. 
Proximal end detection offers many advantages over distal end detection in that the 
signal-to-background ratio is greatly increased (Yoshida et al., 1988). With distal end 
face detection of fluorescence, the totally internally reflected incident radiation has to 
be filtered from the fluorescence which is carried by higher order modes in the fibre. 
The fluorescent signal generated by the immunoreaction is very low. Typically, only 2% 
of this is recaptured by the fibre, under optimal conditions (Love et a l 1991). 
Therefore, a very small signal must be separated from a very large background signal. 
This is avoided with proximal end face detection.
One of the difficulties with using this system is that the fibre has to be aligned in the 
optical system, so that the laser light is optimally launched down the fibre, without the 
aid of an initial fluorescent signal. The excitation and detection of the resulting 
fluorescence signal was carried out at the proximal end o f the fibre and so exact 
alignment o f the proximal end face in the laser beam is important The launch conditions 
affect the sensitivity o f the system. The detected signal has been shown to be 
approximately proportional to the area of the illuminated spot on the end face of the 
fibre (Love and Button, 1988). Glass et al. (1987), showed that the signal level from a 
fibre-optic evanescent fluorosensor is a highly sensitive function of the numerical 
aperture o f excitation and collection, showing an eighth power dependence of sin 0m„, 
the external launch angle. Therefore, if the fibre is not aligned correctly in the optical 
system, filling all the launch angles, the signal can be adversely affected. Walczak et al. 
(1992), chose a more conservative 25° launch and collection angle in their optical 
measurements. Although more signal intensity could be obtained at higher angles of up 
to 0C (36.8°), the ease of optical alignment and insensitivity to perturbations of the light 
into solution yielded the more conservative approach. Lin et al. (1994) used a moulded 
polystyrene integrated lens optical fibre, which increases the efficiency of light coupling 
between the light source, the fibre and the detector. The integrated lens also serves to 
decrease the positional tolerance within the optical path, thus alleviating the difficulty 
in alignment o f the fibre. The moulded polystyrene also has the added advantage of 
reducing the effect o f V-number mismatch (Anderson et al., 1993), as the mould 
material also holds the fibre in position.
Alignment reproducibility was found to have a coefficient o f variation of approximately
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14%, when a one-step assay was repeated 7 times, using a new fibre probe for each 
assay. This indicates that there is some variability in the alignment procedure. Other 
variables such as differences in the polishing quality for different fibres, slight variations 
in the pumping rate etc., may have contributed to the variability but care was taken to 
reduce these effects.
Antibody-antigen interactions generally have high affinity constants, which confers high 
sensitivity to immunoassays. The price to be paid, however, is irreversibility. Reversible 
immunoassays can be developed if the dissociation rate of the antibody-antigen reaction 
is sufficiently fast, so that the analyte will dissociate in a short enough time to allow 
rapid re-equilibration to be established in response to a change in concentration. Astles 
and Miller (1993), reported a reversible immunosensor for phenytoin, based on 
homogenous fluorescence energy transfer immunoassay. The sensor had a response time 
of 15 minutes. As an alternative to reversibility, the fibre probes can be regenerated with 
conditions which will break the antibody-antigen bond, allowing reuse of the fibre probe, 
for subsequent assay measurements. Physical and chemical variables can be used to 
manipulate and control antibody antigen reactions, such as surface tension, pH, ionic 
strength, temperature and the presence of dehydrating agents or chaotropic salts. The 
conditions for breaking an antibody-antigen bond cannot be predicted, as the nature and 
strength of the bond is an intrinsic property of a particular antibody-antigen pair, 
depending on the combination of the amino acid residues found in the binding site. For 
example, increasing the ionic strength of the buffer works well for dissociating, 
electrostatic bonds, but where mainly hydrophobic interactions prevail, the opposite is 
true, and chaotropic salts are required (Jefferies and Deverill, 1992).
The effect o f regenerating the immunosensing surface of an aligned fibre was 
investigated as an alternative to aligning a new fibre for each assay. A single fibre could 
be used for multiple immunoassays. Relatively good regeneration was obtained when 
0.1M glycine/HCl, pH 2.5, was used as the regeneration solution, and the coefficient of 
variation was <6% for 7 regenerations. This regenerating solution was used to dissociate 
the antibody from the immunoaffinity support (section 2.4.2.2), during the purification 
of the antibody. Problems due to air bubbles in the flow system meant it was necessary 
to realign the fibre at irregular intervals, and so the variability associated with the 
realignment was introduced. The baseline signal after the regenerating solution was 
pumped out of the flow cell and refilled with 1% (w/v) BSA, was higher than the initial
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baseline signal. It was observed that the baseline increased progressively with further 
regenerations. This indicated that some of the immunocomplex remained associated with 
the fibre, with each regeneration. This could be due to the fact that the antibody is 
polyclonal in nature, and the bonds for the higher affinity antibodies are more difficult 
to break. More likely however, is the probability that the acidic solution is causing 
denaturation of the immobilised antibody, resulting in the exposure of hydrophobic 
regions in the protein. Labelled antibody can non-specifically adsorb to these 
hydrophobic regions.
Bright et al. (1990), regenerated the distal tip o f a fibre optic immunosensor with 0.1M 
phosphoric acid, up to 50 times without significant inactivation of the immunosensing 
surface. The fibre probe had to be immersed in the acidic solution for 10 minutes for 
each regeneration. Wijesuriya et al. (1994), investigated the regeneration properties of 
an acidic solution, pH 1.75, containing 50% ethylene glycol, a basic solution, pH 11.0, 
containing 50% ethylene glycol and a 50% ethanol solution. The mixture of the acid or 
base with ethylene glycol reduces the attractive forces between the antibody and antigen 
due to electrostatic interactions and Van der Waals/hydrogen bonding interactions. 
Hydrophillic proteinaceous antigens were found to dissociate from their antibody, using 
these buffers, with the exception of very high affinity antibodies. A monoclonal antibody 
of moderate affinity was found to dissociate cleanly from its hydrophobic antigen with 
50% ethanol solution. However, this was attributed to the fact that the antigen was more 
soluble in the ethanol solution. Different dissociating solutions may have improved the- 
dissociation of the CHLDH from the anti-CHLDH antibody coated fibres. However, due 
to the fact that realignment was required when air bubbles were introduced into the flow 
cell and denaturation of the immobilised antibody appeared to be occurring, it was 
decided to use a new fibre for each assay.
One-step and two-step immunoassays were performed on the fibres and the rate of the 
initial binding reaction determined using linear regression, as shown in Figure 4.11.5.1. 
The reaction is pseudo first-order and, therefore, the initial rate of binding is directly 
proportional to the analyte concentration. The binding kinetics of antigen by immobilised 
antibody is described by Sadana and Sii (1992).
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For antigen (Ag) binding to an immobilised antibody (Ab), the rate of binding is given
by;
iu * ,c s(r0-r1)-*.1r1 (“•«)
where
Tj = the surface concentration of antibodies which are bound by antigen at time t 
r 0 =  total concentration o f the antibody binding sites on the surface 
k, = association constant (or forward reaction rate) for Ab-Ag binding 
k j = dissociation constant (or reverse reaction rate) of Ab-Ag binding 
Cs = concentration o f antigen close to the surface
For initial binding kinetics, «  ro, since very few of the binding sites of the 
immobilised antibody are occupied. Also, k jQ ro  »  k.^Tj, since the reverse reaction is 
very slow for moderate to high affinity antibodies, and dynamic equilibrium is not 
reached for relatively short times. Therefore;
dr. dr. (A -s—i=*.c_r0=— (4.7)
dt 1 dt
and so, the initial rate o f the reaction is solely dependent on the rate of antigen binding,' 
and the reaction is considered pseudo first-order, as both the capture and labelled 
antibody are in considerable molar excess.
Diffusion plays an important role in antibody-antigen binding reaction, especially if one 
of the reactants is immobilised. There is a surface layer (-100 pm thick) which is static 
and antigen must diffuse across this layer before binding to the antibody. If the reaction 
rate at the surface is faster than the diffusion rate of the antigen to the surface, the 
reaction is said to be ‘diffusion-limited’ . This is assuming there is no flux due to 
convection, which is true in this case because of the small sample volume (the solution 
is considered stagnant). The time taken for an immunoreaction to reach equilibrium is 
dependent on the diffusion coefficient. However, as the rate measurements are to be 
made during the initial phase of the reaction, there is no need to wait for equilibrium
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to occur. Regardless o f whether the assay is under reaction or diffusional control, the 
reaction rate is proportional to the initial bulk concentration of antigen. This means that 
kinetic measurements are feasible for the measurement of antigen concentrations (Place 
et al., 1991). In conclusion, the concentration of the labelled and capture antibody must 
be in excess to ensure that the immunoreaction follows pseudo first-order reaction 
kinetics, and therefore, is proportional to the antigen concentration. One would only 
expect deviation from linearity if high analyte levels saturate fibre binding sites quickly 
bringing about an equilibrium.
The initial binding slope of the curve was determined by linear regression. The first 1 
minute of the signal was ignored. This was to remove non-specific fluorescence signals 
resulting from background fluorescence from the fluorescein content of the bulk 
solution, which may be coupled back into the fibre by scattering or which diffuses in 
and out of the evanescent zone by convection (pumping). Fluorescence resulting from 
non-specific adsorption is also removed. Bluestein et al. (1991), reported that 90% of 
these non-specific effects are removed within the first 10 seconds of signal monitoring. 
The initial binding rate was then determined over the next one minute of signal 
monitored, and this was attributed to the immunoreaction. The linear range of the two- 
step assay was wider than that o f the one-step assay due to the hook effect as described 
earlier. Increasing the labelled antibody concentration should increase the linear range 
of the one-step assay.
The one-step assay gave much lower overall binding rates than the two-step assay.. 
Shriver-Lake et al. (1993), compared the detection sensitivity of a one and two-step 
assay. The one-step assay employed different monoclonal antibodies as the capture and 
labelled antibodies, which bound to non-interfering epitopes of a small molecule, 
pseudexin (m.w. 16,500). For the one-step assay, the antigen and labelled antibody are 
allowed to bind in solution, forming a FITC-antibody/antigen complex, which on 
pumping into the flow cell binds with the immobilised capture antibody. By using non­
interfering monoclonal antibodies, the binding of the antigen to the fibre immobilised 
antibody is not blocked. The two-step assay was performed using the same batch of 
polyclonal antibodies against a large molecule, botulinum toxin (m.w. 150,000), for the 
preparation of the capture and labelled antibody, the capture antibody being affinity- 
purified. The overall signal for the two-step assay was lower than the one-step assay. 
This reason for this was attributed to the fact that the blocking of some of the epitopes
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by the capture antibody reduces the number of epitopes for the second antibody, and 
hence, the rate of binding.
CHLDH is a large molecule (m.w. 140,000), and so the polyclonal antibodies raised 
against it bind to many epitopes on its surface. This means that for the two-step assay, 
there is a sufficient number of epitopes remaining for the labelled antibody to bind, after 
the antigen has bound to the capture antibody. For reasons cited earlier, there is a 
reduced number of epitopes available for the capture antibody to bind, in a one-step 
assay, thereby reducing the rate of binding. There is also the factor of steric hindrance, 
the labelled antibody preventing easy access o f the capture antibody. The diffusion 
coefficient for the larger complex for the one-step assay is also decreased, thus affecting 
the rate o f binding.
Both the one-step and the two-step immunoassay for CHLDH, gave equivalent 
sensitivity (0.03 pg/ml), although the magnitude of the response was very different. For 
CHLDH, concentrations lower than 0.03 pg/ml, no signal over background was detected. 
Shriver-Lake et al. (1993), achieved much lower detection limits (1 ng/ml), using 
tapered optical fibres, which improves fluorescence detection (Anderson et al., 1993). 
A competitive immunoassay was performed using FITC-labelled CHDLH. A fixed 
concentration of FITC-CHLDH (20 pg/ml) and varying concentrations of CHLDH, 
competed for binding to the immobilised anti-CHLDH antibody, resulting in an inverse 
relationship between signal slope and antigen concentration. The working range of the 
assay, that is the region o f the steepest part of the concentration-response curve, was 1.0, 
- 10.0 pg/ml, using 20 pg/ml, as the labelled antigen concentration. The working range 
could be adjusted by varying the concentration of the immobilised antibody (which is 
fixed due to the limited fibre surface area), or the concentration of the labelled antigen 
(Oroszlan et al., 1993). A lower detection limited can be achieved by lowering the 
concentration of the FITC-labelled CHLDH. At lower antigen concentrations i.e. <1.0 
pg/ml, the labelled antigen concentration is too high to allow the difference in the 
fluorescence signal to be measured. Concentrations greater than 10 pg/ml were not 
measured.
Finally, the effect of solution viscosity on the rate of antibody-antigen binding was 
tested. It was expected that for higher viscosity solutions, the rate of diffusion would be 
lowered and, hence, the rate of binding would be decreased. The opposite result was 
obtained, in that the rate o f signal accumulation increased with increased solution
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viscosity. A possible explanation for this is that the increased signal is not due to 
increased rate of accumulation but rather more efficient coupling of the fluorescence 
back into the fibre. Love et al. (1991) showed, using sucrose solutions, that the 
fluorescence signal was proportional to N.A."4material. In other words, the N.A.material 
decreases with increased viscosity, and as the N.A.materia| decreases the signal increases 
(Equation 4.4).
The BIAcore™ allows direct monitoring of biomolecular interactions without the 
requirement for labelling one of the biocomponents involved (section 1.4.3.2.2). 
Furthermore, the dextran strands of the immobilisation matrix, are mobile in three 
directions, and approximate more closely to a volume rather than an area. Immobilised 
biomolecules are thus, in effect, ‘ still in solution’ . These properties of the BIAcore™ 
allows the determination of the kinetic properties o f antibodies (Johne et al., 1993), 
under real conditions, as the immobilisation of antibodies to conventional solid surfaces 
can alter the association and dissociation properties o f the antibody molecules. The 
determination of the concentration of one of the binding partners can also be carried out. 
An assay procedure for the determination of the concentration of p2-microglobulin 
(Application note 201, Pharmacia Biosensor AB), using a monoclonal antibody as the 
immobilised molecule and polyclonal second antibody to amplify the signal was 
reported. Real-time biospecific interaction analysis using a direct (no amplification 
second antibody) or multi-step binding technique is suitable for concentration, 
determination of proteins with large molecular weights (above about 10,000 Da). For 
smaller molecules, such as theophylline, a competitive binding assay can be used, as the 
total mass of analyte which can be bound to the sensor chip surface is too small for 
confident direct measurement, and sandwich immunoassays cannot be applied when the 
analyte lacks multiple antigenic sites or epitopes (Application note 202, Pharmacia 
Biosensor AB).
A direct, two-step and one-step immunoassay for CHLDH was set up on the BIAcore™, 
in order to compare the immunoassays, with those set up on the evanescent wave sensor 
(EWS). A direct assay can be set up because the molecular weight of CHLDH is large, 
140,000 Da, and on binding to the immobilised antibody, the mass change is sufficient 
to be transduced directly without signal amplification. With signal amplification (two- 
step assay), the sensitivity of the assay is increased almost two-fold. A higher level of
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sensitivity should have been obtained, had the capture and amplifying antibody not been 
from the same polyclonal source. The use of the same polyclonal antibody results in 
some epitope blocking, thereby reducing the number of sites available for the second 
antibody to bind. This was elaborated on earlier (section 4.12), when discussing one-step 
and two-step evanescent wave immunoassays.
The detection range o f the one-step assay for CHLDH is much narrower when 
determined on the BIAcore™ compared to the EWS. No binding was observed for 
concentrations less than 1.0 pg/ml. The reason for this may be that when the CHLDH 
and anti-CHLDH antibody was premixed by the BIAcore™ autosampler system, the 
sample was allowed to incubate for 1-2 min before passing over the immobilised 
antibody, whereas the premixed sample was injected over the fibre probe immediately 
using the EWS. A higher percentage of the epitopes may have been blocked, due to this 
incubation. It is also possible that the antibody-antigen complexes may have precipitated 
out of solution, at these lower concentrations of antigen. A lower quantity of anti- 
CHLDH was immobilised to the chip surface for the one-step assay (4253 RU) than the 
two-step assay (7531 RU), which may also have contributed to the lower sensitivity. For 
higher concentrations o f CHLDH, no high dose hook effect is seen as with the EWS. 
This is because the antigen is detected directly on the basis of its mass and not 
indirectly via a labelled antibody. Even when the second antibody is no longer in excess, 
the uncomplexed antigen can still bind to the immobilised antibody and cause a mass 
change.
Comparing of the one-step and two-step immunoassays as performed on the BIAcore™ 
and EWS, one can conclude that the one-step assay, which fulfils the criteria for 
biosensing, can be performed with polyclonal antibodies for large antigens, but with a 
large loss in detection sensitivity. Using polyclonal antibodies raised in different species 
may be the answer, as the range of epitopes for the different polyclonals may be 
different. Production of monoclonal antibodies may be time consuming, expensive and 
difficult. This was shown using anti-mouse IgG antibodies in a fluorescence-linked 
immunosorbent plate assay (results not shown). Rabbit anti-mouse IgG (Sigma) and 
sheep anti-mouse IgG (Dako) were used to coat a microtitre plate and a one-step assay 
using rabbit FITC-anti-mouse IgG as the second antibody was set up. The signals 
obtained for the one-step assay using the sheep and rabbit raised antibody as the capture 
and second antibody respectively, was on average 2-fold higher than the assay which
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employed rabbit-raised polyclonal antibodies for both the capture and second antibody. 
One useful application of the BIAcore™, in the development of biosensors, is the 
selection of low affinity monoclonal antibody clones, for the development of reversible 
biosensors.
The BIAcore™ and the EWS were used to determine the effect of increased FITC- 
labelling on the affinity of protein A-purified anti-CHLDH antibody. The optimal 
conditions for the conjugation of FITC to antibodies have been described in Goding 
(1983), to obtain the optimal labelling ratio of 1-4 FITC molecules per antibody 
molecule (The and Feltkamp, 1970a). The lowest degree of conjugation which gives the 
maximum fluorescence is preferred because it will cause the least change in the physical 
and biological properties o f the native protein. With high FITC to protein ratios, the 
isoelectric point of the protein is decreased, which for immunohistochemical staining can 
cause non-specific binding, especially to acidophillic tissue components (The and 
Feltkamp, 1970b). However, the optimal degree o f conjugation immunohistologically 
may not be the optimal degree in the physicochemical sense, or for use in fluorescence- 
linked immunosorbent assays.
Fluorescein isothiocyanate (FITC), probably conjugates to antibodies via the free amino 
groups of the lysine residues. It is not possible to predict, however, how many lysine 
residues are in the binding site o f an antibody. At high levels of conjugation, it is more 
probable that an FITC molecule will react with a lysine residue near or in the binding 
site, causing conformational changes and, hence, affecting the ability of the antibody to, 
bind to its antigen. The effect of FITC conjugation on antibody activity is reviewed in 
Ward and Fothergill (1976). Above a certain F/P ratio, it has been shown that the 
fluorescence of the conjugates does not increase. This was explained by the fact that the 
first fluorophore to attach to the protein will react with the most readily available site, 
which is most likely to produce least distortion to the protein molecule and the 
fluorophore structure. Additional fluorophore molecules are more likely to conjugate 
with less readily available lysine groups, and be more intimate with the protein, and thus 
be more liable to quenching.
The effect of increasing the FITC/protein ratio, on the affinity of anti-CHLDH antibody, 
was determined, using the BIAcore™ and the EWS. Abraham et al. (1991), studied the 
influence of periodate oxidation on monoclonal antibody avidity and immunoreactivity. 
This involved the use of Scatchard analysis and manipulation of inhibition binding data.
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Real-time analysis allows much quicker assessment of such parameters. The BIAcore™ 
monitors the binding of antibody to antigen in real-time. The results clearly show that 
as the F/P ratio increases, the affinity of the anti-CHLDH antibody for CHLDH 
decreases. The total anti-CHLDH antibody bound to the CHLDH-coated sensor chip 
surface after a 20 min incubation, decreased with increasing F/P ratios. This is probably 
due to the progressive dénaturation of the antibody, as the number of FITC molecules 
bound to it increases, resulting in a reduction in its binding ability. At low levels of 
conjugation, 2-4 FITC/antibody, the antibody affinity is only reduced by 20%, compared 
to the control antibody. For higher levels of labelling, 5-8 FITC/antibody, the reduction 
in affinity is greater than 60%.
The BIAcore™ detects antibody-antigen binding on the basis of mass accumulation, and 
therefore, does not require a label species for transduction of the antibody-antigen 
interaction. Therefore, no conclusion could be drawn from the BIAcore™ results about 
how the fluorescence intensity of the conjugates, could compensate for the loss of 
antibody affinity at high labelling ratios, in for example, fluoroimmunoassay situations. 
The EWS was used to determine the affinity of the FITC-labelled anti-CHLDH antibody 
conjugates by measuring the increase in the fluorescence signal as the immunoreaction 
occurred. The results show that although the affinity of the antibody labelled with 5.19 
FITC molecules per antibody molecule, is only 40% of the control (unlabelled) antibody 
(as determined by the experiments performed on the BIAcore™), the high level of 
fluorophore labelling compensates for this, and the steepest binding curve was obtained, 
for this F/P ratio using the EWS. The lack of signal by the even higher labelled 
antibodies must be attributed to a combination of fluorescence quenching and reduction 
in antibody affinity. The optimal ratio for fluoroimmunoassay experiments was taken to 
be 2-5 fluorophores per antibody protein molecule.
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CHAPTER 5
DEVELOPMENT OF AN ELISA FOR THE H- 
SUBUNIT OF HUMAN LDH AND ITS USE IN THE
DIAGNOSIS OF AMI
5.1 M easurem ent of Lactate Dehydrogenase (LDH)
Lactate dehydrogenase (EC 1.1.1.27) catalyses the reaction;
Lactate + NAD+ ^  pyruvate + NADH + H+
The activity of LDH can be measured spectrophotometrically. The equilibrium of the 
above reaction lies far on the side of lactate and NAD+ (Gay et al., 1968). The cofactor 
in the reaction, NADH, absorbs strongly at 340nm, and therefore the activity of LDH 
can be measured by the decrease in absorbance at 340 nm, as NADH is converted to 
NAD*. An important feature of this assay is that the optimal pyruvate concentration 
varies with pH, temperature, isoenzyme and species. Pyruvate is a potent inhibitor of the 
reaction at high concentrations.
LDH can also be measured by the forward reaction, under suitable reaction conditions. 
The NADH formed in the reaction can be measured directly by an increase in the 
absorbance at 340 nm (Amador et a l ., 1963; Gay et al., 1968), or after coupling to the 
reduction of a tetrazolium salt (INT), with phenazine methosulphate (PMS) as an 
intermediate electron carrier, resulting in a strongly coloured product, formazan (Babson 
and Philips, 1965; Nachlas et al., 1960). Formazan absorbs strongly at 500 nm.
Lactate + NAD+ *=? Pyruvate + NADH + H+
NADH + PMS + H+ -> NAD+ +  Reduced PMS 
Reduced PMS + Tetrazolium salt —> Formazan +  PMS
Alternatively, LDH activity can be measured fluorimetrically. NADH, a product of the 
forward reaction is strongly fluorescent at 456 nm when excited at 340 nm. Practically 
however, interference occurs from naturally occurring constituents o f serum which will 
either quench the fluorescence of NADH or fluoresce in a similar region to NADH, 
causing interference. The inner filter effect of serum also restricts the application of 
direct enzyme analysis in serum by fluorescent methods. Passen et al. (1966), obviated 
the problems of light scattering, inner filter effects, quenching and non-specific 
fluorescence by dialysing out the NADH and then measuring the fluorescence.
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5.2 Isoenzymes of LDH
Lactate dehydrogenase (LDH), is present in the human body, in five different tetrameric 
isoenzyme forms. These isoenzymes are composed o f different combinations of two 
different LDH subunit types, H and M (Plagemann et al„ 1960). The two forms have 
different catalytic, physical and immunological characteristics, and are under separate 
genetic control. The five tetrameric isoenzymes are H4 , H3 M, H2 M2, HM3  and M 4  
(alternatively LDHt - LDH5, respectively). The isoenzymes are distributed throughout 
the body, different tissues having a specific isoenzyme pattern of LDH. All five 
isoenzymes are represented in normal human serum. LDHU  predominate in tissues such 
as the heart, kidney, brain, pancreas and erythrocytes while LD H ^ predominate in the 
tissues o f the liver, skeletal muscle and granulocytes.
The isoenzymes of LDH are distinguishable by their chemical composition, kinetic and 
immunological properties (Cahn et ah, 1962). LDHt has a low Km for pyruvate and is 
strongly inhibited by it, whereas LDH 5  has a higher Km for pyruvate and is not inhibited 
by it. The isoenzymes can be separated from one another electrophoretically, LDH, 
being the most fast-moving, migrating towards the anode while LDH5, is the slowest 
moving, migrating toward the cathode. Antiserum against the M* isoenzyme of a species 
will not cross react with its own Hi isoenzyme. H4  is a poorer immunogen and may 
cross react with M4  from other species.
5.3 Myocardial infarction and LDH
When a region of the heart muscle becomes starved of blood, due to a blockage in an 
artery leading to the heart, the cells o f this region die and acute myocardial infarction 
(AMI) is said to have taken place (Higgins et al., 1994). It is generally considered that 
such tissue injury can cause leakage of intracellular enzymes into the circulatory system. 
A consequence of cell death due to myocardial infarction is that the myocardial cell 
membranes soon rupture leading to the release o f a variety of intracellular enzymes such 
as creatine kinase (CK), lactate dehydrogenase (LDH) and glutamic oxaloacetic 
transaminase (GOT), into the circulation. This results in a superimposition of the tissue 
LDH isoenzyme pattern upon the normal serum isoenzyme pattern. AMI can be treated 
successfully if it is diagnosed rapidly. Analysis o f the LDH isoenzyme pattern in the 
serum is one method of diagnosis.
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5.4 Diagnosis of AMI by isoenzyme analysis
LDH isoenzyme analysis is used extensively for the diagnosis of AMI, liver disease and 
myopathies since the total LDH concentration in serum is significantly increased for 
these diseases and the isoenzyme profile o f the tissues involved, represent the 
electrophoretic extremes (i.e. an increase in LDH, and LDH2 or an increase in LDH5 and 
LDH4), and are easily recognised. Other isoenzyme profiles are representative of other 
diseased states such as cancer. Jacobs et al. (1977), reported the clinical significance of 
the ‘isomorphic’ pattern of LDH. The isomorphic pattern is defined as a significant 
increase in the total LDH concentration, with normal or low percentages of individual 
isoenzyme fractions, and with the LDHj/LDH2 ratio less than unity. The isomorphic 
pattern can result from a wide range of different diseases including cardio-respiratory 
diseases, malignancy, fractures and infections.
The heart muscle cells predominantly contain the LDH, isoenzyme whereas serum 
predominantly contains LDH2 (Nisselbaum and Bodansky, 1961). After an episode of 
AMI, serum LDHj increases at 8-12 hours, reaches a maximum at 48-72 hours and 
returns to normal at 8-12 days later. Acute MI is therefore accompanied by elevated 
total LDH, reversed LDH,/LDH2 ratio and an elevation of LDH,.
Diagnosis o f AMI on the basis o f the LDH,/LDH2 ratio flip, as determined by 
electrophoretic methods is commonly used. The isoenzymes are separated by 
electrophoresis on an agar gel and the zones of activity visualised by performing a 
chemical reaction where the substrate yields an insoluble chemical product in the 
presence of the enzyme. The relative activity of each isoenzyme is measured by 
scanning densitometry (Rosalki, 1974). There was much debate in the late 1970’s, 
however, as to whether the determination of the concentration of LDH, alone was better 
for more rapid AMI diagnosis. Usategui-Gomez et al. (1979), reported that for 25% of 
patients diagnosed with MI, the concentration of LDH, was of diagnostic value one day 
earlier than the LDH,/LDH2 isoenzyme ratio. The determination of LDH, concentration 
was carried out using immunochemical techniques. A polyclonal antibody against the 
M-subunit of LDH and a polymer-conjugated second antibody promoted precipitation 
o f all the isoenzymes containing the M-subunit (M4, HM3, H2M2, and H3M), which were 
removed by centrifugation, allowing the activity of the LDH, (H4), to be determined by 
spectrophotometric methods. Gerhardt et al. (1983), also found that the quantitation of 
serum LDH,, was diagnostically more reliable for MI than LDH,/LDH2 ratio. Serum
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LDH, elevation occurs before the ratio of LDH,/LDH2 is greater than unity, thus 
allowing more rapid diagnosis. Weidner (1977), felt that both measurements were 
important.
A similar method for the determination of LDHS with monoclonal antibodies 
immobilised on latex beads was reported by Vaidya et al. (1986).
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Results
5.5 M iniaturised colourim etric assay for total LDH
Standard human LDH samples (0.0 - 2.9 pg/ml) were prepared in 1% (w/v) BSA, and 
the miniaturised assay for total LDH performed as outlined in section 2.14. These LDH 
sample concentrations span across the normal and abnormal range for total serum LDH 
values.
The results of the miniaturised assay are shown in Figure 5.5.1. The error bars on the 
data are present but are too small to be seen. Excellent linearity was obtained over the 
whole range (r=0.999).
Clinical patient samples (obtained from St. James Hospital) were assayed for total LDH, 
using the miniaturised colourimetric assay outlined in section 2.14. The activity of the 
LDH (as determined by automated SMAC analyser in St. James Hospital, Biochemistry 
Dept.) was plotted against the absorbance values obtained for the miniaturised assay. 
From Figure 5.5.2, it can be seen that the miniaturised colourimetric assay based on the 
forward reaction gives good correlation (r=0.983) with the automated analyser, which 
determines LDH activity based on the reverse reaction.
5.6.1 P roduction an d  purification of anti-H 4LDH antiserum
Antisera to human LDH (H/LDH-l isoenzyme), was obtained by immunisation of a 
New Zealand White rabbit (section 2.2.2). The IgG fraction of the antiserum was 
purified by ammonium sulphate salt precipitation followed by protein A (SpA) affinity 
chromatography, as outlined in sections 2.4.1 and 2.4.3. Protein A (isolated from S. 
aureus) binds to the Fc portion of class G immunoglobulins (Surolia et al„ 1982), and 
so isolates specific and non-specific IgG. Results of antiserum titre studies are shown 
in Figure 5.6.1. The titre was shown to be 1:2000.
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Figure 5.5.1
Miniaturised colourimetric assay for LDH. The assay was performed in 96-well 
microtitre plates, as outlined in section 2.14. The assay is Unear for LDH concentrations 
in the range 0.0 - 2.9 pg/ml (n=0.999).
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Figure 5.5.2
Correlation between the miniaturised colourimetric assay for LDH (section 2.14), and 
the LDH activity in patient serum samples, as determined by the automated SMAC 
analyser (performed in St. James’ Hospital). The activity of the LDH is plotted against 
the absorbance at 492 nm obtained in the minaturised assay. The correlation between the 
two assays is excellent (r=0.983).
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Figure 5.6.1
Titre of purified anti-H4LDH antibodies. Serial dilutions (1:25 - 1:12,800) of normal 
rabbit serum (♦), and protein A affinity-purified anti-H4LDH antibodies (■ ) were 
prepared in 0.15M PBS, pH 7.4, and the titre determined as outlined in section 2.5.1. 
The purified antibody has a titre of 1:2000.
LO
o
<§>
CO
-Q
<
log antiserum dilution
166
5.6.2 C haracterisation  of the purified anti-H 4LDH antibodies by SDS-PAGE
The purity of the SpA purified anti-H4LDH was assessed by SDS-PAGE electrophoresis, 
as outlined in section 2.8. The SpA purified anti-H4LDH antibody, SpA purified anti- 
CHLDH and a commercially available rabbit anti-mouse IgG (IgG fraction) were 
electrophoresed under non-reducing conditions, in a 5-20% gradient gel and stained with 
Coomassie Brilliant Blue. The molecular weight markers are shown in Lane 1 (Figure
5.6.2), with rabbit anti-mouse IgG (Lane 2), rabbit anti-CHLDH antibody (Lane 3) and 
rabbit anti-H4LDH (Lane 4). The heavy band (the gel was slightly overloaded) for all 
three samples corresponding to a molecular weight of 160,000-180,000 Da, found 
between molecular weight markers 112,000 Da and 195,000 Da, represents the IgG 
fraction. Two fainter bands are also visible for molecular weights, slightly greater than 
63,000 Da (possibly BSA, m.w. -66,000), and slightly smaller than 52,000. These bands 
appear for the commercial and ‘in-house’ produced antibodies. This was not expected 
as Protein A chromatography should bind IgG alone. However, the amount of 
contaminants compared to IgG was small, and the ‘in-house produced’ antibodies 
compared favourably with the commercial preparation.
5.6.3.1 C onjugation of an ti-H 4LDH to horseradish peroxidase (HRP) enzyme
Protein A purified anti-H4LDH was conjugated with the enzyme HRP, as outlined in 
section 2.5.2. The HRP-anti-H4LDH conjugate and unconjugated antibody, was purified 
from the unconjugated enzyme by salt precipitation as outlined in section 2.4.1, and 
diluted (1:1) with glycerol. The glycerol stabilises the conjugate, allowing it to be stored 
at -20°C, without freezing.
5.6.3.2 D eterm ination of the working dilution of H RP-anti-H 4LDH antibody 
conjugate
The working dilution of HRP-anti-H4LDH was determined as outlined in section 2.5.3. 
Serial dilutions (1:25 - 1:6400) were prepared in 3% (w/v) BSA in 0.15M PBS-Tween, 
pH 7.4. The working dilution of the conjugate was determined to be 1:100 (Figure
5.6.3).
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Figure 5.6.2
Analysis of the purity of the protein A affinity purified antibody, by SDS-PAGE (5-20% 
gradient gel), under non-reducing conditions, and stained with Coomassie Brilliant Blue 
(section 2.8). Prestained molecular weight markers (Sigma SDS-7B), with molecular 
weights ranging from 32-195 kDa were electrophoresed in lane 1. The molecular weight 
markers were triosephosphate isomerase (32 kDa), lactic dehydrogenase (35 kDa), 
fumarase (52.5 kDa), pyruvate kinase (63 kDa), fructose 6 -phosphate kinase (84 kDa), 
(3-galactosidase (112 kDa) and o^-macroglobulin (195 kDa). Rabbit anti-mouse IgG 
[obtained from a commercial source] (lane 2), rabbit anti-CHLDH antibody (lane 3) and 
rabbit anti-H4LDH (lane 4) were all purified via protein A affinity chromatography. The 
purity of the anti-H4LDH antibody compared favourably with the commercially available 
antibody.
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Figure 5.6.3
Determination of the working dilution of the HRP-anti-H4LDH antibody. Serial dilutions 
(1:25 - 1:6400) were prepared in 3% (w/v) BSA in 0.15M PBS, pH 7.4, and titred as 
outlined in section 2.5.3. The working dilution was determined to be 1:100.
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5.6.4 D eterm ination of H4LDH by two-site sandw ich ELISA.
Samples of H4LDH were prepared in 0.15M PBS, pH 7.4, at concentrations ranging 
from 0.003-2.500 pg/ml, and an ELISA performed as outlined in section 2.5.4. The 
labelled antibody, HRP-anti-H4LDH was used at its working dilution of 1:200. The 
ELISA plate was blocked with 0.5% (w/v) gelatin, as there appeared to be some non­
specific binding by the labelled antibody to BSA. M4LDH (LDH-5) was the negative 
control. The results are plotted on a linear/log scale and the standard curve shown in 
Figure 5.6.4. The curve is linear across the whole range, 0.003-2.500 pg/ml (r=0.998).
5.7 Specificity of anti-H 4LDH antibody for the H subunit of LDH
A two-site sandwich ELISA was performed with 0.00 - 3.63 pg/ml H4LDH prepared in 
0.15M PBS, pH 7.4, 0.00 - 3.63 pg/ml H4LDH in 2.00 pg/ml M4LDH in PBS and 0.00 - 
1.50 pg/ml M4LDH in PBS. The labelled antibody, HRP-anti-H4LDH was used at its 
working dilution of 1:100. Figure 5.7.1 shows that the antibody is specific for the H- 
subunit of LDH and does not bind to the M-subunit. No binding was observed for the 
range of concentrations of the M4LDH (LDH5). When the H4LDH was prepared in PBS 
containing 2 pg/ml M4LDH, the same curve was obtained as for the H4LDH prepared 
in PBS alone. This indicates that there is no cross-reactivity with the M-subunit of LDH. 
The specificity of the antibody was also shown by Western blotting (Figure 5.7.2). The 
LDH isoenzymes were electrophoresed on a 5-20% gradient polyacrylamide gel (section 
2.8.1) and blotted onto nitrocellulose paper as outlined in section 2.16. The blot yielded, 
two strong positive bands for the H4LDH isoenzyme and no bands for the M4LDH 
isoenzyme.
An attempt was made to probe all five isoenzymes of LDH and to test the reactivity of 
the antibody with each one. With PAGE, all five isoenzymes run as a single band, since 
all five isoenzymes have similar molecular weights. The five isoenzymes can be 
separated, however, on the basis of the net charge on the protein. The separation is 
performed in 1% (w/v) agarose gels. The isoenzymes were electrophoresed in agarose 
gels, and blotted onto nitrocellulose paper, as for the polyacrylamide gels (section 2.16). 
The pore size of the 1% (w/v) agarose gels, however, is very large and diffusion of the 
isoenzymes occurred during the blotting procedure. Following probing with the HPR- 
anti-H4LDH, no clear banding could be seen due to the diffusion of all the isoenzymes 
into one another.
170
Figure 5.6.4
Determination of the linear range of the two-site sandwich ELISA for H4LDH. Samples 
(0.003 - 2.500 ]ig/ml) were prepared in 0.15M PBS, pH 7.4, and the ELISA performed 
as outlined in section 2.5.4. The second antibody, HRP-labelled anti-H4LDH was used 
at its working dilution of 1:100. Absorbance values were plotted against the log H4LDH 
concentration. The assay was linear across the whole range (r=0.998), indicating that the 
ELISA is not very sensitive.
log LDH-1 concentration (ug/ml)
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Figure 5.7.1
Specificity of the anti-H4LDH antibody for the H subunit of human LDH. A two-site 
sandwich ELISA was performed with 0.00 - 3.63 pg/ml H4LDH (□), 0.00 - 1.50 jig/ml 
M4DLH (0) and 0.00 - 3.63 pg/ml H4LDH prepared in 2.0 pg/ml M4LDH (■), as the 
antigens. No cross-reactivity of the anti-H4LDH antibody with the M4LDH is observed.
log LDH-1/LDH-5 concentration (ug/ml)
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Figure 5.7.2
Specificity of the anti-H4LDH antibody for the H subunit of human LDH, by western 
blotting analysis. Western blotting was carried out as outlined in section 2.16. H4LDH 
(lanes 2 and 5), M4LDH (lanes 3 and 6 ) and normal rabbit serum (lanes 1 and 4) were 
blotted onto nitrocellulose paper and probed with HRP-anti-H4LDH antibody. Strong 
positive bands were obtained for the H4LDH samples only, indicating specificity for the 
H-subunit of human LDH.
1 2 3 4 5 6
173
5.8 Isoenzyme analysis
Patient serum samples (obtained from St. James’ Hospital, Dublin), with normal (<350 
U/L total LDH as determined by SMAC automated analyser) and abnormal (>350 U/L 
total LDH), were tested in the ELISA as outlined in section 5.6.4. The antibody is 
specific for the H-subunit of human LDH, and so will bind to H4, H3M, H2M2 and HM3 
forms of LDH, but not the M4 form. From the results shown in Figure 5.8.1, only one 
‘abnormal’ sample shows an elevation of the H-subunit. For all other ‘abnormal’ 
samples, the absorbance values were in the same region as those of the normal samples. 
The isoenzyme profiles of all the samples tested in the ELISA (normal and abnormal), 
were prepared, as outlined in section 2.15. The relative percentages of each of the 
isoenzymes for each sample was determined after scanning densitometry. Three 
examples of ‘normal’ and ‘abnormal’ samples are shown in Figures 5.8.2 and 5.8.3, 
respectively. All the normal samples show typical normal serum isoenzyme patterns, 
with the ratio of LDHX/LDH2 less than unity. All of the abnormal samples isoenzyme 
profiles had an LDHj/LDHz ratio less than unity, with the exception of one sample 
(marked with -►), which gave a ratio greater than unity. This was the same sample which 
showed elevated H-subunit levels as determined by the ELISA.
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Figure 5.8.1
Two-site sandwich ELISA for the H-subunit of LDH, performed on patient serum 
samples, with normal and elevated levels of total LDH. The samples were obtained from 
St. James’ Hospital. Only one sample (-*~), with elevated total LDH, showed an increased 
level of the H-subunit containing isoenzymes, compared to ‘normal’ samples, as 
determined by the ELISA.
LDH activity (Units/L)
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Figure 5.8.2
Isoenzyme analysis (section 2.15) of patient serum samples with normal levels of total 
LDH. The samples were obtained from St. James’ Hospital. In all the ‘normal’ patient 
samples ( 3  examples of normal patient samples a, b and c are shown here), the ratio of 
LDH,/LDH2 (HyHjM) was less than unity. The ratio (if greater than unity), is often used 
as an indicator of myocardial infarction.
1 2 3 4 5
LDH Isoenzyme Type
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Figure 5.8.3
Isoenzyme analysis (section 2.15) of patient serum samples with elevated (abnormal) 
levels of total LDH. All of the ‘abnormal’ patient samples (three examples of patient 
samples with elevated LDH levels are shown here, x, y and z) with the exception of one 
(termed x), gave a LDHj/LDH2 ratio of less than unity. If the ratio is greater than unity, 
this is often used as an indicator of myocardial infarction. The sample (x), also gave an 
elevated level of the H-subunit of LDH as determined by the ELISA (Figure 5.8.1).
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5.9 Discussion
Work has recently been reported on the use of microtitre plate readers in 
spectrophotometric enzyme assays (Butler et al., 1988; Cribb et al., 1989). The 
advantages of miniaturising assays to 96-well plate format include; speed of assay 
performance, economy in the use of the reagents, high throughput of samples, small 
sample volumes required, automatic mixing of samples and good temperature and time 
control.
The colourimetric assay for total LDH was miniaturised on the basis of volume 
reduction, while maintaining the optimal concentration of the assay reagents in the final 
assay mixture. The reagent concentrations and the assay conditions used were 
established by Gay et al. (1968). The determination of total LDH in serum is a weighted 
sum of the activities of the five isoenzymes of LDH. The portion of the total activity 
produced by each isoenzyme is a function of the inherent characteristics of each 
isoenzyme as they relate to temperature, pH, direction of the reaction, substrate 
concentration, coenzyme concentration, buffer and the relative amount of each 
isoenzyme present. The assay conditions outlined by Gay et al. (1968), approach optimal 
activity for any distribution of isoenzymes, for the forward reaction; i.e. conversion of 
lactate to pyruvate. This is important where the serum activity of one isoenzyme of LDH 
is increased, as in the case of myocardial infarction. The pH of the miniaturised assay 
was maintained between pH 8 .5-8.6 , the final lactate concentration at 45 mM and the 
NAD concentration at 1.5 mM. The NAD concentration for the forward reaction, should , 
be greater than 6 mM, but in the presence of the electron acceptor phenazine 
methosulphate (PMS) and the tetrazolium salt, 2-(p-iodophenyl)-3-(p-nitrophenyl)-5- 
phenyltetrazolium chloride (INT), NAD at concentrations greater than 1.5 mM has no 
effect (Babson and Philips, 1965).
For miniaturisation the assay volumes were reduced while maintaining the optimal 
concentration of assay reagents for the forward reaction, in the final assay mixture. The 
total assay volume in the microtitre plate well is 245 pi. The reagents were premixed 
in appropriate ratios in order to simplify the reagent addition process. An eight-tip 
multichannel was used for rapid and accurate addition of the reagents. Timing is critical 
only after the addition of the ‘colour reagent’ (section 2.14), as the LDH remains 
completely inactive in the absence of NAD. One unit of LDH activity is defined as the 
amount of enzyme which will yield 1 pg formazan under the conditions of the assay
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method. Therefore, a standard curve of formazan can be prepared and used for LDH 
activity determination. Alternatively, commercial serum containing known amounts of 
LDH can be used as standards and unknowns compared with this.
The assay used for the determination of LDH, was chosen for several reasons. It has 
been suggested that the forward reaction gave more accurate results, the colour produced 
being linear with enzyme concentration. Pyruvate, the substrate for the backward 
reaction is a potent inhibitor of LDH activity, when present in high concentrations, but 
if the pyruvate concentration is kept low, inaccuracies result when assaying serum 
samples with elevated LDH activity. The optimal pyruvate concentrations for enzymes 
of the heart, liver and serum are different. Also, the reverse reaction in the absence of 
a colourimetric indicator would require an ultraviolet spectrophotometer microtitre plate 
reader, which is not readily available in most laboratories. The assay also requires that 
the temperature be accurately controlled, multiple timed readings and processing of data. 
The simplicity and brevity of the colourimetric forward assay used made it more suitable 
for miniaturisation.
Polyclonal antibodies against the H4 isoenzyme of human LDH were produced in New 
Zealand White rabbits. By choosing the H4 isoenzyme, the antibodies produced were 
specific for the H-subunit of LDH and did not cross react with the M-subunit. The H 
form of LDH is a poorer immunogen than the M form. Antisera produced against the 
H form will generally not cross react with the M form from the same species but will 
crossreact with the H and M form from other species. The cross-reactivity of the- 
antiserum was tested against heart LDH isolated from bovine, chicken and porcine 
sources, and the M4 isoenzyme isolated from human muscle. The antiserum was seen 
to cross react to some extent with bovine and porcine LDH but not with the chicken 
heart LDH or the human M4 LDH. The reason why the antiserum did not crossreact with 
the chicken heart LDH is probably because it is from a non-mammalian source. Serum 
proteins are poor immunogens in closely related species, since there is normally only 
minor structural differences between the same molecule in closely related species. 
Chickens are phylogenetically more distant from humans than pigs or cows (Catty and 
Raykundalia, 1988).
The antiserum was purified by Protein A (SpA) chromatography, resulting in an IgG 
fraction containing specific and non-specific ‘host’ antibodies. The ELISA developed for 
the measurement of H4LDH is not very sensitive. The measurable concentration range
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spans across 4 orders of magnitude, and a large change in H4LDH concentration, only 
results in a small change in absorbance. The reason for the poor sensitivity could be due 
to low affinity antibodies, or the fact that the low titre antiserum (the H subunit is a 
poor immunogen), was purified by SpA chromatography. Coating plates with 
immunospecifically affinity-purified antibodies generally results in a more sensitive 
immunoassay, as there is a higher percentage of specific antibody coated to the plate. 
Preparation of an affinity column for purification was not feasible as the purified antigen 
is too expensive.
Patient serum samples with normal and elevated levels of total LDH were obtained from 
St. James Hospital. These samples were assayed for total LDH using an automated 
SMAC analyser in the Biochemistry Dept., at St. James Hospital. Normal samples had 
total LDH activities <350 U/L and abnormal samples had total LDH activities >350 U/L. 
It is expected that the purified anti-H4LDH antibodies will bind to four of the 
isoenzymes of LDH containing the H subunit, i.e. H4, H3M, H2M2 and HM3. However, 
in a two-site ELISA, where two antibodies, capture and second labelled antibody, must 
bind to the analyte, the efficiency of detecting the different isoenzymes may not be 
equal. Steric hindrance by the M-subunit in the HM3 and H2M2 isoenzyme may result 
in these isoenzymes not being detected with the same efficiency as the H4 and H3M 
isoenzymes.
On AMI, H4 (LDH,) and H3M (LDH2), the predominant isoenzymes found in the , 
myocardium, are released into the serum, resulting in elevated total LDH, flipped 
LDH,/LDH2 ratio and an elevation of LDHj in the serum. An increase in the serum 
concentration of CK-MB, an isoenzyme of creatine kinase is also observed for up to 24 
hours after AMI, but it normalises again after 24 hours, and the LDHj/LDH2 ratio 
becomes important. The measurement of the LD H j/LD ^ ratio by electrophoretic 
methods was established first (Starkweather et al., 1966). When this ratio exceeds 0.76, 
it has been reported to be 100% sensitive and 91% specific, for acute MI (Weidner, 
1982). It should be noted however that the LDHj/LDHj isoenzyme flip can also occur 
in non-AMI patients such as young pregnant females.
With the advent of immunochemical methods for the measurement of a single 
isoenzyme, LDH,, several clinical studies were undertaken by various groups, to 
evaluate whether total LDHj concentration, LDH/LDHj concentration ratio or
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LDH,/total LDH concentration ratio, gave the best efficiency (the incidence of true 
positives to true negatives), specificity (the incidence of results below a predetermined 
cutoff limit among patients without myocardial infarction) and sensitivity (the incidence 
of results above a predetermined cutoff limit among patients with myocardial infarction), 
for the diagnosis of AMI. All the studies were in agreement that the determination of 
LDH, allows accurate diagnosis of AMI earlier than the ratio of LDH/LDHj (Gerhardt 
et al„ 1983; Foo et al., 1981; Fogh-Andersen et al., 1982). Since there is more LDH, 
than LDH2 isoenzyme in the myocardium, sensitive quantitation of increased LDH, in 
serum would signal the existence of myocardial necrosis before the time when LDH, 
exceeds LDH2 in the serum.
The isoenzyme profiles of all the ‘normal’ and ‘abnormal’ serum samples were prepared 
and analysed for a LDH,/LDH2 ratio greater than unity. Only one patient sample gave 
this result. All of the samples were also tested in the ELISA system to compare the H 
subunit of LDH concentration in the normal and abnormal samples. Only the sample 
which gave the LDH,/LDH2 ratio flip, showed an elevation of the H subunit over those 
obtained for the normal samples. No conclusion can be drawn from these results as it 
is not known which patients suffered from AMI. The ELISA developed does not 
specifically measure LDH, but possibly all isoenzymes containing the H-subunit. Also 
the ELISA is not very sensitive due to the poor antiserum obtained. An alternative 
method would be immunoprecipitate the M subunit, and detect the LDH, isoenzyme by 
ELISA following centrifugation. The use of monoclonal antibodies may be required to, 
develop an immunoassay of sufficient sensitivity. LDH, has been quantitated to date by 
activity measurements after immunochemical precipitation of the M-subunit containing 
isoenzymes. Delanghe et al. (1990), stated that the catalytic properties of creatine kinase 
(CK), another enzyme released into the circulatory system after AMI, decreased with 
enzyme age, as reflected by a steady state increase in the activation energy of the 
catalysed reaction. They concluded that mass concentration measurement by 
immunochemical methods was better for infarct sizing than measurement of catalytic 
activity. The same may be true for LDH determination, as the rate of enzyme 
inactivation (half-life) is different for the different isoenzymes, and mass concentration 
measurements (immunoassay) of LDH, may be more accurate than activity 
measurements, after the immunoprécipitation step.
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In conclusion, an ELISA for the determination of the H-subunit of LDH was 
investigated as a method of detecting elevated LDH, and LDH2 (a consequence of AMI) 
in patient serum samples. The results however were inconclusive, although one clear 
positive was obtained. If a more sensitive immunoassay for LDH, was developed, using 
monoclonal antibodies perhaps, LDH, could be detected immunologically after 
precipitation of the four other isoenzymes. Rapid detection of LDH, using an evanescent 
wave immunosensor, as described in chapter 4, would be feasible.
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CHAPTER 6
CONCLUSIONS
6 Conclusions
The research aimed to develop an evanescent wave optical immunosensor, for the 
determination of the clinically important diagnostic enzyme, lactate dehydrogenase. It 
was intended that the sensor be used for the determination of LDH in human serum 
samples, for the diagnosis of acute myocardial infarction. However, due to time and cost 
limitations, a model system using chicken heart LDH (kindly donated by Baxter Dade), 
was developed. This antigen was less expensive and highly immunogenic and thus 
allowed the production of large quantities of polyclonal antibodies.
In chapter 3, the production of these antibodies was described. A high titre antiserum 
(1:32,000) was raised, and the antibodies were purified by antigen-specific affinity 
chromatography. The antibodies were characterised for purity by size exclusion HPLC 
and SDS-PAGE analysis. Following labelling with HRP, a two-site sandwich ELISA for 
the quantitation of CHLDH was developed, which was subsequently used for the fibre 
ELISAs (chapter 4). The purified antibodies were also labelled with the fluorescent 
label, FITC, and the conjugates characterised by HPLC with PDA detection. The FITC- 
labelled antibodies were used in the optical fluoroimmunosensor, as described in chapter
The optical immunosensor development was outlined in chapter 4. Capture antibody was 
immobilised onto the exposed core of optical fibres by a procedure which involved 
silanisation of the silica surface and the use of the heterobifunctional crosslinker, GMBS. 
The immobilisation procedure was optimised using ELISA techniques. The binding of 
antibody and antigen was probed by the evanescent wave generated at the surface of the 
exposed core optical fibre, via the fluorescently-labelled antibodies or antigens. The 
binding reaction was shown to follow pseudo first-order reaction kinetics, and so the 
initial slope of the binding curve was proportional to the concentration of LDH. One- 
step and two-step immunoassays were performed, using the same polyclonal antibodies 
as the capture and labelled antibodies. The lower detection limit of both assays were 
found to be the same, although the signals obtained from the two-step assay were higher 
than those obtained from the one-step assay.
Attempts were made to regenerate the fibres in situ in the flow cell. However, these 
were unsuccessful as the immunocomplex was not completely broken, by the 
regeneration conditions chosen, and air bubbles were introduced into the flow cell, when 
left in situ. Reproducible alignment of the fibre was also difficult, and introduced
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considerable error (CV of 14.4%), into the sensor system. The effect of the sample 
matrix viscosity was determined, and showed an inverse relationship to the numerical
aperture of the sensor probe.
The BIAcore™ monitors immunoreactions in real-time, without the requirement for 
reporter labels. One-step, two-step and direct (no second antibody) immunoassays were 
performed using this sensor. The BIAcore™ assays were found to be less sensitive in 
terms of the lower detection limit compared to the evanescent wave immunosensor 
(EWIS). However in terms of reproducibility and automation, the BIAcore™ was found 
to be far superior.
The effect of fluorophore-to-protein labelling ratio on the affinity of the anti-CHLDH 
antibody was determined using both sensor systems. As the number of fluorophore per 
antibody molecule increases, the affinity of the antibody for CHLDH decreased. 
However, for use as the labelled species in EWIS, larger signals were obtained using 
higher F/P ratios, up to 5 FITC/antibody molecule, thereby compensating for the 
reduction in affinity.
In chapter 5, a colourimetric assay for the determination of total LDH levels in serum 
samples was miniaturised, and was shown to correlate well with results obtained using 
an automated clinical analyser, based on a different reaction mechanism.
Antibodies were raised against the H subunit of human LDH. The antibodies were 
purified by protein A affinity chromatography, and characterised by SDS-PAGE and 
Western blotting techniques, for purity and specificity, respectively. The antibodies were 
then labelled with HRP and a two-site sandwich ELISA developed for the quantitation 
of human heart LDH. This ELISA was shown to be very poor in terms of sensitivity. 
An attempt was made to see if such an ELISA system could be used as an indicator of 
AMI, by measuring an increase in the H subunit of LDH in the blood. Approximately, 
50 normal and abnormal (elevated total LDH) patient serum samples were screened. 
Only one sample showed a reversed H /H 3M ratio, indicative of AMI. This sample also 
showed elevated H subunit concentration as determined by the ELISA. However, due 
to the poor sensitivity of the ELISA, and the fact that only one sample out of 50 proved 
positive, the results were deemed inconclusive.
With a more sensitive immunoassay system, an optical immunosensor for the rapid 
determination of the onset of AMI could be feasible. This system would probably work 
best if the M subunit containing isoenzymes were first immunoprecipitated and removed
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using anti-M subunit antibodies. The H4 isoenzyme alone could then be determined 
using the EWIS.
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